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Summary 
Sphingosine kinase 1 (SphK1) is a biologically active lipid which plays a significant 
role in the growth, survival, migration of the cell, as well as a role in anti-apoptosis 
and enhances cell immortalization. SphK1 is involved in the crucial S1P signalling 
pathway which can catalyse sphingosine phosphorylates to S1P in an ATP-
dependent manner. Our study examined the effect of SphK1 on gastric cancer cell 
line, its clinical significance in gastric cancer progression and the role in 
chemoresistance with the prediction that SphK1 is a potential pharmacologic 
target.Our results demonstrated that the inhibition of SphK1 expression and/or its 
kinase activity could down-regulate AKT/mTOR survival signalling pathway, 
leading to reduced chemoresistance of gastric cancer cells, suggesting that 
SphK1might be a potential novel target for the treatment of gastric cancer. 
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General Introduction
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1.1 Gastric cancer 
1.1.1 General introduction 
Gastric cancer (GC) causes a significant health issue worldwide, being the fifth most 
common cancer and second leading cause of cancer related death. An estimated 
1,033,701 new cases and 782,685 deaths occured in 2018, ranking the fifth leading 
cause of morbidity and the third leading cause of mortality around the world (Bray 
et al., 2018). 
China has the largest number of GC patients worldwide, and according to the 
National Central Cancer Registry of China (NCCRC), 410,400 new GC cases were 
diagnosed, and about 293,800 GC-related deaths occurred in 2014 in China (Yang 
et al., 2018). The incidence in men is 2-fold higher than that in women. The incidence 
rate of GC is approximately 30/100,000. GC is more common in rural areas rather 
than urban areas. The incidence in men is 2.4 times as high as that in women. Among 
patients older than 44 years, the morbidity rate is higher in men than in women. It is 
estimated that there was an increase of 365,000 GC cases in comparison with those 
in 1990, leading to more than 96,000 deaths.  
Although the absolute number is increased, the incidence of  new GC cases has 
declined since 1990 (Collaborators, 2020).The slowing decline is most likely 
explained by the long-term low and stable prevalence of Helicobacter pylori (HP) 
infection (Ferro et al., 2014). By contrast, incidence rates of gastro-oesophageal-
junction adenocarcinomas are on the rise (Pohl et al., 2010).  
Despite declining incidence and mortality rates, advancements in the understanding 
of the epidemiology, pathology, molecular mechanisms and therapeutic options and 
strategies for gastric cancer, the burden and strain on healthcare systems remains 
high. Due to the large number of GC patients in China and Asia, tailor-made 
treatment strategies are still needed. 
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1.1.2 Aetiology 
1.1.2.1 Helicobacter pylori (HP) 
HP infection is the most important cause of sporadic gastric cancer (Bornschein et 
al., 2010). Persistent HP infection can promote normal epithelium atrophy, and then 
intestinal epithelium, dysplasia and adenocarcinoma (Leung et al., 2004, Mera et al., 
2005, Fukase et al., 2008). Studies have confirmed that HP infection can cause 
interactions among bacteria, hosts and the environment, promote tissue damage, and 
cause chronic inflammatory lesions and tumours (Wang et al., 2014b). In addition, 
HP is involved in tumour cell proliferation, apoptosis, and epigenetic modification 
of oncogenes, leading to tumorigenesis associated with inflammatory lesions (Wang 
et al., 2014b). However, the question remains as to whether the eradication of HP 
can prevent the process of gastric cancer? After 15 years of follow-up, it has been 
demonstrated in a large sample population that HP eradication significantly reduces 
the incidence of gastric cancer (Odds Ratio, OR = 0.61, 95% CI 0.38-0.96) (Ma et 
al., 2012). In addition, in severe mucosal lesions and the elderly group, eradication 
of HP can also prevent the occurrence of gastric cancer (Li et al., 2014b). For patients 
with early gastric cancer after surgery, whether the eradication of HP is effective is 
inconclusive, a study has shown that after surgery, HP eradication significantly 
reduces the incidence of metachronous gastric cancer compared to placebo (HR = 
0.50, p = 0.03) (Choi et al., 2018). Furthermore, recent research result showed that 
patients who had a family history could also benefit from eradication of HP (Choi et 
al., 2020). 
 
1.1.2.2 Epstein Barr Virus (EBV) 
EBV preferentially exists in gastric cancer cells and lymphoid stroma, and normal 
epithelial cells are mostly free of EBV (Wu et al., 2000). In recent years, with the 
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establishment of molecular classification of gastric cancer and the rise of 
immunotherapy, EBV-related gastric cancer has gradually received attention. It is 
suggested that EBV-related gastric cancer may have independent biological and 
clinical characteristics. A study showed that patients with EBV-positive metastatic 
gastric cancer treated with pembrolizumab had an amazing objective response rate 
(ORR) which initially confirmed that EBV-positivity could be used as a potential 
molecular marker to predict the response of immunotherapy (Kim et al., 2018). 
However, it is limited by the characteristics of retrospective studies and needs further 
verification. It is believed that the in-depth study of the molecular mechanism of 
EBV-related gastric cancer could provide a theoretical basis for the refinement of 
the molecular classification of gastric cancer and development of new drugs. 
 
1.1.2.3 Hereditary diffuse gastric cancer (HDGC) 
Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant genetic disease 
with CDH1 (Cadherin 1) mutation. For CDH1 mutation carriers, prophylactic total 
gastrectomy is recommended between the ages of 18 and 40 years. Baseline 
endoscopy is required before preventive total gastrectomy. A frozen section should 
be performed during the operation to confirm that the proximal edge contains 
oesophageal squamous mucosa and the distal edge contains duodenal mucosa to 
ensure complete removal of gastric tissue. Prophylactic total gastrectomy does not 
require D2 lymphadenectomy. Prophylactic gastrectomy is not recommended before 
the age of 18, unless there are members of the family who have been diagnosed with 
gastric cancer before the age of 25. Carriers of CDH1 mutations who choose not to 
undergo prophylactic gastrectomy should receive an endoscopy every 6-12 months 
and undergo multiple random biopsies for screening. Women with CDH1 mutations 
have an increased risk of breast cancer (cited from NCCN Guidelines Version 4.2019 
Gastric Cancer). 
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1.1.3 Classification 
1.1.3.1 Anatomical 
1.1.3.1.1 Siewert classification 
Due to the fact that the incidence, geographical distribution, causes, clinical disease 
course and treatment are different in non-cardia gastric cancers and gastro-
oesophageal-junction cancers (cardia), it is of great importance to classify the 
anatomical location in tumour. The Siewert classification is widely used to 
categorise gastro-oesophageal-junction cancers (Siewert and Stein, 1998):  
• Siewert I: The epicentre of tumour is located 1-5cm above the gastro-
oesophageal junction 
• Siewert II: The epicentre of tumour is located 1-2cm above and below the 
gastro-oesophageal junction 
• Siewert III: The epicentre of tumour is located 2-5cm below the gastro-
oesophageal junction. 
However, it is not clear whether there are biological differences between Siewert 
type II and type III (Demicco et al., 2011). Furthermore, due to the lack of precise 
criteria for identifying gastro-oesophageal-junction adenocarcinomas, the Siewert 
classification has been under criticism.  
In the 8th edition of the TNM staging of gastric cancer published by the Union for 
International Cancer Control (UICC) and the American Joint Committee on Cancer 
(AJCC) in 2018, tumours where the epicentre is located within 2cm distal to gastro-
oesophageal-junction and tumour does not invade gastro-oesophageal-junction are 
classified as gastric cancer. Therefore, some cases of Siewert type II 
gastroesophageal junction cancer were reclassified as gastric cancer, which will 
inevitably affect the future treatment strategy of gastroesophageal junction cancer. 
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1.1.3.1.2 Borrmann’s classification 
Borrmann‘s classification was established in 1926. This classification has 4 
subtypes, depending on the macroscopic appearance of the lesion (Sendler et al., 
1995). 
• Type I: polypoid fungating,  
• Type II: ulcerative with elevated distinct borders,  
• Type III: ulcerative with indistinct borders,  
• Type IV: diffuse, indistinct borders.  
Type I and II: localized types, Types III and IV: infiltrative Types (Figure 1.1) 
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Figure 1.1Borrmann’s classification. Figure reproduced from Surgical Treatment: 
Evidence-Based and Problem-Oriented, Chapter-Preoperative staging for gastric cancer, 
writing by J R Siewert et al. 
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1.1.3.2 Histological  
Although the majority of GC are gastric adenocarcinomas, their architecture, growth, 
cell differentiation, histogenesis, and molecular pathogenesis vary, which accounts 
for the diversity of histopathological classifications. The Lauren (Lauren, 1965) and 
WHO classifications are currently the most commonly used classifications.  
 
1.1.3.2.1 Lauren classification 
There are two main types of GC according to Lauren classification, termed intestinal 
type and diffuse type. These two types of GC have different biological, aetiological 
and epidemiological characteristics. 
Intestinal type: tumour cells are arranged in a tubular or glandular structure and are 
often associated with intestinal metaplasia (Lauren, 1965). This type of GC has a 
tendency to lymphoid or vascular invasion and is most commonly seen in older male 
patients. It occurs in the antrum of the stomach, and shows a better prognosis (Qiu 
et al., 2013, Zheng et al., 2007). 
Diffuse type: Tumour cells lack glandular structure (Lauren, 1965). The mucus 
inside the cell pushes the nucleus to one side to form signet-ring cell carcinoma. 
Diffuse type presents in the body of stomach in women and young people and is 
prone to peritoneal metastasis and worse prognosis (Qiu et al., 2013, Chen et al., 
2016). 
 
1.1.3.2.2 WHO classification 
The WHO classification is composed of five main histopathological types. 
Compared with the simple and powerful Lauren classification, the advantage of the 
WHO classification is that the system allows comparison with the histological 
classifications of cancers in other parts of the gut. The WHO classification is based 
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on the predominant histological patterns of the carcinoma, namely tubular, papillary, 
mucinous, poorly cohesive and rare variants. In contrast to the Lauren classification, 
the WHO tubular and papillary carcinomas are histologically similar to the intestinal 
type. Likewise poorly cohesive carcinomas (including those composed partly or 
totally of signet ring cells) is equivalent to the diffuse type histologically (Waldum 
and Brenna, 1993). 
 
1.1.3.3 Molecular classification 
As a part of The Cancer Genome Atlas (TCGA) project, the TCGA research team 
integrated the analysis of total cell-based array analysis based on somatic cell 
number analysis of 295 gastric cancer patients' tissues and blood samples without 
chemotherapy. Subsequence analysis, DNA methylation array analysis, mRNA 
sequence analysis, microRNA sequence analysis, and data measured based on 
protein array analysis were undertaken. In 2014, the molecular classification of GC 
was published (Cancer Genome Atlas Research, 2014) (Figure 1.2).  
 
GC was divided into 4 subtypes, namely: 
• Chromosomally unstable tumour (CIN) (50%) 
• Microsatellite instability tumour (MSI) (21%) 
• Genomically stable tumour (GS) (20%) 
• EBV-infected tumour (EBV) (9%) 
 
1.1.3.3.1 CIN type 
This type accounts for about 50% of GC. It usually occurs at the gastro-oesophageal-
junction, and most of them belong to the intestinal type of Lauren (Lauren, 1965). 
Chromosomal instability often exhibits significant aneuploidy and in-situ 
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amplification of receptor tyrosine kinases (RTK). Almost all RTKs have in situ 
amplification of genes, and many of them have been blocked by existing or 
developing drugs (Cancer Genome Atlas Research, 2014). In addition, due to 
amplification of cell cycle regulatory genes, inhibiting cyclin dependent kinases，
such as cyclin E1 (CCNE1), cyclin D1 (CCND1) and cyclin dependent kinase 6 
(CDK6)) could represent potential therapeutic targets. In addition, there are many 
Tumour Protein (TP53) mutations (71%) in chromosomal instability. Frequent TP53 
mutations are related to chromosomal aneuploidy (Cancer Genome Atlas Research, 
2014). 
 
1.1.3.3.2 MSI type 
MSI type accounts for about 21% of gastric cancers. It usually occurs in the gastric 
antrum or pylorus and is more common in women and the elderly. The age at first 
diagnosis is high (median age 72 years). This type of DNA hypermethylation 
includes MSI-associated gastric 5'-C-phosphate-G-3' (CpG) island methylation and 
hypermethylation of the characteristic MutL Homolog 1 (MLH1) promoter (Cancer 
Genome Atlas Research, 2014). Hypermethylation of the MLH1 promoter can cause 
defects in the mismatch repair system, leading to the occurrence of gastric cancer 
(Wen et al., 2017). Due to abnormal DNA repair mechanisms, high DNA mutation 
rates include mutations in several genes that activate oncogenic signalling proteins, 
such as mutations in Phospatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic 
Subunit Alpha (PIK3CA), Epidermal Growth Factor Receptor 3 (ERBB3), 
Epidermal Growth Factor Receptor 2 (ERBB2), and epidermal growth factor 
receptor (EGFR) (Cancer Genome Atlas Research, 2014).  
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1.1.3.3.3 GS type 
This type accounts for about 20% of gastric cancers, and the age at first diagnosis is 
low (median age 59 years). Most of them are Lauren diffuse type (73%) (Cancer 
Genome Atlas Research, 2014). Genome-stable phenotypes include Cadherin-1 
(CDH1) mutations (37%), Ras Homolog Family Member A (RHOA) mutations, or 
RHO family GTPase-activated protein gene fusion (Claudin l8-Rho GTPase 
activating protein, CLDN18-ARHGAP fusion) (Cancer Genome Atlas Research, 
2014). CDH1 germline mutations are closely related to hereditary diffuse gastric 
cancer. However, germline analysis only shows that two CDH1 genes are 
polymorphic, but neither is a causative factor for hereditary diffuse gastric cancer. 
RHOA mutations are characteristic mutations that are stable in the genome 
(Thumkeo et al., 2013). CLDN18-ARHGAP fusion and RHOA mutations are 
mutually exclusive, and their incidence in GS gastric cancer accounts for 62% 
(Cancer Genome Atlas Research, 2014). Recognition of the fusion of these mutant 
genes indicates that genes can provide new ideas for future research and 
development of drugs. 
 
1.1.3.3.4 EBV type 
This type accounts for about 9% of all patients. It mostly occurs in the fundus and 
body of stomach and is more common in men. EBV-positive types have high levels 
of CpG island methylation, and EBV-positive DNA hypermethylation levels are 
higher than any other cancer (colorectal cancer, endometrial cancer, etc.) reported 
by TCGA (Cancer Genome Atlas, 2012, Cancer Genome Atlas Research et al., 2013, 
Brennan et al., 2013). Cyclin-dependent kinase Inhibitor 2A (CDKN2A) 
(p16INK4A) promoter hypermethylation is common in EBV-positive types. 
CDKN2A is an important tumour suppressor gene, which belongs to the cell cycle-
dependent kinase inhibitor gene family. It can regulate cell proliferation and 
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apoptosis, and methylation of its promoter can promote tumorigenesis (Lee et al., 
2012c). PIK3CA mutations are common in EBV-positive types, 80% of EBV-
positive types have non-silent PIK3CA mutations and their mutation sites are 
scattered; while other subtypes have only 3% to 42% PIK3CA mutations. A new 
frequent amplification site on chromosome 9p24, including Janus kinase 2 (JAK2), 
cluster of differentiation 274 (CD274), and programmed cell death 1 ligand 2 
(PDCD1LG2) gene amplification has been found (Cancer Genome Atlas Research, 
2014). The JAK2 gene encodes a receptor tyrosine kinase and is a potential 
therapeutic target. The CD274 and PDCD1LG2 genes encode Programmed death 
ligand 1 and 2 (PD-L1 and PD-L2) proteins, respectively. PD-L1 and PD-L2 are 
immunosuppressive proteins and may become therapeutic targets for anti-tumour 
immune responses. The results of the TCGA study indicate that JAK2 inhibitors and 
PD-1/2 antagonists may be effective in the treatment of EBV-positive gastric cancer 
(Cancer Genome Atlas Research, 2014). 
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Figure 1.2 Molecular characterisation of gastric carcinomas subtypes  
CIN=chromosomally unstable tumours. EBV=Epstein-Barr virus-infected tumours. 
CIMP=CpG island methylation phenotype. MSI=microsatellite unstable tumours. Figure 
reproduced from (The Cancer Genome Atlas Research et al., 2014).  
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1.1.4 Therapy  
1.1.4.1 Staging 
The most widely used method for staging is the American Joint Committee on 
Cancer (AJCC) TNM staging. The latest 8th staging system was released in 2018. 
This staging system is based on tumour invasion depth (T), lymph node metastasis 
(N), and with or without distant metastasis (M). This staging system requires at least 
15 lymph nodes for accurate staging (Table 1.1). 
The 8th edition of the TNM staging system for gastric cancer changed the single 
staging system to three staging systems, including clinical staging (cTNM), 
pathological staging (pTNM), and pathological staging (ypTNM) after neoadjuvant 
therapy. This new classification system solves the shortcomings of patients who 
cannot be well stratified in a single stage and guided for treatment. Based on previous 
data, Li et al. has verified the rationality of ypTNM staging. It is the largest study on 
the prognostic value of ypTNM staging at present (Li et al., 2018b), and proposes 
that the new classification of ypTNM staging may be helpful for predicting patient 
prognosis (Table 1.2). 
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Table 1.1 TNM classification of carcinoma of the stomach 
T  Primary Tumor  
Tx  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
Tis  Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, 
high-grade dysplasia 
T1  Tumor invades the lamina propria, muscularis mucosae, or submucosa  
 T1a  Tumor invades the lamina propria or muscularis mucosae  
 T1b Tumor invades the submucosa  
T2  Tumor invades the muscularis propria*  
T3 Tumor penetrates the subserosal connective tissue without invasion of the 
visceral peritoneum or adjacent structures**, *** 
T4 Tumor invades the serosa (visceral peritoneum) or adjacent structures**, *** 
 T4a Tumor invades the serosa (visceral peritoneum)  
 T4b Tumor invades adjacent structures/organs  
*A tumor may penetrate the muscularis propria with extension into the gastrocolic or 
gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the 
visceral peritoneum covering these structures. In this case, the tumor is classified as T3. If 
there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, 
the tumor should be classified as T4.  
**The adjacent structures of the stomach include the spleen, transverse colon, liver, 
diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and 
retroperitoneum.  
***Intramural extension to the duodenum or esophagus is not considered invasion of an 
adjacent structure, but is classified using the depth of the greatest invasion in any of these 
sites.  
N Regional Lymph Nodes  
Nx Regional lymph node(s) cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in one or two regional lymph nodes 
N2 Metastasis in three to six regional lymph nodes  
N3 Metastasis in seven or more regional lymph nodes 
 N3a Metastasis in seven to 15 regional lymph nodes  
 N3b Metastasis in 16 or more regional lymph nodes  
 
M  Distant Metastasis  
M0  No distant metastasis  
M1  Distant metastasis  
Reproduced from NCCN Guidelines Version 4.2019 Gastric Cancer 
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Table 1.2 AJCC cTNM 8th 
 N0 N1 N2 N3 
T1 I IIA IIA IIA 
T2 I IIA IIA IIA 
T3 IIB III III III 
T4a IIB III III III 
T4b IVA IVA IVA IVA 
M1 IVB IVB IVB IVB 
 
AJCC pTNM 8th 
 N0 N1 N2 N3a N3b 
T1 IA IB IIA IIB IIIB 
T2 IB IIA IIB IIIA IIIB 
T3 IIA IIB IIIA IIIB IIIC 
T4a IIB IIIA IIIA IIIB IIIC 
T4b IIIA IIIB IIIB IIIC IIIC 
 
AJCC ypTNM 8th 
 N0 N1 N2 N3 
T1 I I II II 
T2 I II II III 
T3 II II III III 
T4a II III III III 
T4b III III III III 
M1 IV IV IV IV 
Reproduced from NCCN Guidelines Version 4.2019 Gastric Cancer 
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1.1.4.2 Surgical Treatment 
1.1.4.2.1 Early gastric cancer treatment (EGC)  
Early gastric cancer (EGC) is a tumour of T1 and N+/-. Treatment for early gastric 
cancer can be roughly divided into 3 categories (Japanese Gastric Cancer, 2020).  
• T1a patients without lymph node metastasis-suitable for  ESD / EMR.  
• T1b patients without lymph node metastasis -suitable for  D1+/D1.  
• T1 patients with lymph node metastasis -suitable for  D2. 
 
1.1.4.2.1.1 Definition of EGC 
Early gastric cancer is defined as infiltration of the mucosa or submucosa, with or 
without lymph node metastasis (T1a, N+/-). For some early gastric cancers, 
endoscopy (EMR / ESD) can be used as an alternative to gastrectomy (Isomoto et 
al., 2009), but it should be performed in a medical centre with extensive experience. 
 
1.1.4.2.1.2 Definition of endoscopic resection 
• Endoscopic mucosal resection (EMR) 
The submucosal injection of normal saline lifts the lesion and surrounding mucosa 
and removes it with a high-frequency steel trap snare. 
• Endoscopic Submucosal Dissection (ESD) 
The submucosal injection of normal saline lifts the lesion and surrounding mucosa 
and use a high-frequency electrosurgical knife to remove the mucosa around the 
lesion and the submucosa from the appropriate muscle layer (Japanese Gastric 
Cancer, 2017). 
 
18 
 
1.1.4.2.1.3 Indications for ESD  
Tumours with less likelihood of lymph node metastasis, accompanied by no 
lymphovascular invasion, which is suitable for endoscopic resection (Hirasawa et al., 
2009). 
Tumours clinically diagnosed as T1a and differentiated-type, non-ulcer, ≤2cm.  
 
1.1.4.2.1.4 New indication for ESD 
JCOG0607 (Hasuike et al., 2018) conducted long-term follow-up of two types of 
patients who previously belonged to the ESD expanded indications (non-ulcer > 2cm 
and ulcer ≤ 3cm). The results showed that the 5-yrs OS was 97.0% (95% CI, 95.0-
98.2%), therefore, the original expanded indication was changed to absolute 
indication. 
 
1.1.4.2.2 Localised gastric cancer treatment 
1.1.4.2.2.1 Definition of gastrectomy, D1 and D2 
Radical gastrectomy is the main treatment for localised gastric cancer. Gastrectomy 
has undergone more than 100 years development since Billroth completed the first 
human gastrectomy in 1881. During the whole of the last century, efforts to improve 
the quality of surgery, improve patient survival and reduce postoperative 
complications have never stopped. Gastrectomy is a procedure that removes a part 
of the stomach or the whole stomach which can be divided into total gastrectomy, 
distal gastrectomy and proximal gastrectomy. Gastrectomy for gastric cancer should 
remove the stomach and lymph nodes around the stomach - the perigastric lymph 
nodes (D1). In addition, lymph nodes around the celiac axis vessels should be 
removed (D2). The total number of lymph nodes removed must not be less than 15 
(cited from NCCN guideline for gastric cancer Version 4.2019-December 20, 2019). 
19 
 
• D1 definition 
D1 resection requires removal of the stomach and the greater and lesser omenta, 
along with removal of the lymph nodes along left and right gastric vessels, and the 
left and right gastroepiploic vessels. 
 
• D2 definition 
In addition to a D1 resection, the lymph nodes along the common hepatic artery and 
splenic artery should be removed. 
 
There is still controversy about the range of D2 surgery between East and West 
surgeons. In the East, the left gastric artery (No. 7) lymph node belongs to D1, but 
in the West this group of lymph nodes belongs to D2. In addition, based on the 
JCOG0110 study (Sano et al., 2017), splenectomy is only indicated for tumours 
involving the greater curve of the stomach. Removal of the No. 10 group nodes is no 
longer a routine requirement for D2 dissection. JCOG0110 compared the effect of 
splenectomy on the survival of patients and found that splenectomy resulted in 
increased postoperative complications (30.3% vs. 16.7%, p = 0.0004) with no benefit 
to survival. Only 6 of the 254 patients in the splenectomy group had No.10 lymph 
node metastasis, and the metastasis rate was only 2.36% (Sano et al., 2017). 
Therefore, No.10 lymph node dissection is no longer included in the range of D2 
lymphadenectomy. However, in the NCCN guidelines, Western surgeons still 
recommend clearing No. 10 lymph node. 
 
1.1.4.2.2.2 D2 or D1  
There are still many controversies concerning gastrectomy procedure between 
Eastern and Western surgeons. Leading Japanese, Chinese and South Korean 
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surgeons contend that D2 surgery is necessary for GC patients, while in contrast, 
Western surgeons have traditionally argued that D1 surgery is satisfactory for GC 
patients. In addition, Western surgeons also argued that D2 surgery can increase the 
complication rate of surgery and does not improve the survival of patients. Therefore, 
Western surgeons actively apply neoadjuvant radiotherapy and chemotherapy to 
their patients, in order to supplement the disadvantage of the lesser extent of the D1 
procedure. However, with the results of the 15-year follow-up Dutch study (Songun 
et al., 2010), Western and Eastern surgeons have begun to reach a consensus. This 
Dutch study has shown that the D2 procedure has a lower local recurrence rate and 
a lower gastric cancer-related mortality rate than the D1 procedure. However, the D2 
procedure has a higher complication rate than the D1 procedure. The data from high 
volume cancer centres in East Asia have shown that the mortality rate of operation 
related complications is very low, basically less than 13-17% (Wang et al., 2019c). 
 
1.1.4.2.2.3 Laparoscopic or Open gastrectomy (LG or OG) 
In 1994 Kitano from Japan completed the first laparoscopic gastrectomy.  
Laparoscopy has rapidly developed in the last 20 years due to its advantages such as 
minimally invasive approach and magnified field of view allowing clearer 
identification of the fine anatomy. Laparoscopic gastrectomy has become one of the 
standard treatment options for early gastric cancer, and its feasibility for advanced 
gastric cancer is also being verified. 
Yu et al. (Yu et al., 2019) recently released the 3-year follow-up results of CLASS-
01, which enrolled 1056 patients from 14 centres in China. Among patients with 
locally advanced distal gastric cancer, the 3-year Disease Free Survival (DFS) rate 
was 76.5% in the laparoscopic group compared with 77.8% in the open group; the 
3-year Overall Survival (OS) rate was 83.1% and 85.2% (HR 1.19; 95% CI, 0.87 to 
1.64; p = 0.28), respectively. Recurrence rates were comparable in both groups (HR 
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1.15; 95% CI, 0.86 to 1.54; p = 0.35). This study provided the preliminary 
confirmation that the long-term efficacy of laparoscopic gastrectomy for locally 
advanced distal gastric cancer is not inferior to open gastrectomy, and the previous 
safety results have also been published (Hu et al., 2016). According to the 
completion rate of D2 lymphadenectomy (99.4% versus 99.6%; p = 0.845), 
postoperative complication rate (95% CI, -1.9 to 6.6; p = 0.285), and postoperative 
mortality (95% CI, -0.4 to 1.4; p = 0.289), the results were similar in both groups.  
During the same period, the Korean small sample study COACT 1001 (Park et al., 
2018) also released their results. 5-year OS in the study was 85.1% compared with 
84.1%, respectively (laparoscopic assisted surgery group and open surgery group of 
patients with locally advanced distal gastric cancer). The 5-year DFS was 74.5% and 
78.7%, respectively. Again, laparoscopic surgery showed the same long-term effects 
as open surgery. The results of the JCOG1401 (Katai et al., 2019) study in Japan 
confirmed the safety of laparoscopic assisted total or proximal gastrectomy in 
patients with clinical stage I.  
The results of the trials above herald the prospect of expanding indications for 
laparoscopic treatment of gastric cancer. It became essential to standardise the 
technology and processes of laparoscopic surgery in order to roll out the service from 
specialist trial centres to more general hospitals. Therefore, in 2018, China also 
released the Expert Consensus on Gastrointestinal Reconstruction and Surgical 
Operation Guideline for Complete Laparoscopic Stomach Cancer Surgery (2018 
Edition) in order to guide clinical surgeons to standardise the development of full 
laparoscopic gastrectomy. 
 
1.1.4.2.2.4 Laparoscopic gastrectomy after neoadjuvant chemotherapy 
Laparoscopic gastrectomy has become the mainstream surgical method for gastric 
cancer surgery in many countries. Neoadjuvant chemotherapy may cause changes in 
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the tissue which can alter the ease with which surgery can be performed. Whether 
laparoscopic surgery can achieve the same effect and safety rates after neoadjuvant 
chemotherapy is still controversial. Li et.al (Li et al., 2019b) initiated a randomised 
trial to address this question. The study enrolled 96 gastric cancer patients with cT2-
4aN+M0 GC. The results showed that compared with the open group, the 
laparoscopic group had a reduced rate of postoperative complications (20% versus 
46%; p = 0.007). This is the first study in the world to confirm that laparoscopic 
gastrectomy is as safe as open gastrectomy after neoadjuvant chemotherapy. 
Surprisingly, laparoscopic surgery reduces the rate of postoperative complications. 
However, the implications surrounding long-term oncological effects are yet to be 
reported.  
 
1.1.4.3 Neoadjuvant treatment 
Neoadjuvant (or perioperative) chemotherapy is administered as an approach for 
“downstaging and downsizing” a locally advanced tumour before curative resection 
and dealing with potential metastatic cells thereafter. Furthermore, for GC patients 
at a high risk of developing distant metastases, neoadjuvant chemotherapy helps 
reduce the risk by eliminating potential cancer cells and informing sensitive 
therapeutic regimens for postoperative adjuvant chemotherapy.  
However, there has been no consensus worldwide so far. 3Neoadjuvant 
chemotherapy is also frequently applied in patients in Europe according to studies 
such as the MAGIC trail (Cunningham et al., 2006) and FLOT (Al-Batran et al., 
2016). Due to the tendency of Europeans and Americans to have more intraperitoneal 
fat than Asians, there are fewer patients who can undergo D2 radical gastrectomy, 
so neoadjuvant chemotherapy and chemoradiotherapy will bring extra survival 
benefits to these patients. However, this is more controversial in Asia. The fact that 
Asian patients are thinner in body shapes makes it easier for them to achieve D2 
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radical gastrectomy. Chinese gastric cancer guideline recommends neoadjuvant 
chemotherapy should be used for T3/T4 and lymph node positive patients, but in 
South Korea, their guidelines do not recommend the usage of neoadjuvant 
chemotherapy on patients. Japan has recently started recommending neoadjuvant 
chemotherapy for patients with large bulky lymph nodes (Japanese Gastric Cancer, 
2017). 
However, in comparison with surgery alone, the benefits of this approach have been 
demonstrated by multiple clinical trials. In the MAGIC study (Cunningham et al., 
2006), 503 stage II and III gastric cancers patients were enrolled and randomly 
divided into surgery group (n=253) and perioperative chemotherapy group (n=250) 
with 3 cycles of the epirubicin, cisplatin, and fluorouracil (ECF) regimen. The 5-year 
OS rate was 23% (95% CI, 16.6 to 29.4) compared with 36% (95% CI, 29.5 to 43). 
The OS (hazard ratio (HR) 0.75; 95% CI, 0.60 to 0.93; p = 0.009) and progression 
free survival (PFS) (HR 0.66; 95% CI, 0.53 to 0.81; p < 0.001) were better in the 
perioperative chemotherapy group than in the surgery group. The conclusions of the 
study show that perioperative ECF can effectively reduce tumour size, reduce 
tumour staging, and prolong progression-free survival and overall survival of 
patients, and thereby the position of neoadjuvant chemotherapy in the treatment of 
gastric cancer has been established and written into the NCCN guidelines.  
In the FNCLCC and FFCD study (Ychou et al., 2011), 224 gastric cancer patients 
were assigned to neoadjuvant and adjuvant chemotherapy (n = 113) with cisplatin 
plus fluorouracil or surgery alone (n = 111). It also proved that perioperative 
chemotherapy has better OS (OS rate 38% vs 24%; HR 0.69; 95% CI, 0.50 to 0.95; 
p < 0.02) and DFS (DFS rate 34% vs 19%; HR 0.65; 95% CI, 0.48 to 0.89; p < 0.003). 
At the same time, subgroup analyses implied that gastroesophageal junction (GEJ) 
tumour patients benefited from this therapy. However, as some patients in the above 
studies did not achieve D2 radical gastrectomy, the current standard treatment for 
24 
 
gastric cancer is postoperative chemotherapy. Thus, these studies can only 
preliminarily highlight the important role of neoadjuvant chemotherapy in gastric 
cancer, but they cannot change clinical practice worldwide.  
In the FLOT4 (Al-Batran et al., 2016) study, there were 716 patients with T2 + and 
N + GC at 28 centres in Germany, randomly assigned 1:1 to the ECF (n = 360) and 
FLOT (Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel) (n = 356) groups. The 
OS in the ECF group (35 months) was found to be worse than that in the FLOT group 
(50 months, HR 0.77; 95% CI, 0.63 to 0.94; p = 0.012). 3-year OS rate was 48% in 
the ECF group in comparison with 56% in the FLOT group. PFS was also elevated 
in the FLOT group (30 months) compared with the ECF (18 months) group (HR 0.75; 
95% CI, 0.62 to 0.91; p = 0.004). Perioperative study to compare ECF and FLOT 
regimens in the treatment of such patients and subsequently, the FLOT regimen 
demonstrated sufficient superiority, replacing the ECF regimen in the NCCN 
guidelines. FLOT regimen showed sufficient superiority and replaced the ECF 
regimen in the NCCN guidelines. However, because the FLOT regimen is a three-
drug combination, the tolerance in the Asian population still needs to be verified, the 
conclusions from this trial should be carefully referenced. 
Furthermore, since 2012, Ji et al. have launched and completed the first phase III 
international randomised controlled trial of pre-operative chemotherapy 
(RESOLVE), which enrolled a total of 1094 patients. It was the first to confirm that 
neoadjuvant chemotherapy reduced the risk of tumour recurrence by 21%, which 
was presented at the 2019 ESMO LBA (Late-Breaking Abstract) section and named 
the Latest Breaking Research. The study proved, for the first time, that preoperative 
chemotherapy was the preferred option for locally advanced GC and this is an 
important study to prove preoperative chemotherapy significantly improves survival 
and will become the new standard of treatment. Many Chinese patients are at 
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advanced stage of gastric cancer when diagnosed, and it is expected that nearly 50% 
of patients could benefit from the neoadjuvant model.  
Therefore, the above research has illustrated that perioperative chemotherapy can 
improve the survival of GC patients, though not every patient can benefit from 
perioperative chemotherapy and the relative toxicity and side effects can 
significantly prolong the treatment time. Issues such as the optimal operation time, 
the optimal number of cycles, the optimal pre- and postoperative interval, and the 
effect on the operation are unresolved and still require more study. 
 
1.1.4.4 Adjuvant treatment 
The ACTS-GC study makes S-1 (Tegafur/gimeracil/oteracil) the standard adjuvant 
chemotherapy regimen for patients with stage II/III gastric cancer (Sakuramoto et al., 
2007). These studies have shown that the patients have benefited significantly from 
single-agent S-1 chemotherapy. Since then, how to stratify and target treatment of 
patients has become a hotspot for clinical attention. Furthermore, the CLASSIC trial 
(Bang et al., 2012) also indicated improved OS and DFS (postoperative combined 
capecitabine and oxaliplatin, XELOX/CapOX). The JACCRO GC-07 (Yoshida et 
al., 2019) study included patients who underwent D2 radical gastrectomy for 
pathological stage III GC and compared the effectiveness of S-1 combined with 
docetaxel versus S-1 alone. The results show that S-1 combined with docetaxel can 
significantly improve the 3-year DFS rate (65.9% versus 49.6%, HR 0.632, p = 
0.0007). Therefore, S-1 combined with docetaxel protocol is now recommended as 
the new standard for adjuvant chemotherapy after D2 radical surgery in patients with 
stage III gastric cancer (Yoshida et al., 2019). In addition, the results of the 
JCOG1104 study (Yoshikawa et al., 2019), which included patients with 
pathological stage II GC, were updated. These results have shown that the 3-year 
relapse-free survival (RFS) of the S-1 treatment in the 8-cycle and 4-cycle groups 
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was 93.1% and 89.8% (HR 1.84), with OS rates of 96.1% and 92.6% (HR 3.34), 
respectively. The non-inferiority of using 4-cycle S-1 has not been demonstrated. 
Considering the efficacy, S-1 adjuvant chemotherapy is recommended to continue 
for one year for patients with pathological stage II gastric cancer. 
 
1.1.4.5 Targeted treatment 
Screening for effective chemotherapy and drug-resistant populations can save 
patients from unnecessary pain caused by chemotherapy and reduce the burden on 
national health economics. Cheong et al. (Cheong et al., 2018) did a post hoc analysis 
for the CLASSIC trial (Bang et al., 2012) to develop gene panels of granzyme B 
(GZMB), Tryptophanyl-tRNA synthetase (WARS), secreted frizzled-related protein 
4 (SFRP4), and caudal type homeobox 1 (CDX1) in order to predict who would  
benefit from adjuvant chemotherapy. The study showed that, based on this panel, 
patients could be divided into high-risk group (40%, 250/625), intermediate-risk 
group (47%, 296/625), and low-risk group (13%, 79/625). The 5-year OS rate of the 
three groups of patients were 66.0%, 74.8%, and 83.2% (p = 0.012). In addition, 
researchers used this panel to divide patients into adjuvant chemotherapy benefit 
group and adjuvant chemotherapy no benefit group. In the adjuvant chemotherapy 
benefit group, the 5-year OS rate was 80% and 64.5% in the subgroup receiving 
adjuvant therapy compared with the subgroup treated with surgery alone (HR 0.47, 
p = 0.0015). However, in the adjuvant chemotherapy non-benefit group, the 5-year 
OS rates of the two subgroups were 72.9% and 72.5%, respectively (p = 0.71) 
(Cheong et al., 2018). However, this panel was based on retrospective research data 
and needs to be verified in a prospective study. 
In 2010, the ToGA study (Bang et al., 2010) became a milestone for targeted 
treatment of gastric cancer, and trastuzumab became the first-line treatment for 
patients with HER-2 positive metastatic gastric cancer. Later, REGARD (Fuchs et 
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al., 2014) and RAINBOW (Wilke et al., 2014) studies supported the use of 
ramucirumab combined with paclitaxel as a standard drug for second-line treatment 
in patients with metastatic gastric cancer. Additionally, a study by Li et al. supported 
the use of apatinib as a standard drug for third-line treatment of metastatic gastric 
cancer (Li et al., 2016a). Despite this research in the field of targeted therapy has 
also faced some difficulties. The failure of EXPAND (Eatock et al., 2013), REAL3 
(Waddell et al., 2013) and AVAGAST (Van Cutsem et al., 2012) trials has made 
scholars once again recognise the importance of relevant molecular markers and the 
selection of indication populations. 
 
1.1.4.5.1 HER-2 inhibitor 
In 2018 the findings of the JACOB study (Tabernero et al., 2018) were published. 
The study included patients with metastatic gastric cancer with strong positive HER-
2 expression. The results showed that the OS in pertuzumab combined with 
trastuzumab and chemotherapy group was 17.5 months whereas the OS of 
pertuzumab plus chemotherapy group was 14.2 months, and there was no statistically 
significant difference between the two groups (p = 0.057). Although pertuzumab has 
been successful in breast cancer, HER-2 expression in gastric cancer is 
heterogeneous, with weak expression and incomplete membrane staining. The 
pertuzumab group did not show significant survival benefit. 
 
 1.1.4.5.2 Poly-ADP ribose polymerase (PARP) inhibitor 
The GOLD study included patients with metastatic gastric cancer who had 
progressed after or during first-line chemotherapy, compared with treatment with 
olaparib (PARP inhibitor) combined with paclitaxel versus paclitaxel monotherapy. 
In the entire population, the OS of the olaparib group was 8.8 months, and the 
paclitaxel only group was 6.9 months (HR 0.79, p = 0.026). In the ataxia 
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telangiectasia mutated protein (ATM)-negative population, the OS of the olaparib 
group and the paclitaxel group were 12.0 months and 10.0 months (HR 0.73, p = 
0.25). The olaparib group did not show survival benefits (Bang et al., 2017). Olaparib 
has shown efficacy in a phase II study (Study 39) (Bang et al., 2015), especially in 
ATM-negative patients.  The different doses of olaparib in both GOLD and Study 
39 (namely 100mg and 300mg) could possibly be the reason. Other studies of PARP 
inhibitors in other tumour types showed that BRCA (BReast CAncer) mutation or 
gene mutations involved in homologous recombination repair can improve the 
efficacy after using the PRAP inhibitor, but these relationships are not clear in the 
GOLD study and need to be further analysed. 
 
1.1.4.6 Immunotherapy treatment 
Unlike other treatments, immunotherapy aims to fight tumours by activating the 
body's own immune system. It has become the fifth important tumour treatment 
method. The American immunologist James P Alison and the Japanese 
immunologist Tasuku Honjo were awarded the 2018 Nobel Prize for Physiology or 
Medicine in recognition of their pioneering contribution in discovering the braking 
mechanisms of human immune regulation. Gastric cancer research is relatively 
lagging due to strong heterogeneity, insufficient mutation load in tumours, and 
unclear pathogenic mutations. In 2018, due to improvements in the results in gastric 
cancer immunotherapy, the food and drug administration (FDA) approved 
pembrolizumab and nivolumab for the treatment of gastric cancer. 
 
 1.1.4.6.1 Pembrolizumab 
In the KEYNOTE-059 study, Cohort 1 included gastric cancer patients with second-
line or multi-line treatment. The safety and efficacy of 200mg of pembrolizumab 
was evaluated (Fuchs et al., 2018). The results showed an overall response rate (ORR) 
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of 11.6%. Patients were stratified according to the expression level of PD-L1. The 
ORR of the PD-L1 high expression group was 15.5% and the low expression group 
was 6.4%. Compared with third-line apatinib treatment (Ruan et al., 2017), 
pembrolizumab increased ORR (Li et al., 2016a), but whether the OS and PFS are 
prolonged remains to be verified. At the same time, phase III studies related to this 
study have also been initiated (NCT02872116, NCT02743494). The results of 
KEYNOTE-061 showed that the comparison of pembrolizumab with the standard 
second-line paclitaxel treatment has not indicated that pembrolizumab can achieve a 
significant survival benefit. The OS of the two groups was 9.1 months and 8.3 
months (HR 0.82, p = 0.4211). The PFS was 1.5 months and 4.1 months (HR 1.27), 
respectively, and the safety of the pembrolizumab group was significantly better than 
that of the paclitaxel group (Shitara et al., 2018). In addition, subgroup analysis 
showed that patients with high PD-L1 expression or microsatellite instability high 
(MSI-H) may benefit from pembrolizumab treatment. 
 
 1.1.4.6.2 Nivolumab 
The CheckMate-032 study included patients after second-line treatment of 
metastatic gastroesophageal junction cancer. Patients were assigned into three 
groups comparing nivolumab 3mg/kg, nivolumab 1mg/kg combined with 
ipilimumab 3mg/kg and nivolumab 3mg/kg combined with ipilimumab 1mg/kg. The 
results showed that the ORR of the three groups were 12%, 24%, and 8%. The 1-
year PFS rates were 8%, 17%, and 10%, and the 1-year OS rates were 39%, 35%, 
and 24%, respectively. Grade 3-4 adverse events were 17%, 47% and 27%. In 
addition, ORR was not related to PD-L1 expression (Janjigian et al., 2018).  
Although nivolumab 1mg/kg combined with ipilimumab 3mg/kg showed good ORR 
and survival benefit, the adverse events of grade 3-4 toxicity were as high as 47%, 
which limited the clinical practical application of this regimen.  
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At present, other checkpoint inhibitors, tumour vaccines, and adoptive immune cell 
therapies have all shown good prospects for clinical application. Combining targeted 
therapy and chemotherapy to improve efficacy may be the future direction.  
 
1.1.4.7 Future perspectives 
GC is a serious fatal disease. In the past, due to the fact that gastric cancer is not a 
major tumour burden in Western countries, there has been relatively little research 
focusing on GC. However, in recent years, with the continuous and in-depth studies 
from Chinese and other oriental scholars research has advanced and is ongoing. 
Similarly, as discussed in previous sections, advances have been made in standard 
treatments and management of gastric cancer patients. Despite this gastric cancer 
still remains a substantial burden worldwide. As such research into novel biomarkers 
of new potential therapeutic targets, as well as gaining a fuller understanding of the 
biological mechanisms underlying the disease and the development of therapy 
resistance are essential.  
 
1.1.5 Limitations and future therapy design  
Whilst progress has been made in the optimisation and combination of therapies 
available for gastric cancer patients there remains an urgent need to further advance 
this field due to the high mortality and incidence rates associated with this cancer. 
Further work based on understanding the molecular biology and interactions 
involved in this cancer type as well as the identification of novel therapeutic targets 
are needed to improve diagnostic, detection and therapeutic options for patients as 
well as combating therapy resistance.  
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1.2 Sphingosine 1 Phosphate 
The Ceramide-Sphingosine-Sphingiosine-1-phosphate (S1P) rheostat was first 
proposed in 1996 (Cuvillier et al., 1996). In this rheostat (Figure 1.3), Ceramide and 
sphingosine promote cellular apoptosis and S1P leads to cell growth.  
S1P is the key molecule in the Ceramide-Sphingosine-S1P rheostat whose functions 
were recognised approximately 30 years ago (Zhang et al., 1991). S1P is involved in 
wide range of biological function (Sukocheva, 2018), including regulation of cellular 
proliferation (Zhang et al., 2015), survival (Datta et al., 2014), migration (Zhao et 
al., 2015), invasion (Li et al., 2016b) cell differentiation (Romani et al., 2018), 
angiogenesis (Dai et al., 2017), immune cell tracking (Liao et al., 2018) and 
chemoresistance (Matula et al., 2015). 
The Ceramide-Sphingosine-S1P rheostat involves several important enzymes. 
Sphingosine is generated from the deacylation of ceramide, which is also acylated to 
ceramide by ceramide synthase (Ohta et al., 1994). Sphingosine kinases (SphKs), 
present in two isoforms, namely Sphingosine Kinase 1 and Sphingosine Kinase 2 
(SphK1 and SphK2), can catalyse the phosphorylation of sphingosine to synthesise 
S1P (Foss et al., 2009) which is dephosphorylated by S1P phosphatases (SGPPs) to 
sphingosine. S1P also can be secreted from the cell by ATP-binding cassette A1 
(ABCA1) (Sato et al., 2007), ATP-binding cassette C1 (ABCC1) (Mitra et al., 2006), 
ATP-binding cassette G2 (ABCG2) (Takabe et al., 2010) and, subsequently, can 
directly bind to the Sphingosine-1-phosphate receptor 1-5 (S1PR1-5) G protein-
coupled receptors on the cell surface in paracrine or autocrine manners, a process 
termed ‘inside-out’ signalling (Takabe et al., 2008). Furthermore, S1P also can be 
degraded into ethanolamine-1-phosphate and C16 fatty aldehyde through S1P lyase 
(SGPL1) which is the only exit in the entire metabolic pathway (Pyne and Pyne, 
2010, Peest et al., 2008).  
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Hence, the S1P rheostat and S1P signalling have key functions and disruption of this 
can lead to various pathological states including cancer (Gao et al., 2017) Similarly, 
alterations in key enzymes involved in regulating this rheostat can tip the balance 
between apoptosis and proliferation, promoting cell death or survival and having key 
implications in cancer development and progression. A key interest of the current 
study was the implications of SphK1 in gastric cancer. The following sections outline 
the related progress in mechanistic and clinical research surrounding SphK1, 
especially, focusing on the role of SphK1 in tumour growth and drug resistance. 
 
 
 
Figure 1.3 Ceramide-Sphingosine-S1P rheostat 
PHB2, Prohibitin 2; COX, Cytochrome c oxidase ; HDACs, Histone deacetylases ; ABC, 
ATP-binding cassette; PalCoA, palmitoyl-CoA; PE, phosphoethanol-amine; SGPP1, S1P 
phosphatase 1. Figure reproduced from (Kunkel et al., 2013) 
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1.3 Sphingosine Kinases (SphKs) 
There are two Sphingosine kinases, SphK1 (Kohama et al., 1998) and SphK2 (Liu 
et al., 2000), which have been identified and characterised in mammalian cells. Each 
isoform has a differing cellular location with SphK1 predominantly being located in 
the cytoplasm and SphK2 predominantly located in the nucleus, potentially 
implicating differential functions of each isoforms, though there exists the potential 
for both isoforms to move to other subcellular compartments (Taha et al., 2006, 
Alemany et al., 2007, Pyne et al., 2009). In recent years, there have already been 
many orally biological drugs targeting SphK1 and they have also been proved to 
have both anti-tumour (Kreitzburg et al., 2018) and anti-inflammatory (Nagahashi et 
al., 2018b) activity in vivo and in vitro. Thus, as for the treatment of cancer patients, 
SphK1 was regarded as a potential therapeutic target. In the following section, I will 
briefly introduce the role of SphK1 in cancer and cancer treatment. 
 
1.3.1 Structural Characteristics of SphKs 
As discussed above, isoforms of SphKs exist. Furthermore, through molecular 
identification of SphKs, a 49 kDa protein was purified from rat kidney (Olivera et 
al., 1998). Subsequently, two variants, namely SphK1a (382 amino acids) and 
SphK1b (388 amino acids) were cloned and characterised (Kohama et al., 1998).  
In humans, SphK1 is located on chromosome 17q25.2 and SphK2 lies on 19q13.2 
which are produced from distinct genes. Human SphK1 is 384 amino acids is size 
and SphK2 is 618 amino acids in size, with the two isoforms sharing 80% similarity 
and 45% of their sequence identities (Liu et al., 2000). There are five highly 
conserved regions, termed C1 to C5, existing in all known eukaryotic SphKs, and 
these regions are believed to be essential for ATP binding and catalysis (Leclercq 
and Pitson, 2006). A key report by Wang et al (Wang et al., 2013) described the 
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crystal structure of SphK1and provided a new direction to design SphK1 inhibitors, 
which has aided in the development of more effective and specific inhibitors. The 
crystal structure of SphK1 contained 9-364 residues and was composed of a 2 
domain architecture with 9 α helices, 17 β strands and α 310-helix. N-terminal 
domain (NTD) residing 91-50, 357-364 and including C1-C3 domains was α/β 
folded and contains 6α helices and 6β chains. The C-terminal domain (CTD) residing 
151-356 and containing the C4 and C5 domains contained 11 β-chains and 4 helices. 
Analysis of protein sequence motifs and structural classification showed that SphKs 
were classified to the phosphofructokinase (PFK)-like superfamily and shares the 
same protein folds with ceramide kinase (Wang et al., 2013) (Figure 1.4). 
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Figure 1.4 Structure of SphK1. Figure reproduced from (Wang et al., 2013), N-terminal 
domain (NTD), C-terminal domain (CTD). 
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1.3.2 Implication of SphK1 in Cancer Progression and PrognosisIn light of the 
role of SphK1 in generation of S1P and its potential to contribute to cancer many 
studies have focused on exploring the expression of SphK1 in human cancer. These 
studies have collectively demonstrated that the expression levels of SphK1 are 
frequently altered in many different types of human cancers further supporting its 
links to cancer and potential as either a therapeutic target or biomarker (Li et al., 
2008, Kawamori et al., 2006). At the same time, more evidences indicate that high 
expression SphK1 is correlated with poor outcome for cancer patients (Pyne et al., 
2012b, Zhang et al., 2014b).  
 
1.3.2.1 Clinical relevance  
1.3.2.1.1 Gastric Cancer (GC) 
Li et al. (Li et al., 2009) reported that the mRNA and protein levels of SphK1 were 
higher in gastric cancer cell lines than in normal gastric epithelial cells. Compared 
with paired adjacent normal tissues, SphK1 protein levels were upregulated in GC 
tissue. In this study, in total 115 of 175 GC patients (65.7%) showed high expression 
of SphK1 protein, while the expression of SphK1 in adjacent normal gastric tissues 
was undetectable. Furthermore, significant differences in SphK1 expression levels 
were found in patients at different clinical stages (p = 0.003), T stage (p = 0.035), M 
stage (p = 0.020) and venous invasion (p = 0.037). In addition, patient with higher 
SphK1 expression had shorter OS compared with those with lower SphK1 
expression (p = 0.0019), and observed a cumulative 5 year survival rates of patients 
with  high SphK1 expression of 23.85% (95% CI 0.1585-0.3185) in upregulation 
group compared with 49.66% (95% CI, 0.2707-0.5225) in the downregulation group, 
(Li et al., 2009). Subsequently, in a more recent study, Wang et al. analysed the gene 
expression data from the Gene Expression Omnibus (GEO) dataset. In this study 24 
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common differentially expressed genes were screened, in which SphK1 was found 
to have a higher fold change in GC tissues and peripheral blood. The expression of 
SphK1 in tumour tissue was higher than that in normal tissue in one dataset. In 
addition, S1P produced by SphK1 was more prominent in tumour patients’ serum 
than in normal patients’ serum in another dataset (Wang et al., 2018b).  
 
1.3.2.1.2 Colon Rectal Cancer (CRC) 
In CRC, Kawamori et al., (Kawamori et al., 2009) reports that SphK1 was strongly 
stained in 89% (42/47) of colon cancer tissues compared with normal tissues and 
adenoma. At the same time, the expression of SphK1 in colon cancer with metastasis 
was higher than that in colon cancer without metastasis. Furthermore, it was noted 
that mouse model had a higher levels of S1P in the blood with colon cancer compared 
to controls, without colon cancer. Additionally, the SphK1-/- mouse model receiving 
azoxymethane (AOM) had significantly reduced incidence of colon cancer, 
indicating the SphK1/S1P pathway could be a key contributor to colon cancer 
progression and a potential target for cancer therapy (Kawamori et al., 2009). 
Another recent study showed that 92.4% (280/303) of patients showed SphK1 
positive expression in CRC tissues.  About 206 died (67.99%, 206/303) and of these 
patients 193 (93.7%) were SphK1 positive patients. Meanwhile, the expression of 
SphK1 was related to TNM stage (p = 0.042), with SphK1 expression shown to be 
positively related to mortality (Tan et al., 2014). Furuya et al., (Furuya et al., 2017) 
reported that 96% (27 / 28) of mice formed tumours in wild type group, while in the 
SphK1 knockout group, only 59% (17 / 28) of mice formed tumours (p < 0.001) in 
the study of AOM induced colon cancer formation in mice. This result indicated that 
SphK1 played an important role in tumour growth. Furthermore, the staining 
intensity of SphK1 was higher in CRC tissue compared with adjacent normal tissue 
(p = 0.02). 
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1.3.2.1.3 Lung Cancer (LC) 
In LC, one study (Yang et al., 2019) indicated that the mRNA and protein levels of 
SphK1 in Non-small Cell Lung Cancer (NSCLC) tissues were significantly 
increased compared with normal paired tissue and it was noted that the expression 
of SphK1 in late stage was significantly higher than that in early stage. Wang et al. 
(Wang et al., 2019b) study included 1926 NSCLC patients, 720 lung 
adenocarcinoma (Ade) patient and 524 lung squamous cell carcinoma (SCC) patients 
who were followed up 20 years ago from KM plotter database. It showed that high 
expression of SphK1 had a better OS compared with low expression of SphK1 in 
NSCLC (p < 0.0001) and Ade patients (p = 0.014), but not in SCC patients (p < 
0.094). At the same time, evaluating the prognostic value of SphK1with different 
clinical parameters, it was found that SphK1 was a risk factor in stage I and III 
patients, but a protective factor in stage II patients. Furthermore, it was also a risk 
factor in patients receiving chemotherapy or radiotherapy. Another recent study 
(Gachechiladze et al., 2019) showed that SphK1 was stronger stained in cancerous 
tissue than surrounding stroma (p < 0.0001). Interestingly, overexpression of SphK1 
was related to short OS in the postoperative chemotherapy plus in the surgery group, 
while not in surgery alone group (p = 0.035). The same trend has been found in DFS 
analysis, but with no statistical significance (p = 0.09). From this study, it was found 
that high expression of SphK1 was related to the poor prognosis in the chemotherapy 
plus surgery group, but not in surgery alone group. It suggested a role of SphK1 in 
chemotherapy resistance and it could be a good biomarker. However, due to the 
retrospective study and limitation of sample size, more evidence was needed to prove 
the hypothesis. 
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1.3.2.1.4 Breast Cancer (BC) 
In BC, Zhu et al. (Zhu et al., 2017) reported that Sphk1 was upregulated in BC 
patients (p < 0.0001) in which 59.4% of patients showed enhanced mRNA 
expression levels of SphK1 in BC tissue compared to paired normal tissue and the 
expression of SphK1 in 40.6% patients was downregulated. Immunochemical 
analysis found that the patients with SphK1 strong expression, moderate expression 
and weak expression were 32%, 46.7% and 21.3% respectively in 122 BC patients, 
but no SphK1 expression was noted in 15 normal tissues. Overexpression SphK1 
was significantly related to the lymph nodes metastases, positive lymph nodes 
number and distant metastases. Multivariate analysis showed that SphK1 was an 
independent prognosis factor of OS (HR 0.196; 95% CI 0.058‐0.655; p = 0.0081). 
Another study (Acharya et al., 2019) reported that the expression of SphK1 was 
related to poor relapse-free survival (RFS) in triple negative breast cancer (TNBC) 
patients. The transcript levels of SphK1 were highly expressed in TNBC-derived cell 
lines. These results indicate that SphK1 may play an important role in BC and might 
serve as a predictor. Acharya et al. (Acharya et al., 2019) reported that the mRNA 
expression of SphK1 in TNBC was higher than that in paired normal tissue through 
analysing the GEO data (GSE27447). At the same time, using TCGA data to verify 
the hypothesis, the expression of SphK1 in TNBC was significantly higher than that 
in normal tissue. Furthermore, the high expression of SphK1 was related to the poor 
RFS. At the same time, high expression of SphK1 was found at both mRNA and 
protein levels in TNBC derived cell lines. 
 
1.3.2.1.5 Other types of Cancer  
Li et al. (Li et al., 2008) reported that compared with adjacent non-cancerous brain 
tissue, both mRNA and protein levels of SphK1 were increased in primary 
astrocytomas. The high SphK1 expression was found in astrocytoma tissues (41.2%, 
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100 /243). The OS of patients who had high SphK1 protein levels was reduced (18 
months) compared to patients who had low SphK1 protein levels (40 months). Hence 
this work highlights that the upregulation of SphK1 may be an independent 
prognostic indicator of survival for astrocytoma patients (Li et al., 2008). A study 
from Li et al. (Li et al., 2016c) showed that the protein expression level of SphK1 
was significantly elevated in pancreatic cancer tissue compared with normal tissue. 
SphK1 high expression was related to OS (p < 0.001) of pancreatic cancer patients 
and different clinical parameters. Interestingly, SphK1 was associated with clinical 
stage not only in early stage, but also in late stage. Furthermore, SphK1 was an 
independent prognostic factor of pancreatic cancer patients (HR 1.395, 95% CI 
1.107-1.758, p = 0.005). All of these indicated that SphK1 may serve as a prognosis 
biomarker of pancreatic cancer patients.  
 
1.3.2 Intracellular function 
SphK1 has been demonstrated to play a significant role in regulating oncogenesis, 
and its biological functions are associated with tipping the balance between apoptotic 
(Guillermet-Guibert et al., 2009) and pro-survival signalling (Akao et al., 2006, 
Pchejetski et al., 2005). Wang et al (Wang et al., 2018b) reported that knockdown of 
SphK1 inhibited cell invasion, migration, apoptosis and proliferation, leading to cell 
cycle arrest in vitro, as well as inhibited tumour growth in vivo. Furthermore, it was 
found that miR-330-3p could target the promoter region of SphK1 and inhibit the 
growth of tumour cells. The same effect could be observed using inhibitors (FTY720, 
Fingolimod). These studies indicated that SphK1 was expected to become a new 
molecular marker and a new therapeutic target for GC. Another study (Kohno et al., 
2006) reported that mechanistically, knockdown of SphK1 reduced the expression 
of Cyclooxygenase-2 (COX-2) expression and prostaglandin E2 (PGE2). On the 
contrary, overexpression of SphK1 increased the expression of COX-2. SphK1 
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increase colon carcinogenesis by regulating the expression of COX 2 and PGE2. 
Furthermore, Knockdown of SphK1 inhibits cell growth, proliferation, migration, 
and invasion, and increases apoptosis. In addition, knockdown of SphK1 expression 
inhibited tumour growth in an animal model. Mechanistically, silencing SphK1 
could inhibit the extracellular signal-regulated kinase (ERK) signalling pathway 
(Yang et al., 2019). It has been reported that SphK1 is the direct target of Micro-
RNA-28-5p (miR-28-5p). miR-28-5p negatively regulated SphK1 and SphK1 
promoted the growth, apoptosis and invasion of tumour cells in vitro (Chen et al., 
2019). Acharya et al. (Acharya et al., 2019) also reported that high expression of 
SphK1 resulted in increased the lung metastasis tumour size in vivo. It was also found 
that SphK1 through regulating the downstream gene Fascin1 (FSCN1) regulated 
TNBC cell proliferation and apoptosis. The expression of SphK1 and FSCN1 was 
consistent in expression patterns in TNBC tumour. The following study showed that 
SphK1 regulated the NF-κB signalling pathway by regulating the transcription of 
FSCN1. However, the SphK1 / FSCN1 / NF-κB signalling pathway was related to 
the poor prognosis of TNBC patients (p = 0.003). Using small molecule targeted 
drugs to inhibit SphK1 and NF-κB reduced the size of primary tumour and lung 
metastasis (Table 1.3).  
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Table 1.3 Expression of SphK1 in different type of cancer 
Tissue Sample N Comments O
S 
Refs 
Gastric 
cancer 
mRNA 4 Increased in tumour compared with paired 
normal tissue. 
Y (Li et 
al., 
2009) Protein 175 65.7% of patients had high SphK1 in the 
cancer lesion compared with adjacent 
normal tissue. Patient survival reduced 
when expression of SphK1 is high 
mRNA 3 SphK1 in tumour tissue was higher than 
that it is in normal tissue.  
N (Wang 
et al., 
2018b) Serum 3 S1P produced by SphK1 was more 
expressed in tumour patients’ serum than 
its in normal patients’ serum. 
Protein 136 44.1% of patients had high pSphK1 
(Ser225) in the gastric cancer tissue 
compared with adjacent normal tissue. 5 
year OS rate is 79.3 versus 98.3%. 
Y (Hanyu 
et al., 
2018) 
Breast 
cancer 
mRNA 1269 SphK1 expression increased in tumour 
samples. Reduced DFS with high SphK1 
expression in whole patient cohort. 
Y (Ruckh
aberle 
et al., 
2008) 
Protein 304 High SphK1 expression in ER+ patient 
tumours tissues were related to DFS. 
Y (Long 
et al., 
2010) 
mRNA 32 59.4% patients of SphK1expression was 
increased and the expression of SphK1 in 
40.6% patients was downregulated 
Y (Zhu et 
al., 
2017) 
Protein 122 SphK1 was an independent prognosis 
factor of OS 
mRNA 56 The mRNA expression of SphK1 in TNBC 
was higher than that in paired normal 
tissue  
Y (Achar
ya et 
al., 
2019) 
Lung 
cancer 
Protein 25 5 carcinoid, 10 squamous and 10 
adenocarcinoma samples. All had high 
SphK1 expression compared with normal 
matched tissue 
N (Johnso
n et al., 
2005) 
173 Overexpression of SphK1 was related to 
short OS in postoperative chemotherapy 
plus surgery group, while not in surgery 
alone group (Gachechiladze et al., 2019) 
Y (Gache
chiladz
e et al., 
2019) 
mRNA 31 The levels of SphK1 in NSCLC tissues 
were significantly increased compared 
with paired normal tissue 
N (Yang 
et al., 
2019) 
Protein 
mRNA 3170 High expression of SphK1 had a better OS 
compared with low expression of SphK1 
in NSCLC and Ade patients, but not in 
SCC patients  
Y (Wang 
et al., 
2019b) 
Colon 
cancer 
Protein 28 (75%) of adenocarcinomas had positive 
SphK1 stain 
N (Kohno 
et al., 
2006) 
47 42/47(89%) of colon cancers had higher 
SphK1 expression compared with normal 
colon tissue 
N (Kawa
mori et 
al., 
2009) 
303 92.4% (280/303) patients showed SphK1 
positive expression in CRC tissues. 
Y (Tan et 
al., 
2014) 
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90 The stain intensity of SphK1 was higher in 
CRC tissue compared with adjacent 
normal tissue (p = 0.02) 
N (Furuy
a et 
al., 
2017) 
Sacral 
chordo
ma 
cancer 
 
Protein 58 69% (29/42) showed high expression of 
SphK1, whereas 19% (3/16) normal tissues 
showed a high expression of SphK1 (p = 
0.001). High expression of SphK1 was 
related to shorter DFS. 
Y (Zhang 
et al., 
2014a) 
Uterine 
cervica
l cancer 
 
Protein 
 
287 
 
High SphK1 expression was associated 
with different clinical parameters and OS. 
Y (Kim et 
al., 
2015) 
Pancre
atic 
cancer 
Protein 
 
388 SphK1 was significantly elevated in 
pancreatic cancer tissue compared with 
normal tissue. SphK1 high expression was 
related to OS (p < 0.001) 
Y (Li et 
al., 
2016c) 
Adreno
cortical 
carcino
ma 
 
mRNA 20 SphK1 expression was correlated with 
tumour size (p = 0.001) and OS (p = 0.03), 
Y 
 
(Xu et 
al., 
2016) 
Protein 46 
Table modified from from (Pyne and Pyne, 2010) 
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1.3.3 Implication of SphK1 in chemotherapeutic resistance  
Surgery alone is no longer considered to be the standard treatment (Cunningham and 
Chua, 2007). A combination of radical surgery with individualised perioperative 
chemotherapy (Al-Batran et al., 2016), postoperative chemotherapy (Sasako et al., 
2011), radiotherapy (Lee et al., 2012b) and optimum target therapy (Bang et al., 2010) 
has been accepted as the optimum treatment for GC. However, there are still 
problems with this comprehensive treatment, that is, the cellular resistance to 
chemotherapy. As we can see in clinical practice, not all patients benefit from 
chemotherapy, therefore, identifying the patients who can benefit from 
chemotherapy in advance and clarifying the mechanism of chemoresistance has 
become the hot topic in the area of GC treatment (Cheong et al., 2018).  
In recent years, research has indicated that chemotherapy resistance occurs when the 
expression of SphK1 is enhanced, such as, si-SphK1 significantly increased 
chemosensitivity of AsPC-1 and PANC-1 cells to gemcitabine. (Li et al., 2016c). 
Furthermore, downregulated expression of SphK1 sensitised the function of 
docetaxel and camptothecin in LNCaP and PC-3 cells (prostate cancer cells), 
respectively (Pchejetski et al., 2008). Similarly, enhanced SphK1 activity was 
demonstrated to result in daunorubicin resistance in leukaemia cells (Sobue et al., 
2008), cisplatin resistance in lung cancer cells (Min et al., 2005) docetaxel resistance 
in prostate cancer cell (Alshaker et al., 2016) and oxaliplatin resistance in colon 
cancer cells (Nemoto et al., 2009). Furthermore, an additional study has 
demonstrated the ability of SphK1 to bring about the overexpression of transcript 
levels of the downstream transcription factor, E2F7, mediating the chemoresistance 
of anthracycline in head and neck squamous cell carcinomas (HNSCC) (Hazar-
Rethinam et al., 2015). Another study has demonstrated the capacity of a SphK 
inhibitor to repair the resistance to etoposide and doxorubicin through inducing 
apoptosis, a finding that is identical to the observation that reduced ceramide 
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accumulation and sustained SphK1 activity may result in chemotherapeutic 
resistance (Heffernan-Stroud and Obeid, 2013). Yang et al. (Yang et al., 2014) 
reported that the expression of SphK1 in drug-resistant cells H69AR was 
significantly higher than that in H69. Downregulating the expression of SphK1 in 
H69AR increased the sensitivity of cells to chemotherapeutic drugs, promoted cell 
apoptosis and G0 / G1 phase arrest in the cell cycle. The expression of SphK1 in 
lung cancer chemo-resistant patients was significantly increased compared with 
those in sensitive patients. The expression of SphK1 was significantly related to the 
stage, sensitivity to chemotherapy and OS (p < 0.05) (Yang et al., 2014). 
A relationship between bioactive sphingolipid levels and drug resistance may 
possibly contribute to the relationship between SphK1 and the sensitivity of cancer 
cells to chemotherapeutics and radiotherapeutics. Indeed, daunorubicin sensitivity, 
linked with low S1P and high ceramide levels, could be recovered in daunorubicin-
resistant cells line if SphK1 activity was inhibited (Sobue et al., 2008). This 
suggested that the ceramide-sphingosine-S1P rheostat played a significant role in 
daunorubicin-induced cytotoxicity. Hence, taken together with the previous 
examples, it was clear that SphK1 played a biologically significant role in 
chemotherapeutic drug resistance. However, the mechanism related to SphK1 in 
chemotherapeutic drug resistance is still not fully understood. 
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Table 1.4 Chemotherapy resistance of SphK1 in different type of cancer 
Drug Cancer 
type 
Vivo 
or 
Vitro 
Comment Ref 
Docetaxe
l and 
Camptot
hecin 
Prostate 
cancer 
(PC-3 and 
LNCaP) 
In 
vitro/ 
in 
vivo 
High expression of SphK1 inhibited 
sensitivity of Docetaxel/Camptothecin  
(Pche
jetski 
et al., 
2005) 
Camptot
hecin 
Prostate 
cancer 
(PC-3 and 
LNCaP) 
In 
vitro 
The treatment of PC3 cells with 
Camptothecin induced up-regulation of the 
SphK1  
(Aka
o et 
al., 
2006) 
Daunoru
bicin 
 
Leukaemia 
 
In 
vitro 
Inhibited SphK increased the daunorubicin-
sensitivity of daunorubicin-resistant cells. 
(Sobu
e et 
al., 
2008) 
Docetaxe
l and 
Camptot
hecin 
 
Prostate 
cancer 
(PC-3 and 
LNCaP) 
In 
vitro/ 
in 
vivo 
SphK1 inhibiter sensitized LNCaP and PC-3 
cells to docetaxel and Camptothecin. 
(Pche
jetski 
et al., 
2008) 
Gemcita
bine 
Pancreatic 
cancer 
(BxPC-3 
and Panc-
1) 
In 
vitro 
A high level of SphK1was associated with a 
robust intrinsic pancreatic cancer cell 
chemoresistance toward gemcitabine. 
(Guill
ermet
-
Guibe
rt et 
al., 
2009) 
5-FU CRC 
(HCT-116, 
RKO, 
SW480 
and 
SW620) 
In 
vitro 
With 5-FU treatment, the siRNA-SphK1 
treated HCT116 cells exhibited dose-
dependent cytotoxicities. 
 
(Tan 
et al., 
2014) 
Oxaliplat
in, 
Cisplatin 
and 
Docetaxe
l 
 
Oesophage
al and 
gastric 
cancer 
(OE21, 
OE33 and 
AGS) 
In 
vitro 
 
Drug resistance was associated with 
increased SphK1 expression.  
(Matu
la et 
al., 
2015) 
Doxorubi
cin 
 
Head and 
neck 
squamous 
cell 
carcinomas 
(HNSCC) 
In 
vitro/ 
in 
vivo 
SphK1 as a potential mediator of E2F7-
dependent drug resistance, due to E2F7-
deficient keratinocytes were selectively 
sensitive to doxorubicin. 
(Haza
r-
Rethi
nam 
et al., 
2015) 
Gemcita
bine  
 
Pancreatic 
cancer 
(AsPC-1 
and 
PANC-1)  
In 
vitro 
si-SphK1 significantly increased 
chemosensitivity of AsPC-1 and PANC-1 
cells to gemcitabine. 
(Li et 
al., 
2016c
) 
Docetaxe
l  
 
Prostate 
cancer 
(PC-3) 
In 
vitro 
Overexpression of SphK1 cells had 
significant resistance to docetaxel. 
(Alsh
aker 
et al., 
2016) 
  
47 
 
1.3.4 Therapeutic implication of SphKs targeted therapy 
As outlined in previous sections, SphK1 has been strongly linked to contributing to 
cancer development and progression, through its capacity to influence traits such as 
proliferation and chemotherapy resistance and is frequently dysregulated in 
numerous human cancers. Hence SphK1 has been subject to intense scientific study 
as a potential therapeutic target. There have already been many biological inhibitors 
developed targeting SphK1 and these have demonstrated both anti-tumour (French 
et al., 2006) and anti-inflammatory activity in vivo (Maines et al., 2008). Furthermore, 
a number have progressed to clinical trials. A number of such examples are outlined 
in the following section and Table 1.5.  
 
1.3.4.1 Sonepcizumab 
The anti-S1P antibody sonepcizumab targeting anti-VEGF therapy refractory renal 
clear cell carcinoma (RCC) patients has been evaluated in a phase II clinical trial 
(Pal et al., 2017). In this study, 40 RCC patients who had previously received a 
median of 3 therapy courses were involved in this multi-centre trial. The results 
showed that the OS was 21.7 months, however, it did not achieve the primary end 
point based on 2 months PFS (Pal et al., 2017). Although 10% of patients showed a 
partial response with median duration response of 5.9 months with no major toxicity, 
its efficacy in metastatic RCC was not impressive. However, there is need of future 
studies to focus on the way that systemic S1P induces tumour growth and metastasis 
and using lipid-specific antibodies in patients to improve the neutralisation of 
systematic S1P signalling.  
 
1.3.4.2 Sphingosine Kinase 1 Inhibitor (SK1-I) 
SK1-I, a sphingosine analogue and competitive inhibitor of SphK1, has been 
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reported to be able to decrease glioblastoma growth and proliferation in cell lines 
and mouse models (Kapitonov et al., 2009). Another study showed that SK1-I can 
induce the phosphorylation of tumour protein (TP53) at Ser15, activating the 
downstream pro-apoptosis B-cell lymphoma-2 (BCL-2) family. Importantly, the 
downregulation of Beclin-1 (BECN1) and autophagy related 5 (ATG5), the key 
regulators of autophagy, significantly reduced the cytotoxicity of SK1-I in cancer 
cells (Lima et al., 2018). A further study has indicated that SK1-I could inhibit the 
production of SphK1 in a mouse model, reduce the burden of primary tumours, the 
degree of lymph node metastasis and lung metastasis. In conjunction with this, the 
study also demonstrated the capacity of SK1-I to reduce peritumoral lymphatic 
vessel density in vivo (Nagahashi et al., 2012). SK1-I was a sphingosine analogue 
and a competitive inhibitor of SphK1, but its effect was still in preclinical research, 
thus more safety and effectiveness data were needed to confirm the anti-tumour 
function. 
 
1.3.4.3 PF543 
In addition, another specific small inhibitor, named PF-543, a powerful SphK1 
selective inhibitor which has 100 times greater affinity for SphK1 over SphK2 
(Schnute et al., 2012) has also been utilised as a therapeutic for targeting SphK1. 
However, PF543 was originally reported to be lacking in cytotoxicity in cancer cells 
(Wang et al., 2014c). Subsequently, PF543 has been shown to reduce S1P in cancer 
cells, but did not inhibit cell growth (Paugh et al., 2008). PF543 having no effect on 
cell growth may be due to its inability to produce ceramides that promote apoptosis 
(Paugh et al., 2008). However, recent studies have demonstrated PF543 efficacy 
where it inhibited the growth and proliferation in TNBC,  CRC  cells and in xenograft 
mouse models (Ju et al., 2016). This controversy may be due to the different tissue 
types. PF-543 has also be shown to induce programmed necrosis, through regulating 
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the expression level of lactate dehydrogenase (LDH) release, mitochondrial 
membrane potential collapse and mitochondrial P53-cyclophilin-D (Cyp-D) 
complexation. Furthermore, PF543 reduced the growth of cancer cell significantly 
in vivo (Ju et al., 2016). 
 
1.3.4.4 Fingolimod (FTY720) 
The structure of fingolimod (FTY720) was first discovered in 1995 (Cordi et al., 
1995). A sphingosine analogue drug, FTY720 was approved by the American FDA 
for the treatment of multiple sclerosis (MS) in 2010 (Cohen et al., 2010). FTY720 
can be phosphorylated by SphK2 to generate P-FTY720, functionally acting as an 
antagonist of S1PR1, though FTY720 and P-FTY720 possess significantly different 
biological functions, with FTY720 suppressing the function of SphK1 which 
performs related functions through the S1PR1 signalling pathway (Brinkmann et al., 
2002). A subsequent study by Saddoughi et al. (Saddoughi et al., 2013) showed that 
FTY720 mediated protein phosphatase 2A (PP2A)/Receptor-interacting 
serine/threonine-protein kinase 1 (RIPK1)-dependent programmed necrosis through 
targeting I2PP2A/SET and inhibited lung tumour growth (Saddoughi et al., 2013). 
Similarly, a more recent study highlighted the efficacy of FTY720 in ovarian cancer. 
In their study Kreitzburg et al. (Kreitzburg et al., 2018) showed that FTY720 
increased the sensitivity of tumour cells to carboplatin and tamoxifen in vitro. 
FTY720 combined with carboplatin or tamoxifen effectively inhibited tumour 
growth and was able to shrink tumour size in vivo, compared with single drug alone, 
effects that were mechanistically suggested to result from the capacity of FTY720 to 
induce the production of ceramide, enhancing apoptosis (Kreitzburg et al., 2018). 
Overall, it can be concluded from the above studies that creative strategies like 
inducing ceramide or inhibiting S1P metabolism and/or signalling, through strategies 
such as targeting SphK1 have great potential as future anticancer therapies. The 
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development and efficacy testing of small molecule inhibitors to SphK1 and related 
pathways represents a key step in clinical application of such therapies. Scientific 
attention is required to refine improve and fully comprehend the mechanistic actions 
of these therapies.  
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Table 1.5 Small inhibitor of SphK1 in different cancer type 
Drug Cancer Type Vitro/ 
Vivo 
Comments Refs 
MP-A08 Embryonic 
kidney 
(HEK293),Lu
ng cancer 
(A549) Breast 
cancer 
(MCF7) 
In 
vitro/ 
In vivo 
MP-A08 reduced the growth of human 
lung adenocarcinoma tumours in a 
mouse xenograft model. 
(Pitm
an et 
al., 
2015) 
Safingol Esophageal 
and gastric 
cancer (OE21, 
OE33 and 
AGS) 
In vitro 
 
Safingol a SphK1 inhibitor, was 
cytotoxic as a single agent and acted 
synergistically with cisplatin in gastric 
cancer cell lines. 
(Matu
la et 
al., 
2015) 
SKI-II 
(2-(p-
hydroxya
nilino)- 
4-(p-
chloroph
enyl)thia
zole) 
Gastric cancer 
SGC7901e 
In vitro The results showed that SKI-II 
reversed the drug resistance in human 
GC cells and enhanced the antitumor 
effect of DDP. 
(Liu 
et al., 
2014) 
Multiple 
Myeloma 
(MM)  
 
In 
vitro/ in 
vivo 
Combination FTY720 with SKI-II 
resulted in synergistic inhibition of 
MM growth.  
 
(Beid
er et 
al., 
2017) 
SK1-I 
(BML-
EI411) 
 
Glioblastoma In 
vitro/ in 
vivo 
SK1-I decreased glioblastoma growth 
and proliferation in vitro and in vivo. 
(Kapi
tonov 
et al., 
2009 
Breast Cancer  In vivo SK1-I to reduce peritumoral lymphatic 
vessel density in vivo. 
(Naga
hashi 
et al., 
2012) 
Head and neck 
squamous cell 
carcinomas 
(HNSCC) 
In 
vitro/ in 
vivo 
SK1-I enhanced the sensitivity of SCC 
cells to doxorubicin in vitro and in 
vivo. 
(Haza
r-
Rethi
nam 
et al., 
2015) 
Colon Cancer 
(DLD, HT29) 
Brest Cancer 
(MCF7, 
BT474),  
Lung Cancer 
(H460)  
In vitro SK1-I induced the phosphorylation of 
TP53 at Ser15, activating the 
downstream BCL-2 family, 
significantly reduced the cytotoxicity 
of SK1-I in cancer cells. 
(Lima 
et al., 
2018) 
Fingolim
od 
(FTY720
) 
Lung Cancer In vitro FTY720 mediated PP2A/RIPK1-
dependent programmed necrosis 
through targeting I2PP2A/SET and 
inhibited lung tumour growth. 
(Sad
doug
hi et 
al., 
2013 
Ovarian 
cancer 
(COV362, 
CAOV3)  
 
In 
vitro/ in 
vivo 
FTY720 increased the sensitivity of 
tumour cells to carboplatin and 
tamoxifen in vitro.  
(Krei
tzbur
g et 
al., 
2018
) 
Multiple 
Myeloma 
(MM)  
In 
vitro/ in 
vivo 
Combination FTY720 with SKI-II 
resulted in synergistic inhibition of 
MM growth.  
(Beid
er et 
al., 
2017) 
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PF543 CRC (HCT-
116) 
In 
vitro/ in 
vivo 
PF-543 intravenous injection 
significantly suppressed HCT-116 
xenograft tumour growth. 
(Ju et 
al., 
2016) 
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1.3.5 SphK1 and downstream signalling pathway 
As implicated previously, SphK1 has the potential to play an important role in 
regulating oncogenesis (Akao et al., 2006, Pchejetski et al., 2005). In keeping with 
this, a number of studies have demonstrated the connection between SphK1 
upregulation and the development of malignant phenotypes of various cancers, such 
as proliferation (Yuza et al., 2018), anti-apoptosis (Tsukamoto et al., 2015), 
angiogenesis (Dai et al., 2017), migration (Yuza et al., 2018) and invasion (Yuza et 
al., 2018). Early indications of SphK1’s role in cancer were reported by Xia et al. 
(Xia et al., 2000) who demonstrated overexpression of SphK1 could increase its 
enzyme activity and promote growth in vivo and in vitro. The group also found that 
SphK1 was involved in the regulation of Harvey Rat Sarcoma Viral Oncogene 
Homolog (HRAS) signalling pathway, which could be suppressed by the 
overexpression of the G82D dominant-negative kinase SphK1 mutant. These early 
findings were key in defining SphK1 as an oncogene.  
Yin et al. (Yin et al., 2019) reported that GC cells promoting autophagy in human 
peritoneal mesothelial cells (HPMCs), was inhibited by blocking TGF-β1 secreted 
by GC cells, while inhibition of SphK1 expression in HPMC can inhibit TGF-β1-
induced autophagy. SphK1 regulates HPMC autophagy and promotes the growth of 
GC cells in vitro and in vivo. Overexpression of SphK1 can induce fibrosis in 
HPMCs. Mechanically, elevated SphK1 levels promoted tumour bioactive 
sphingolipid dysregulation, of which ceramide decreased and S1P increased (Yin et 
al., 2019).  
Furthermore, in addition to the clinical expression profiling described in the previous 
sections, Wang et al., also explored the functional implications of SphK1 in GC in 
vitro and in vivo (Wang et al., 2018b) Silenced SphK1 significantly inhibited the 
proliferation, migration, and invasion in cells line. Silencing the expression of 
SphK1 also blocked the cell cycle and induced apoptosis in cell lines, inhibiting 
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tumour growth and suppressing S1P levels at the same time. Furthermore, 
knockdown of SphK1 also inhibited tumour growth in vivo. The same study showed 
that miR-330-3p directly targets SphK1 playing an anti-tumour role. miR-330-3p 
could inhibit the tumour growth in vivo. Furthermore, using chemical inhibitors, such 
as FTY720 (SphK1 inhibitor) and VPC23019 (S1PR1 inhibitor), inhibited the 
expression of SphK1 and S1PR1 and exerted antitumor effects in vivo and in vitro 
(Wang et al., 2018b). 
Another study demonstrated that the deletion of SphK1 inhibited the growth of 
thymic lymphomas in p53 null mice and extended the survival time. SphK1 enhances 
the expression of sphingosine and ceramide, in order to mediate P53 tumour 
surppressive role in cancer, and also influence the cell cycle process and 
chemosensitivity (Heffernan-Stroud et al., 2012). The study of Liu et al. (Liu et al., 
2019) indicated that SphK1 was overexpressed in colon cancer, which affected the 
prognosis, metastasis and survival of patients. SphK1 affected the metastasis through 
affecting cancer cell epithelial-to-mesenchymal transition (EMT). At the same time, 
elevated expression of SphK1 promoted the expression of phosphorylated focal 
adhesion kinase (p-FAK), p-protein kinase B (AKT) and matrix metalloproteinase 
2/9 (MMP2/9). FAK small inhibitors inhibited the expression of the above proteins 
and the inactivation of FAK signalling pathways (Liu et al., 2019). 
In recent years, research discovered that SphK1 is a target of microRNA (miRNA), 
and that this will subsequently impact many downstream signalling pathways. A 
study by Wang et al., (Wang et al., 2019a) demonstrated that miR-506-3p directly 
targeted and inhibited SphK1 expression in osteosarcoma. In this study, transfection 
with miR-506-3p mimics reduced the ability of invasion of osteosarcoma cell lines, 
which could be subsequently reversed through SphK1 overexpression. Furthermore, 
miR-506-3p played an important role in mesenchymal to epithelial transition (MET) 
and autophagy. Similarly, a study by Cao et al., (Cao et al., 2019), also highlighted 
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a link between SphK1 and miR-128 in papillary thyroid cancer (PTC) and follicular 
thyroid carcinoma (FTC) (Cao et al., 2019). In this study SphK1 was identified as a 
target of miR-128 and the expression of SphK1 was reduced in PTC and FTC tissues 
where it notably showed a negative correlation with miR-128 expression. 
Additionally, the inhibitory effect of miR-128 on growth rate and tumour weight 
identified using in vivo models also appeared to suppress SphK1 expression 
suggesting that SphK1 plays an important role in the occurrence and development of 
cancer and affects different signalling pathways. 
Nuclear Factor Kappa B (NF-κB) is well established as a key signalling pathway in 
apoptosis and as being involved in cancer development and progression (Zhang et 
al., 2017). In keeping with SphK1’s role, links between SphK1 and NF-κB have been 
previously observed. One such study by Alvarez et al. (Alvarez et al., 2010) have 
demonstrated a role for SphK1/S1P in apoptosis through regulation of NF-κB 
signalling by ubiquitination of tumour-necrosis factor (TNF) receptor-associated 
factor 2 (TRAF2), the lysine 63-lpolyubiquitination of receptor-interacting 
serine/threonine-protein kinase 1 (RIP1), phosphorylation of inhibitor of NF-κB 
kinase (IκB kinase), inhibitor of NF-κB (IκBa) and the degradation of IκBa (Alvarez 
et al., 2010). Further links have also been demonstrated in a subsequent study by 
Liang et al. (Liang et al., 2013) indicating that overexpression of SphK1 and 
subsequent upregulation of S1P drives a persistent amplification loop from SphK1 / 
S1P / S1PR1 to NF-kB / IL-6 / STAT3 (Liang et al., 2013). 
 
1.4 Sphingosine 1 phosphate receptors (S1PRs) 
S1P regulate a variety of biological functions through binding to its receptors, the 
Sphingosine 1 phosphate receptors (S1PRs). S1PR1 was the first receptor identified 
in this family, discovered in 1990 and initially named endothelial differentiation 
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gene 1 (EDG1) (Hla and Maciag, 1990). Subsequently, the other 4 receptors in this 
group (S1PR2-S1PR5) were identified in the following years. These five receptors 
are expressed in different tissues and cells (Takabe et al., 2008) and have different 
biological functions (Brocklyn, 2010), but they all have a high affinity for 
extracellular S1P. The S1PR receptors are members of the G-protein coupled 
receptors (GPCRs), and widely exist in many types of cells (Jeffery et al., 2011). 
Due to the role in cancer progression, an increasing scientific interest has been 
focused on establishing the functions of the S1PRs family in a variety of cellular 
processes, including cell differentiation, migration, survival, angiogenesis, calcium 
homeostasis, inflammation and immunity which is further highlighted in section 
1.4.2. 
 
1.4.1 Structural Characteristics of S1PRs 
S1PR1 is a 382 amino acids GPCR which includes a heterotrimeric G protein 
consisting of α, β and γ subunits to transduce intracellular signalling.  Due to β and 
γ subunits being similar, G proteins are assorted into four different groups Gs, Gi/o, 
Gq/11, and G12/13 based on the difference of α subunit. S1PR1 through the binding 
of Gi and β-arrestin, allows binding of src proto-oncogene, non-receptor tyrosine 
kinase (Src) leading to receptor internalization mediated activation of downstream 
pathways (Pyne and Pyne, 2017). 
S1PR1 consists of 3 parts (Parrill et al., 2000) 
• Seven hydrophobic transmembrane a-helices (TM1-TM7) 
• Three extracellular loops on N terminus (ECL1-ECL3) 
• Three intracellular loops on C terminus (ICL1-ICL3) 
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1.4.2 Function and signalling of S1PRs 
1.4.2.1 The function of S1PR1 
In recent years, many studies have suggested that abnormal regulation or signalling 
of the Interleukin-6 (IL6)-Janus kinase (JAK)-Signal transducer and activator of 
transcription (STAT3) signalling pathway in tumours can be defined as a key 
mechanism for the initiation and progression of cancer (Bollrath et al., 2009, 
Grivennikov et al., 2009, Hedvat et al., 2009). S1PR1, a Gi family protein, was a key 
receptor found to be expressed on T and B lymphocytes (Jeffery et al., 2011). Many 
studies also have indicated that S1PR1 has an important role in mediating the 
activations of IL6-JAK-STAT3 signalling pathway (Priceman et al., 2014). S1PR1 
promoted the accumulation of regulatory T cells (Tregs) in tumours, thereby 
affecting the recruitment and activation of CD8+T cells. In addition, S1PR1 in 
CD4+T cells activated STAT3 and JAK/STAT3-dependent Treg migration 
(Priceman et al., 2014). Another study showed that the expression of S1PR1 was 
significantly increased in STAT3-positive tumours. The same study showed that 
STAT3 was a transcription factor of S1PR1. STAT3 regulated the expression of 
S1PR1, accelerating the growth and metastasis of tumours in a STAT3-dependent 
manner. On the contrary, tumour STAT3 activity, tumour growth and metastasis are 
suppressed if S1PR1 function is lost. S1PR1 can also activate JAK2 while activating 
STAT3. Hence, S1PR1 signalling regulation of STAT3 activity, seemed a major 
positive feedback loop for persistent STAT3 activation in cancer cells and the 
tumour microenvironment as well as for malignant progression (Lee et al., 2010).  
Scientific research has also emphasised the importance of myeloid cells in distant 
metastasis of tumour cell colonies. A study by Deng et al. (Deng et al., 2012) has 
shown that upregulation of S1PR1-STAT3 in tumour cells induced activation of 
S1PR1-STAT3 in various cells at the primary tumour site before metastasis, leading 
to the formation of a niche before metastasis. Targeting S1PR1 or STAT3 in myeloid 
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cells can disrupt the existing pre-metastatic niche. The S1PR1-STAT3 pathway 
enables myeloid cells to enter blood vessels, trigger distant organ 
microenvironments, and mediate the continued proliferation and survival of 
themselves and other stromal cells in future metastatic sites. The same study also 
demonstrated, through analysis of tumour-free lymph nodes from cancer patients, 
increased myeloid infiltration, increased STAT3 activity and survival signals (Deng 
et al., 2012).  
More recently, a study by Pi et al., demonstrated that elevated miR-302-367 levels 
in endothelial cells reduced angiogenesis and promoted vascular stability in vivo and 
in vitro. As part of this study, it was shown that down-regulation of ERK1/2 in 
endothelial cells increased miR-302-367 expression and inhibited expression of 
S1PR1, supressing angiogenesis and improving blood vessels stability. In contrast, 
blocking S1PR1 in endothelial cells had anti-angiogenic and anti-vascular 
stabilisation effects in mouse model. Therefore, S1PR1 was shown to have a crucial 
role in tumour angiogenesis (Pi et al., 2017).  
Taken together, S1PR1 appears to be linked to processes and signalling pathways 
involved in cancer development and progression and hence, S1PR1 may be a 
potential therapeutic target in the treatment of various tumours.  
 
1.4.2.2 S1PR1 and Clinical significance 
It has been difficult to target STAT3 therapeutically (Hong et al., 2015), as outlined 
above, STAT3 induced S1PR1 transcription, could result in STAT3 and IL-6 
continued activation. This unique S1PR1-dependent axis may be an attractive 
intervention target, as some reports suggest that disruption of the S1PR1 signal 
eliminates this cycle of STAT3 amplification. 
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A study by Nagahashi et al., (Nagahashi et al., 2018b) highlighted the potential of 
targeting the SphK1/S1P/S1PR1 axis with FTY720 to alleviate tumour progression 
caused by pro-inflammatory cytokines and macrophage infiltration. During this 
study they demonstrated that S1P produced by tumour-induced SphK1 in the pre-
metastatic niche increased recruitment of macrophages to the lung and induced IL-6 
signalling pathways important for breast cancer lung metastasis. In contrast, 
treatment with FTY720 inhibited IL-6, macrophage infiltration, and S1P-mediated 
signalling pathways in the lung induced by a high-fat diet, and significantly reduced 
the formation of metastases. Furthermore, utilising a mouse model, the group also 
demonstrated that FTY720 could reduce obesity-related inflammation, S1P 
signalling, and lung metastasis, thereby extending survival concluding that 
sphingolipid signalling might be an effective target for preventing obesity-related 
breast cancer metastasis (Nagahashi et al., 2018b).  
As outlined previously, STAT3 plays key roles in various cancers but is difficult to 
target clinically. Work conducted by Liu et al,, demonstrated S1PR1 persistently 
activated STAT3 activating B-cell-like tumour cells synergy while inhibition of 
S1PR1 expression, using shRNA in lymphoma cells, negatively regulated the 
expression of downstream genes of STAT3, which were closely related to the 
survival, proliferation, tumour invasion and immunosuppression of tumour cells. 
Furthermore, the same study showed that FTY720 inhibited S1PR1 activity, down-
regulated STAT3 activity and inhibited lymphoma cell growth in vitro and in vivo. 
Therefore, targeting S1P / S1PR1 may be an effective new treatment modality for 
the treatment of cancer (Liu et al., 2012). 
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1.5 Conclusion 
SphK1, S1P signalling and S1PRs all appear to hold great potential in therapeutic 
design. There is considerable information focusing on the role of S1P receptors in 
cancer. Similarly, SphK1 expression and importance in cancer has also been heavily 
documented. S1P release from the cells has the potential to function in a number of 
ways, influencing nearby cells to modify the environment or promote angiogenesis 
as well as acting in an autocrine fashion to promote growth/survival and inhibit 
apoptosis. Of particular importance is the association of SphK1 with therapy 
resistance including chemotherapy resistance, which represents a key issue arising 
in many cancer types and having significant impact on patient mortality and 
morbidity. Therapeutic targeting of this pathway or molecules involved is an exciting 
prospect for the generation of novel treatments to target cancer progression or 
therapy resistance. The current study will focus on the role of SphK1 in gastric 
cancer patients and its potential as a target therapy in reducing the aggressive nature 
or combat chemotherapy resistance in this aggressive cancer type.  
 
1.6 Aims and objectives 
The aims and objectives of the current project were as follows: 
1) To assess SphK1 expression in clinical gastric cancer tissue, its relevance 
to patient survival and its potential as a biomarker 
2) To functionally characterise the cellular role of SphK1 in gastric cancer 
cell models 
3) To explore the potential of targeting SphK1 using inhibitor compounds in 
the response of gastric cancer cell and patient derived cell lines to 
chemotherapeutic agents 
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4) To gain insight into potential mechanisms that may be involved in 
SphK1’s role in gastric cancer. 
 
It is hypothesised that enhanced SphK1 expression will be associated with 
poorer clinical prognosis, a more aggressive cellular phenotype and reduced 
sensitivity to chemotherapeutic agents and that targeting or inhibiting SphK1 
will reduce the aggressive nature of the cells and enhance sensitivity to 
chemotherapeutics. 
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Chapter II 
 
Methods and materials
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 2.1 Cells 
Seven gastric cancer cell lines (823, HGC27, 7901, AGS, NUGC3 and MKN28) and 
normal epithelium cell line (GES1) were used to explore SphK1 expression across a 
range of gastric cancer cell types. Subsequently, two cell lines were chosen and used 
for in vitro SphK1 knockdown model generation and functional assay investigation 
and are outlined in Table 2.1. The human AGS cell line was purchased from the 
American Type Culture Collection (ATCC, Manassas, VA, USA). The human 
HGC27 cell line was purchased from the European Collection of Authenticated Cell 
Cultures, (ECACC, UK). 
Both HGC27 and AGS cell lines were routinely cultured in Dulbecco's Modified 
Eagle Medium (DMEM) / Ham’s F12 with L-Glutamine medium (Sigma-Aldrich, 
Inc., Dorset, UK), supplemented with antibiotic antimycotic solution (Sigma-
Aldrich, Inc. Dorset, UK), and 10% foetal calf serum (FCS) (Sigma-Aldrich, Inc., 
Dorset, UK), and incubated at 37.0°C, 5% CO2 and 95% humidity. The remaining 
five cell lines are outlined in Table 2.2. 
Gastric cancer patients’ primary cells were obtained from Peking University Cancer 
Hospital (PKUCH) (Table 2.3). Information on the isolation and culture of primary 
CG cells is outlined in section 2.5.4.
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Table 2.1 Cell lines used for in vitro functional analysis 
Cell line Organism Morphology Ethnicity Gender Sources and features Growth Conditions 
AGS Homo sapiens Epithelial Caucasian Female 
This is a hyperdiploid human cell line. The modal 
chromosome number was 49, occurring in 60% of 
cells 
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
HGC27 Homo sapiens Epithelial 
East Asian 
 NA 
Tissue original from the metastatic lymph node 
from a gastric cancer patient diagnosed 
histologically as undifferentiated carcinoma.  
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
Table 2.2 Cells used for SphK1 expression screening 
Cell line Organism Morphology Ethnicity Gender Sources and features Growth Conditions 
823 Homo sapiens Epithelial 
African, 
European, 
East Asian, 
Native 
American 
Female 
This is a hyperdiploid human cell line. The modal 
chromosome number was 49, occurring in 60% of 
cells 
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
7901 Homo sapiens Epithelial Caucasian  Male 
Tissue original from the metastatic lymph node 
from a gastric cancer patient diagnosed 
histologically as undifferentiated carcinoma.  
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
NUGC3 Homo sapiens Epithelial Caucasian Male 
Tissue original from gastric adenocarcinoma 
metastatic site: brachialis muscle. 
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
MKN28 Homo sapiens Epithelial East Asian Male 
Tissue original from gastric tubular 
adenocarcinoma metastatic site: liver 
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
GES1 Homo sapiens 
Normal 
stomach cell  Caucasian Male 
Derived from sampling site: fetal stomach, 
epithelial mucosa. 
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
AGS Homo sapiens Epithelial Caucasian Female 
This is a hyperdiploid human cell line. The modal 
chromosome number was 49, occurring in 60% of 
cells 
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
HGC27 Homo sapiens Epithelial 
East Asian 
 NA 
Tissue original from the metastatic lymph node 
from a gastric cancer patient diagnosed 
histologically as undifferentiated carcinoma.  
Grown in DMEM supplemented with 10% FCS 
and antibiotics at 37ᵒC in 5% CO2 
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Table 2.3 Gastric cancer primary cells used for drug test 
Name Origin Tissue type Cell morphology Lauren Type TNM stage Differentiation Location 
SphK1-H 67 year-old male  Adenocarcinoma Epithelial Diffuse cT3N2M0 Poorly differentiated Gastric antrum 
SphK1-L 45 year-old male Adenocarcinoma Epithelial Intestinal cT4aN1M0 Moderate- poorly differentiated 
Gastric antrum 
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2.2 Primers 
Primers used in the current study were designed using Beacon designer software 
(PREMIER Biosoft International, Palo Alto CA, USA), synthesised by Sigma-
Aldrich (Dorest, UK) and are outlined in Table 2.4. 
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Table 2.4 Primers used in this study 
Function Target gene/sequence Name of Primer Sequence 
Screening of clinical 
samples and cell lines 
using q-PCR and 
conventional PCR 
SphK1 
SphK1 F8 5’- TTGCTGATGTGGACCTAGA 
SphK1 R8 5’- CACTGCAAACACACCTTTC 
SphK1 F1 5’- ACCATTATGCTGGCTATGAG 
SphK1 ZR1 5’-ACTGAACCTGACCGTACAGAGACAGCAGGTTCATGG 
Cytokeratin-19 (CK-19) CK-19 F8 5’-AGCCACTACTACACGACCAT CK-19 ZR8 5’-ACTGAACCTGACCGTACATCGATCTGCAGGACAATC 
Sequences for ribozyme 
synthesis SphK1 
SphK1 rib 1F 5’-CTGCAGGGCTCCAAGCGCAAGGCCTGATGATCCGTGAGGA 
SphK1 rib 1R 5’-ACTAGTGCCCCTACTTGGTATATGTGCCCGTGGTTTCGTCCTCACGGACT 
SphK1rib 2F 5’-CTGCAGTGAGCATCAGCGTGAAGGACTGATGAGTCCGTGAGGA 
SphK1 rib 2R 5’-ACTAGTGCAGCCCCTTTTGGCTGAGGCTGAAATTTCGTCCTCACGGACT 
SphK1 knockdown 
verification by q-PCR 
SphK1 F1 5’- ACCATTATGCTGGCTATGAG 
SphK1 ZR1 5’-ACTGAACCTGACCGTACAGAGACAGCAGGTTCATGG 
Screening on cell lines 
by PCR Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
GAPDH F8 5’-GGCTGCTTTTAACTCTGGTA 
GAPDH R8 5’-GACTGTGGTCATGAGTCCTT 
Sphk1 knockdown 
verification by q-PCR 
GAPDH F2 5’-CTGAGTACGTCGTGGAGTC 
GAPDH ZR2 5’-ACTGAACCTGACCGTACACAGAGATGATGACCCTTTTG 
Transgene insertion and 
orientation screening 
T7F promoter T7F 5’-TAATACGACTCACTATAGGG 
Ribozyme common sequence RbBMR 5’-TTCGTCCTCACGGACTCATCAG RbToPF 5’-CTGATGAGTCCGTGAGGACGAA 
BGHR site BGHR 5’-TAGAAGGCACAGTCGAGG 
• Z Sequence ‘ACTGAACCTGACCGTACA’ is italicised 
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2.3 Antibodies 
Full details of the antibodies used throughout this this study are outlined in Table 
2.5 and Table 2.6. 
 
Table 2.5 Antibodies used for IHC analysis on gastric cancer biopsies 
Antibody name Host species 
Antibody 
concentration Supplier and catalogue number 
SphK1 (M-209) Rabbit 2μg/ml Santa Cruz biotechnology, SC-48825 
 
Table 2.6 Antibodies used for verification of SphK1 knockdown and validation of 
Kinexus data  
Antibody 
name 
Host 
species 
Molecular 
Weight 
(kDa) 
Antibody 
concentration 
Supplier and catalogue 
number 
SphK1 (M-
209) Rabbit 42 1:1,000 
Santa Cruz 
biotechnology, SC-
48825 
GAPDH 
(6C5) Mouse 37 1:4,000 
Santa Cruz 
biotechnology, SC-
32233 
GAPDH  
(FL-335) Rabbit 37 1:4,000 
Santa Cruz 
biotechnology, SC-
25778 
Akt Mouse 62 1:1,000 Santa Cruz biotechnology, SC-5298 
p-Akt 
(Ser473) Mouse 56 1:1,000 
Santa Cruz 
biotechnology, SC-
81433 
mTOR Rabbit 289 1:1500 Cell Signalling biotechnology, 7C10 
p-mTOR 
(Ser 2448) Rabbit 289 1:1500 
Cell Signalling 
biotechnology, D9C2 
Anti-Mouse 
IgG Rabbit  1:100,000 Sigma-Aldrich, A9044 
Anti-Rabbit 
IgG Goat  1:100,000 Sigma-Aldrich, A0545 
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2.4 General reagents and solutions 
2.4.1 Reagents and chemicals 
2.4.1.1 Solutions and reagents for cell culture 
Ethylene Diaminetetraacetic Acid (EDTA) trypsin 
A stock solution of 10X Tryspin-EDTA (Product number T4174) was purchased 
from Sigma-Aldrich (Dorset, UK). For routine use, stock trypsin was diluted in 
phosphate buffered saline (PBS) to 1X concentration and aliquoted to 25ml aliquots 
before storing at -20°C for long term or 4°C for short term before use. 
 
Phosphate buffered saline (PBS) 
10X Phosphate buffered saline (P5943) was purchased from Sigma-Aldrich, (Dorset, 
UK). PBS was diluted to 1X concentration in distilled water before aliquoting into. 
T 25ml aliquots and storing at room temperature. PBS stocks prepared for tissue 
culture were autoclaved before aliquoting and kept under sterile conditions. 
 
Antibiotics 
A 100X Antibiotic Antimycotic solution (A5955) was purchased from Sigma-
Aldrich (Dorset, UK). The solution was aliquoted into 5ml aliquots, stored at -20°C, 
with one aliquot being added into a 500ml bottle of medium to obtain a 1X final 
concentration.  
 
Foetal Calf Serum (FCS)  
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Foetal Calf Serum was purchased from Sigma-Aldrich, Inc. (Dorset, UK) and 
aliquoted into 25ml aliquots. Aliquots were stored at -20°C until required for tissue 
culture. 
 
MTT (3-(4,5-dimetheylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
Stock solutions of MTT (5.5mg/ml) were prepared by dissolving 110mg MTT 
powder (Sigma-Aldrich, Dorset, UK) in 20ml PBS and filtering through a 0.2µm 
filter. Stock solutions were then covered in foil and stored at 4°C until required.  
 
Cytotoxic drugs 
5-FU and Cisplatin were obtained from Peking University Cancer Hospital which 
was aliquoted into 5ml aliquots, stored at -20°C.  
 
SphK1 inhibitor and S1P 
A SphK1 inhibitor named PF543 and S1P were purchased from TOCRIS, Inc. (UK, 
Catalog No.: 5754; Catalog No.: 1370) and aliquoted into 25ml aliquots. Aliquots 
were stored at -20°C until required for tissue culture. 
 
2.4.1.2 Solutions and reagents for molecular biology 
Tris-Boric-Acid-EDTA (TBE) 
A 10X concentrated TBE buffer (T4415) solution was purchased from Sigma-
Aldrich (Dorset, UK). For use in electrophoresis, this was diluted with distilled water 
into a 1X stock and stored at room temperature. 
 
Diethyl Pyrocarbonate (DEPC) Water 
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DEPC was purchased from Sigma-Aldrich (Dorset, UK). Subsequently, 250ml of 
DEPC solution was added to 4.75L of distilled water before autoclaving and storing 
at room temperature for further use. 
 
Loading buffer (used for DNA electrophoresis) 
Loading buffer was prepared by dissolving 25mg of bromophenol blue (Sigma-
Aldrich, Dorset, UK) and 4g sucrose (Fisons Scientific Equipment, Loughborough, 
UK) in 10ml of distilled water before storing at 4°C. 
 
2.4.1.3 Solutions and reagents for cloning 
LB (Lysogeny Broth) 
Eight grams of low salt granulated power LB Broth (Melford Laboratories Ltd., 
Suffolk, UK) was dissolved in 400ml distilled water. Subsequently the pH value was 
adjusted to 7.0 and the solution autoclaved before storing at room temperature for 
further use. 
 
LB Agar 
Ten grams of low salt granulated powder LB Broth (Melford Laboratories Ltd., 
Suffolk, UK), combined with 7.5g of agar (A1296) (Sigma-Aldrich, Dorset, UK) 
was dissolved in 500ml of distilled water and the pH adjusted to 7.0. Following this, 
the solution was autoclaved and stored at room temperature (forming a solid gel). 
Prior to use, the gel was placed in a microwave and heated until completely melted. 
 
Ampicillin 
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A stock solution of 100mg/ml ampicillin (Melford Laboratories Ltd., Suffolk, UK) 
was prepared by dissolving 1g of ampicillin powder in 10ml of sterile PBS. 
 
2.4.1.4 Solutions and reagents for western blotting 
Lysis Buffer 
Eight point seven six grams of NaCl (150mM), 6.05g of Tris (50mM), 200mg 
Sodium azaide (0.02%, w/v) and 5g Sodium deoxycholate (0.5%, w/v) were 
dissolved in distilled water before adding 15ml Triton X-100 (1.5%, v/v) to a final 
volume of 1L. This lysis buffer stock solution was stored at 4°C. Subsequently, one 
cOmpleteTM, EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics, 
Mannheim, Germany) was dissolved in 50ml of the lysis buffer before being 
aliquoted into 1ml aliquots and stored at -20°C. For phosphorylation studies, 100mM 
of Na3VO4 was added to the lysis buffer at the working concentration of 1mM. 
 
10% (w/v) Ammonium Persulphate (APS) 
One gram of Ammonium Persulphate (Melford Laboratories Ltd., Suffolk, UK) was 
added and dissolved in 10ml of distilled water before being stored at 4°C for future 
use. 
 
10% (w/v) Sodium Dodecyl Sulphate (SDS) 
Fifty grams of Sodium Dodecyl Sulphate (Melford Laboratories Ltd., Suffolk, UK) 
was added and dissolved in 500ml distilled water. The resultant solution was stored 
at room temperature for future use. 
 
Tris Buffered Saline (TBS) 
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One Litre of 10X Tris Buffered Saline  solution (T5912) (Sigma-Aldrich, Dorset, 
UK) was diluted in 9L of distilled water, to give a 1X concentration, and stored at 
room temperature for future use. 
 
Running buffer (for Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis, 
SDS-PAGE) 
One Litre of 10X Tris-Glycine-SDS Buffer solution (T7777) (Sigma-Aldrich, Dorset, 
UK) was diluted in 9L of distilled water, to give a 1X concentration, and stored at 
room temperature for future use. 
 
Transfer buffer 
One Litre of 10X Tris-Glycine Buffer solution (T4904) (Sigma-Aldrich, Dorset, UK) 
was diluted in 9L of distilled water containing 2L methanol, to give a 1X 
concentration, (Fisher Scientific UK, Loughborough, UK) and stored at room 
temperature for future use. 
 
Ponceau S stain 
Ponceau S (P3504) (Sigma-Aldrich, Dorset, UK) was used to prepare a stock 
solution containing 0.1% Ponceau S (and 5% acetic acid (w/v). This solution was 
subsequently stored at room temperature for future use. 
 
2.4.1.5 Solutions and reagents for Kinexus microarray protein lysis 
Six grams of Tris powder (Melford Laboratories Ltd., Suffolk, UK) was dissolved 
in 1.5L distilled water to obtain a 100mM Tris buffer solution. To 50ml of the Tris 
buffer one cOmpleteTM, EDTA-free protease inhibitor cocktail tablet (Roche 
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Diagnostics, Mannheim, Germany), 5ml of 2-mercaptoethonal (10%, v/v), nonident 
P-40 (1%, v/v) and 5ml of 500mM NaFl (50mM) were added before mixing the 
solution thoroughly, aliquoting into 1ml aliquots and storing at  -20°C for future use. 
 
2.4.1.6 Solutions and reagents for immunohistochemical (IHC) staining 
Avidin-biotin complex (ABC) 
The VECTASTAIN® ABC Kit (Vector Laboratories, Inc., CA, USA) was used to 
prepare the ABC complex for use in IHC staining. Four drops of reagent A and 
reagent B were added into 20ml of wash buffer, mixed well and left at 4°C for 30 
minutes prior to use. 
 
2.5 Cell culture, maintenance, storage and revival 
2.5.1 Preparation of growth medium and cell maintenance 
Medium for routine cell culture was prepared by adding 10% FCS ((Sigma-Aldrich, 
Dorset, UK) and antibiotic/antimyotic solution (1% final) (Sigma-Aldrich., Dorset, 
UK) into DMEM Nutrient Mixture F-12 Ham with 15mM HEPES, NaHCO3, 
pyridoxine and L-glutamine  (Sigma-Aldrich, Dorset, UK).  
Following transfection of gastric cancer cells, medium was further supplemented 
with 5μg/ml blasticidin (Melford Laboratories Ltd., Suffolk, UK) (selection medium) 
and was used for initial selection of cells that had been transfected with the pEF6 
plasmid vector. Following the initial selection period, medium containing 0.5μg/ml 
blasticidin (maintenance medium) was used to maintain transfected cells during 
routine culture. 
Cells were cultured in 25 cm2 (T25) and 75cm2 (T75) culture flasks (Greiner Bio-
One Ltd., Gloucestershire, UK) incubated at 37°C, 5% CO2 and 95% humidity. 
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2.5.2 Trypsinisation of adherent cells and cell counting 
Upon reaching 80-90% confluency, cells were typsinised and sub-cultured to 
maintain them and prevent over-confluence. Firstly, the medium was aspirated using 
a glass pipette and the remaining monolayer washed with sterile PBS to ensure 
complete removal of serum which may disrupt the action of trypsin. Subsequently, 
trypsin was added to the flask (1ml for T25 flask, 2ml for T75 flask), agitated to 
ensure coverage of the monolayer and incubated at 37°C, 5% CO2 and 95% humidity 
for a suitable time (dependent on nature of cell line). Following incubation visual 
confirmation of cell detachment was undertaken using the microscope. Detached 
cells were then resuspended in fresh medium to neutralise the trypsin, collected into 
a 30ml universal container (Greiner Bio-One Ltd,. Gloucestershire, UK) and 
centrifuged at 1,700rpm for 5 minutes to pellet cells. Following this, the supernatant 
was removed, using a glass pipette, and the remaining cell pellet re-suspended in a 
suitable volume of fresh medium (dependent on cell size and required cell density 
for application). A Neubauer haemocytometer counting chamber (Mod-Fuchs 
Rosenthal, Hawksley, UK) was then used to count cell numbers in the suspension 
under an Olympus CKX31 microscope at X10 objective magnification (Olympus, 
Tokyo, Japan) and the resulting number converted to number of cells/ml. 
  
2.5.3 Storage and revival of cells 
Cells were detached and resuspended as described in the previous section before 
being divided into 900μl aliquots in pre-labelled CRYO.STM cryotube (Greiner Bio-
One Ltd,. Gloucestershire, UK). Following this, an additional 100μl of 
Dimethylsulphoxide (DMSO) (Sigma-Aldrich, Dorset, UK) was added (10% final 
concentration) and the cryovials capped and then wrapped in tissue paper before 
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placing in the -80°C freezer for short term storage or transferred to liquid nitrogen 
for long term storage. 
For cell revival, the cryotube was removed from either the -80°C freezer or the liquid 
nitrogen stocks and rapidly thawed. Subsequently, the cell suspension was 
transferred to 10mls of pre-warmed medium in a universal container before 
centrifuging at 1700rpm for 5 minutes pellet cells. Following this the supernatant, 
containing remnant DMSO from the preservation step, was removed using a glass 
pipette and the remaining pellet re-suspended in 5ml fresh growth medium before 
transferring to a T25 flask and culturing as described previously. 
 
2.5.4 Primary GC cell isolation and culture 
Gastric tissues were washed three times with PBS and were cleared of the connective 
and necrotic sections. The samples were cut into small fragments of approximately 
1 mm, with 1% collagenase IV (Biosharp, China) incubation at 37℃ for 1h. Then, 
centrifuge the sample to remove undigested tissue and to keep the pellet. The pellet 
was subsequently cultured in Roswell Park Memorial Institute (RPMI) 1640 
(Hyclone, USA) containing 10% FBS (Gibco, Grand Island, NY, USA), 100 U/ml 
penicillin and 100 ug/ml streptomycin at 37℃ in an atmosphere of 5% CO2 and 95% 
air. 
 
2.6 Tissue collection and processing 
2.6.1 Cohort 1 
322 fresh-frozen tissues were used to undertake qPCR transcript analysis in which 
we got total 322 patients in which 183 were paired with tumour tissue and normal 
tissue. Tissue was obtained from cT2-4N0M0 or cT1-4N1-3M0 gastric cancer 
77 
 
patients treated between January 2006 and December 2007 in Peking University 
Cancer Hospital. All specimens were stored in one of the best bio-bank in China with 
global standards. All protocols were reviewed and approved by the local ethics 
committee and informed consent was obtained from the patients before therapy. 
 
2.6.2 Cohort 2 
263 paraffin-embedded tissues were used to undertake IHC protein analysis, Tissue 
was obtained from cT2-4N0M0 or cT1-4N1-3M0 gastric cancer patients treated 
between January 2003 and December 2011 in Peking University Cancer Hospital. 
All protocols were reviewed and approved by the local ethics committee and 
informed consent was obtained from the patients before therapy. 
 
2.7 Total RNA isolation 
RNA was isolated using TRI-reagent (Sigma-Aldrich, Dorset, UK) in accordance 
with the manufacturer's instructions. RNA was extracted from both cell lines and 
also from patient tissues. 
 
Tissue extraction  
Multiple sections were cut from the same clinical patient sample and were collected 
and combined in a 7ml Bijou container before homogenising in 1ml of ice-cold TRI-
reagent with a handheld homogeniser (Cole-Parmer, London, UK). Following 
homogenisation, the lysate was transferred to a 1.5ml Eppendorf tube before 
continuing with the remaining extraction steps outlined in the manufacturer’s 
instructions. 
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Cell lysate 
Following confluency, cell medium was aspirated using a glass pipette and 1ml of 
TRI-reagent was added to the monolayer and a cell scraper (Greiner Bio-one, 
Frickenhausen, Germany) used to ensure full detachment and lysis of cells before 
transferring the lysate to a 1.5ml Eppendorf tube. Subsequently, remaining 
extraction steps outlined in the manufacturer instructions were followed. 
 
Following lysis (as outlined above), the homogenate was kept at room temperature 
for 5 minutes before adding 100μl of 1-bromo-3-chloropane (Sigma-Aldrich, Dorset, 
UK) and shaking vigorously for 15 seconds. The resulting mixture was left for 5-10 
minutes at room temperature before centrifuging at 4°C, 12,000g for 15 minutes 
resulting in phase formation. The upper aqueous phase (containing RNA) was 
transferred into a new, pre-labelled 1.5ml Eppendorf tube containing 500µl of 
isopropanol (Fisher Scientific UK, Loughborough, UK) before shaking vigorously 
for 10 seconds and centrifuging at 4°C, 12,000g for 10 minutes. Following this a 
visible RNA pellet was obtained and the supernatant removed and discarded, before 
washing the pellet in 75% ethanol in DEPC water, through vortexing briefly and 
centrifuging at 7,500g for 5 minutes. Subsequently, the Eppendorf was placed in a 
Techne, Hybrdiser HB-1D drying oven at 50°C to dry out any remaining liquid 
before dissolving the RNA pellet in 20-80μl of DEPC (depending on pellet size) and 
freezing at -80°C until required. 
At the same time, we did have limitations in our study. Firstly, we used fresh frozen 
samples from 2006 to 2007, and we extracted RNA in 2014. Therefore, there is the 
possibility that such long storage could increase RNA degradation and thus affect 
the results of our study. However, it is suggested from the literature that Kelly et al. 
(Kelly et al., 2019) reported that 11 years didn’t affect the integrity and 
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histomorphology preserved under qualified preservation conditions. Biobank of 
PKUCH has been a qualified one with worldwide standards.  
 
2.8 Reverse transcription polymerase chain reaction (RT-PCR)  
RNA samples were first quantified using a NanoPhotometerTM (IMPLEN; Geneflow 
ltd., Lichfield, UK) and standardised to 500ng before being used to generate cDNA 
using the GoScriptTM Reverse Transcription System kit (Promega, Southampton, 
UK). 
Five hundred nanograms  sample RNA was mixed with 1µl of Oligo (dT)15 and 
brought up to 5µl with PCR water in a thin-walled 200µl PCR tube before heating 
in a 2720 Thermal Cycler (Applied Biosystems, Paisley, UK) at 70°C for 5 minutes 
followed by immediately being transfered to ice for 5 minutes. Subsequently, the 
tube was removed from the ice and 15µl of a pre-prepared Mastermix, containing 
4µl GoScriptTM 5X Reaction Buffer, 1.2µl MgCl2, 1µl Nucleotide mix, 0.5µl 
Recombinant RNasin Ribonuclease Inhibitor, 1µl GoScriptTM Reverse Transcriptase 
and 7.3µl nuclease-free water, was added. The sample was then centrifuged briefly 
before being subjected to 25°C for 5 minutes, 42°C for 60 minutes and 75°C for 15 
minutes in a thermocycler. 
cDNA generated was then diluted 1 in 4 with PCR water and was stored at -20°C for 
future use. 
 
2.9 Polymerase chain reaction (PCR) 
GoTaq Green master mix (Promega, Southampton, UK) was used to undertake PCR 
in conjunction with molecule specific primers (outlined in section 2.2). Each 16µl 
reaction contained 8µl GoTaq Green master mix, 1µl forward primer, 1µl reverse 
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primer, 5µl PCR water and 1µl sample cDNA. Following reaction preparation the 
sample was centrifuged briefly before being placed in a 2720 Thermal Cycler 
(Applied Biosystems, Paisley, UK) and undergoing an initial 94°C denaturing for 5 
minutes, followed by 30 -36 cycles of 94°C for 30 seconds, 55°C for 40 seconds, 
72°C for 1 minute and a final 10 minute 72°C extension before holding at 4°C. 
 
2.10 Agarose gel electrophoresis 
Following amplification in the thermocycler, samples were separated using gel 
electrophoresis. Gels were prepared using either a 0.8% or 2% agarose gel, 
dependent on predicted product size. The gels were made by adding the appropriate 
amount of agarose (Melford Chemicals, Suffolk, UK) to 1X TBE and heating in a 
microwave to fully dissolve the powder. Following this, the gel solution was 
removed from the microwave and allowed to cool partially before adding (Z)-4-((3-
Methylbenzo[d]thiazol-2(3H)-ylidene)methyl)-1-propylquinolin-1-ium 4-
methylbenzenesulfonate (SYBR) safe DNA gel stain (Invitrogen, Paisley, UK) at a 
1:10,000 dilution. The gel solution was then poured into an electrophoresis tank 
assembled with plastic combs (SCIE-PLAS, Cambridge, UK) resulting in loading 
well formation when combs were removed. Once the agarose gel had set it was 
submerged in 1X TBE buffer before loading either 4µl of PCR Ranger 100bp DNA 
Ladder/ High Ranger 1000bp DNA Ladder (Geneflow, Litchfield, UK) or 8µl of 
cDNA samples. Samples were then separated at 100V, 50mA and 50W for a 
sufficient amount of time (20-50 minutes). Following separation, the gel and product 
bands were visualised under Blue light and images captured using a Syngene gel doc 
system (Syngene, Cambridge, UK). 
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2.11 Generation of mutant AGS and HGC27 cell lines 
2.11.1 Generation of ribozyme transgenes 
Hammerhead ribozyme transgenes were used to target SphK1 expression in AGS 
and HGC27 cell lines. Hammerhead ribozymes are able to cleave RNA at specific 
cleavage sites (GTG, ATC and TTC). Ribozymes were designed based on the 
predicted secondary structure of SphK1 mRNA (Figure 2.1) according to Zukers 
RNA mFold software (Zuker, 2003). The secondary structure of SphK1 was 
examined for suitable cleavage sites, sitting in the loop regions of the mRNA 
structure, and regions surrounding this used to design complementary sequences to 
specifically target the ribozyme catalytic region to this site. Once designed, ribozyme 
transgene sequences were synthesised by Sigma-Aldrich (Dorset, UK; Table 2.4) 
and were combined using touchdown PCR over a range of annealing temperatures. 
The transgene products were subsequently separated on a 2% agarose gel to confirm 
successful generation of the ribozyme product and the remaining reaction product 
stored at 4°C before cloning using the pEF6/His TOPO system. 
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Figure 2.1 Predicted secondary structure of human SphK1 mRNA predicted by 
Zukers mFold software 
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2.11.2 TOPO TA gene cloning and generation of stable transfectants 
The pEF6/V5-His TOPO® TA expression system (Invitrogen, Paisley, UK) was 
used to generate plasmids for SphK1 knockdown. The expression system allows 
insertion of Taq polymerase-amplified PCR products into the pEF6 plasmid enabling 
constitutive expression in mammalian cells. The structure of the pEF6 plasmid is 
outlined in Figure 2.2  
 
 
 
 
Figure 2.2 Structure of the pEF6/V5-His TOPO vector. Image reproduced from 
pEF6-His TOPO® TA Expression Kit manual, (Invitrogen) 
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The generated ribozyme transgene PCR products were cloned into pEF6/V5-His 
TOPO® plasmid in accordance with the manufacturer’s guidance. A 6µl cloning 
reaction, containing 4µl PCR product, 1µl salt solution and 1µl TOPO vector, was 
prepared, mixed gently and stored on ice before adding 5µl of the cloning reaction 
mix to a vial of One Shot TOP10 Escherichia coli (E. coli) and mixing gently.  The 
vial was then left on ice for between 5 and 30 minutes before transferring the vial to 
a 42°C water bath and heat shocking for 30 seconds. The vial was then immediately 
transferred back into the ice before adding 250µl of S.O.C medium (at room 
temperature) and agitating the tubes at a 45ᵒ angle and 225rpm and 37°C for 1 hour 
on an orbital shaker (Bibby Stuart Scientific, UK). The vial contents were then 
spread onto a pre-prepared ampicillin selective (100µg/ml) agar petri dish and 
incubated overnight at 37°C allowing colony formation. 
Orientation checking was then undertaken on random colonies to ensure the product 
had inserted in the correct orientation and would form a viable product. Ribozyme 
orientation was confirmed using a range of plasmid specific (T7F and BGHR) and 
ribozyme specific (RbToPF and RbBMR). A portion of each tested colony was 
added to three reactions, outlined below:  
 
Reaction 1: Product insertion check 
• GoTaq Green master mix - 8µl 
• T7F plasmid specific forward primer - 1µl 
• BGHR plasmid specific reverse primer - 1µl 
• PCR water -6µl 
Reaction 2: Correct orientation check 
• GoTaq Green master mix - 8µl 
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• T7F plasmid specific forward primer - 1µl 
• RbBMR ribozyme specific reverse primer - 1µl 
• PCR water -6µl 
Reaction 3: Incorrect orientation check 
• GoTaq Green master mix - 8µl 
• T7F plasmid specific forward primer - 1µl 
• RbToPF ribozyme specific forward primer - 1µl 
• PCR water -6µl 
 
Following set up and inoculation of the colony into all reactions, the mixes were 
heated in a 2720 Thermal Cycler (Applied Biosystems, Paisley, UK) using the 
following conditions: 94°C for 5 minutes; 30 cycles of 94°C for 30 seconds, 55°C 
for 40 seconds and 72°C for 1 minute; final extension of 72°C for 10 minutes; 4°C 
hold. The products were then run on a 2% agarose gel stained with SYBR safe before 
analysing the orientation profiles and inoculating those with correct orientation into 
5ml of ampicillin (100µg/ml) selective LB broth in a universal container and 
incubating overnight at 37ᵒC under angled agitation at 225rpm. 
 
2.11.3 Plasmid amplification and extraction 
A GenElute Plasmid MiniPrep Kit (Sigma-Aldrich, Dorset, UK) was used to extract 
plasmid from the amplified bacteria in accordance with the manufacturer guidelines. 
Overnight cultures were centrifuged at 5,000 Relative Centrifugal Force (RCF) to 
pellet the bacteria and the supernatant removed before resuspending the pellet in 
200µl Resuspension Solution containing RNase A and transferring into a 1.5ml 
Eppendorf. Following this, 200µl of Lysis Solution was added and the tube inverted 
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8 times before adding, within 5 minutes, 350µl of Neutralisation and inverting again 
6 times. The solution was then centrifuged at 12,000g for 10 minutes to pellet the 
cell debris and the cleared lysate transferred into a Miniprep Binding Column (pre-
washed with Column Preparation Solution) placed in a Microcentrifuge Tube. The 
tube was then centrifuged for 1 minute at 12,000g and the flow-through liquid was 
discarded before adding 700µl of Wash Solution (containing ethanol) into the 
Miniprep Binding Column and centrifugation at 12,000g for 1 minute followed by 
removal of the flow-through liquid. A final centrifugation at 12,000g for 1 minute 
was undertaken to remove any remaining Wash solution before placing the Miniprep 
Binding Column into a fresh Collection Tube and eluting the plasmid by adding 50µl 
of Elution Solution and centrifuging at 12,000g for 1 minute. The eluted plasmid, 
quantified using the nanophotometer (IMPLEN; Geneflow ltd., Lichfield, UK),was 
then stored at -20°C until required. 
 
2.11.4 Plasmid transfection via electroporation into AGS and 
HGC27 cell lines 
Wild type AGS and HGC27 cells were grown in T75 culture flasks. Upon reaching 
approximately 70-80% confluency cells were trypsinised as previously described, 
transferred into a universal container and centrifuged before resuspending the cell 
pellet in medium and counting cells as previously described. One million cells in 
1ml was added into a 4mm cuvette (Geneflow ltd., Lichfield, UK) along with 3-5µg 
of plasmid, inverted several times and then electroporated under 310V and 1500µA. 
Following electroporation, the cell suspension was seeded into a T25 flask 
containing pre-warmed medium and incubated as described previously. Plasmids 
containing ribozyme transgenes and closed pEF6 control plasmids were used for 
electroporation into cells. In addition, a mock transfection was undertaken for wild 
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type cells without the addition of any plasmid. Following overnight culture, all cells 
were placed in selection medium containing 5µg/ml blasticidin. Selection was 
continued over a 5-14 days period based on how quickly the mock transfected cells 
were killed by the selective antibiotic. Following selection, transfected cells were 
placed and maintained in maintenance medium containing 0.5µg/ml balsticidin. 
 
2.12 Real time quantitative polymerase chain reaction (qPCR) 
qPCR was used to quantify the transcript expression of target genes in cell lines and 
tissue cohorts. AmplifluorTM UniprimerTM Universal system (Intergen company®, 
New York, USA) was utilised in the current study. In this system the Amplifluor 
probe (Uniprimer) contains a 3’ region which is identical to the Z-sequence 
(ACTGAACCTGACCGTACA), contained on one of the qPCR primers for each 
molecule, and a 5’ hairpin structure containing a fluorescent (FAM) tag. 
In its natural state, it forms a hairpin structure and the fluorescent tag is linked to an 
acceptor moiety (DABSYL), quenching the fluorescent signal. Target molecule 
primers were designed as described in section 2.2 with one containing a Z-sequence 
facilitating incorporation of the Amplifluor Uniprimer probe during PCR. This  
incorporation then acts as a template for the Amplifluor Uniprimer probe (outlined 
in Figure 2.3) in later cycles as the Z-tagged primer (present at a lower concentration) 
exhausts, causing break down of the hairpin structure and unfolding by DNA 
polymerase, disrupting the fluorophore - quencher structure and resulting in 
fluorescence emission to be detected.  
Ten microlitre reactions were prepared consisting of 5µl of Precision FAST 2X 
qPCR Mastermix (Primerdesign, Eastleigh, UK), 0.3µl target forward primer, 0.3µl 
target reverse primer [1/10th concentration of forward primer] containing Z-sequence, 
0.3µl Ampliflour Uniprimer probe and a 4.1µl of cDNA and PCR water. The 
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reactions were loaded into a 96 well optical plate (Applied Biosystems, Paisley, UK) 
and run in a StepOne plus Real-Time PCR System (Applied Biosystems, Paisley, 
UK) under the following conditions: 94°C, 10 minute initial denaturing followed by 
60-100 cycles of 94°C for 10 seconds, 55°C for 30 seconds, 72°C for 10 seconds.  
The fluorescent signal was detected during the annealing stage and the threshold 
cycle for each sample determined. Reactions were run simultaneously alongside a 
standard plate containing known transcript concentration of PDPL (108-101), 
allowing formation of a standard curve (example shown in Figure 2.4) and 
subsequently calculation of relative transcript copy number per sample. Sample 
transcript copy number was also normalised against the expression of either the 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or cytokeratin 19 (CK-19) 
housekeeping genes.
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                                                Figure 2.3 Outline of the Amplifluor Uniprimer Universal system
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Figure 2.4 Example of standard curve used in transcript quantification 
A. Reaction curves for range of PDPL standard samples (108 to 10 copy number) B. 
Resultant standard curve based on the threshold cycle and copy number of the of the PDPL 
standard samples.  
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2.13 Immunohistochemistry (IHC) 
Sections of 4-mm thickness from formalin-fixed, paraffin-embedded tissues were 
mounted on poly-L-lysine-coated slides and then deparaffinised in xylene and 
rehydrated through alcohol to distilled water. Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide for 15 min at room temperature. After pressure 
cooking the slides in 10 mmoll-1 EDTA (pH 8.0) for 3 min, the sections were 
incubated with 5% goat serum, then incubated overnight at 4℃ with SphK1 antibody 
(1:200, Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and also without 
primary antibody as a negative control. Primary antibodies were detected using a 
two-step EnVision System (Dako, Glostrup, Denmark). Horseradish peroxidase and 
diaminobenzedene hydrochloride were the enzyme and chromogen used, 
respectively. Staining score was independently assessed by two pathologists. The 
percentage of positive cells and the intensity of cytoplasmic staining were analyzed. 
Thus all final scoring estimations were stratified into four categories: -, 0% of stained 
cells; +, <20% weakly to moderately stained cells; ++, 10–20% intensively stained 
cells and 20–50% weakly stained cells; and +++, 20–50% positive cells with 
moderate-to-marked staining or >50% positive cells. There was a low level of 
discrepancy (<5% cases) among the pathologists in terms of scoring, but a consensus 
was reached after joint review.  
The judgment standard referred to the standard of HER2 in NCCN guide. If 
heterogeneity was also found in the tissues, it will be resected, stained, and 
revaluated by the pathologist. 
 
2.14 Cellular lysis and protein extraction  
At approximately 80-90% confluence cells were harvested for protein extraction. 
Medium was first aspirated and the monolayer washed in PBS. Subsequently PBS 
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was replaced with 5ml of fresh PBS and cells were scraped from the flask using a 
cell scraper, collected and transferred into a universal container. The universal 
container was centrifuged at 2000rpm for 10 minutes to pellet the cells, before 
removing the supernatant and resuspending the cell pellet in 150-300µl of protein 
lysis buffer. The lysate was then transferred to a 1.5ml Eppendorf and placed on a 
Labinoco rotating wheel (Wolf laboratories, York, UK) (25rpm) for a minimum of 
40 minutes at 4°C. Following this, samples were centrifuged at 13,000rpm and 4°C 
for 15 minutes with the resulting supernatant, containing the protein lysate, 
transferred to a new 1.5ml Eppendorf and the pellet, containing insoluble discarded. 
Protein samples were then stored at -20°C until required. 
 
2.15 Protein sample quantification and standardisation 
A Bio-Rad DCTM protein assay kit (Bio-Rad, Laboratories, Hemel-Hempstead, UK) 
was used for protein quantification, using the microplate technique. A serially diluted 
standard was first prepared from 10mg/ml bovine serum albumin (BSA). 
Subsequently, 5μl of either the standard or sample was transferred to fresh wells of 
a 96-well plate. Reagent A’ was then prepared by combining 20µl of reagent S with 
1000µl of reagent A, and 25µl of this reagent A’ solution was added to each standard 
or unknown protein sample. Following this 200μl of reagent B was added to each 
reaction and the plate incubated for 30 minutes for the colorimetric reaction to occur 
Absorbance was then read at 620nm on a ELx800 plate reader (Bio-Tek, Wolf 
laboratories, York, UK) and a standard curve prepared and used to calculate the 
protein concentration of the unknown samples. All samples were diluted to a 
standardised concentration before adding an equal volume of 2x Laemmli sample 
buffer (Sigma-Aldrich, Dorset, UK), boiling at 100°C for 5 minutes and storing at -
20°C until required. 
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2.16 Protein extraction and quantification for KinexusTM 
antibody microarrays 
AGS cells were cultured in two T75 flasks until reaching 80% confluence before 
placing in serum hunger followed by addition of treatments or left in control 
conditions. Cells were then lysed as described in section 2.14, using 500-600µl of 
the Kinexus lysis buffer outlined in section 2.4.1.5.  
A fluorescamine based assay was used to quantify protein samples for the Kinexus 
microarray due to incompatibility of the lysis buffer with the Bio-Rad DC kit. 
Fluorescamine acetone was made by dissolving 15mg of fluorescamine (Sigma-
Aldrich, Dorset, UK) in 5ml absolute acetone (Fisher Scientific UK, Loughborough, 
UK) in a glass vial and stored at 4°C until required in the assay. A standard was 
prepared as described earlier from a BSA stock in PBS and the protein samples were 
diluted 1:10 in PBS. Subsequently, 150μl of each BSA standard or diluted protein 
samples were aliquoted into triplicate wells of a 96-well plate. Following this, 50μl 
of fluorescamine acetone, previously prepared, was added and the plate agitated for 
1 minute. Fluorescence was then detected using a GloMax®-Multi Microplate 
Multimode Reader (Promega, Southampton, UK) with a 365nm excitation and 410-
460nm emission filter and a standard curve generated from the BSA standards. 
Subsequently, sample concentration was determined using the standard curve and 
protein samples standardised to 4mg/ml. Following standardisation, half of the 
sample was sent to Kinexus Bioinformatics (Vancouver, Canada) for analysis on the 
protein antibody microarray and the remaining sample frozen at -20°C.  
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2.17 Tris-glycine sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting 
2.17.1 Gel preparation and PAGE 
Tris-glycine SDS-PAGE was conducted to explore protein expression using an 
OmniPAGE VS10DSYS vertical electrophoresis system (OmniPAGE, Cleaver 
Scientific Ltd., Rugby, UK). The apparatus was assembled in line with the 
manufacturer guidance. Based on protein predicted size, 15ml (enough for two 
resolving gels) of either 8% or 10% resolving gels were prepared according to Table 
2.7 and 5ml (enough for two stacking gels) of stacking gels were prepared according 
to Table 2.8.  
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Table 2.7: Composition of 8% and 10% resolving gel 
Component 8% Resolving gel 10% Resolving gel 
Distilled water 6.9ml 5.9ml 
30% acrylamide mix  
(Sigma-Aldrich, Inc., Dorset, UK) 4.0ml 5.0ml 
1.5M Tris-HCl buffer pH8.8  
(Bio-Rad Laboratories, Hemel Hempsead, 
UK) 
3.8ml 3.8ml 
10% SDS 0.15ml 0.15ml 
10% Ammonium persulphate 0.15ml 0.15ml 
Tetramethylethylenediamine TEMED  
(Sigma-Aldrich, Inc., Dorset, UK) 0.009ml 0.006ml 
*8% gel was used to separate proteins with larger molecular weights (>100kDa) with 10% 
gels being used for lower molecular weight proteins (<100kDa) 
 
Table 2.8: Composition of stacking gel 
Component Stacking gel 
Distilled water 3.4ml 
30% acrylamide mix  
(Sigma-Aldrich, Inc., Dorset, UK) 0.83ml 
0.5M Tris-HCl buffer pH6.8  
(Bio-Rad Laboratories, Hemel Hempsead, UK) 0.63ml 
10% SDS 0.05ml 
10% Ammonium persulphate 0.05ml 
TEMED (Sigma-Aldrich, Inc., Dorset, UK) 0.005ml 
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The resolving gel was firstly prepared, mixed and loaded between the two glass 
plates, leaving sufficient space for the comb and stacking gel. Once added, ethanol 
was added over the top of the resolving gel to prevent an uneven formation. 
Following polymerisation (approximately 30 minutes) the ethanol was tipped off the 
top of the resolving gel and the stacking gel prepared, mixed and added over the top 
of the resolving gel before inserting a Teflon comb into the stacking gel solution. 
After polymerisation of the stacking gel, the loading cassette, containing the glass 
plates was inserted into the electrophoresis tank and 1X running buffer added upto 
the maximum limits. Following this the comb was removed and an appropriate 
volume of protein sample (dependent on comb size) or 8µl of a BLUeye Prestained 
Protein Ladder (Geneflow ltd., Lichfield, UK) was loaded into the wells before 
running the gel at 120V, 50mA and 50W using a EV243 power consort (Topac Inc., 
Cohasset, MA, USA) until sufficient separation had occurred.  
  
2.17.2 Protein transfer to PVDF membrane  
Immobilon-Polyvinylidene fluoride or polyvinylidene difluoride (PVDF) transfer 
membrane (EMD Millipore Corporation, Billerica, MA, USA) was cut to 7.5 x 
7.5cm dimensions before soaking in methanol (Fisher Scientific UK, Loughborough, 
UK) for 30 seconds, rinsing and placing in 1x transfer buffer. In addition, six squares 
of filter paper (Sigma-Aldrich, Dorset, UK) were cut to 8 x 8cm dimensions and 
soaked in 1X transfer buffer. 
Mini Trans-Blot cell (Bio-Rad Laboratories, Hemel-Hempstead, UK) was used to 
transfer proteins from an acrylamide gel to a PVDF membrane. Following 
electrophoresis completion, the electrophoresis tank and cassette was dismantled and 
the stacking gel cut away from the resolving gel. The resolving gel was then carefully 
transferred onto a PVDF membrane in a sandwich like structure consisting of 
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Cathode: fibre pad:3X filter paper: Gel: PVDF membrane:3X filter paper: fibre pad: 
Anode This was then placed into the electrode assembly in the buffer tank before 
filling with 1X transfer buffer, covering with the lid, placing the tank at 4°C and 
running at 100V, 200mA, 50W for 1-2 hours (depending on protein size). 
 
2.17.3 Protein staining and immunoprobing 
2.17.3.1 Ponceau S membrane staining 
Ponceau S stain was used to stain membranes in order to confirm transfer or to aid 
in cutting of membranes. Following transfer the membrane was placed in a weighing 
boat and immersed in Ponceau S whilst shaking. Following this, the membrane was 
washed with distilled water to allow visual confirmation of protein bands. 
 
2.17.3.2 Immunoprobing 
Following blotting the membrane was placed into a 50ml falcon tube, with the 
protein side facing inwards, containing 10ml of blocking buffer (5% low fat milk 
and 0.1% Tween 20 in PBS) before transferring the tube to a roller (Stuart, Wolf 
Laboratories, York), and incubating for one hour at room temperature. Following the 
blocking stage, blocking buffer was discarded and the primary antibody was diluted 
in fresh 5ml blocking solution as outlined in Table 2.6, added into the falcon tube 
and incubated overnight at 4°C. Following incubation with the primary antibody, the 
primary antibody solution was removed and three 10 minutes washes with 10ml of 
wash buffer (0.1% Tween 20 in PBS) conducted to remove unbound primary 
antibody. Following the removal of the last wash buffer, a horseradish peroxidase 
(HRP) conjugated secondary antibody, specific to the species used in the primary 
antibody, was added in 5ml blocking buffer to the falcon tube at concentrations 
outlined in Table 2.6, which was then placed on the roller for 1 hour at room 
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temperature. Following incubation with the secondary antibody, the buffer was 
removed and the membrane washed again 3 times with wash buffer. Following this, 
the EZ-ECL Chemiluminescent Detection Kit (Geneflow ltd., Lichfield, UK) was 
used to detect proteins. Solution A and B were mixed in equal volumes in a Bijou 
and incubated at room temperature for 5 minutes in the dark to equilibrate. Once 
equilibrated, the membrane was removed from the falcon tube and excess wash 
buffer removed before adding the combined EZ-ECL solution over the membrane 
and incubating for 1 minute in the dark. Excess combined EZ-ECL solution was then 
removed and the membrane placed in a G:BOX Chemi XRQ imaging system 
(Syngene, Cambridge, UK) to detect and capture images. In addition to detecting 
proteins of interest, GAPDH expression was also detected as a housekeeping control.   
Image J v1.50c (downloaded from https://imagej.nih.gov/ij/) was used to quantify 
band densities. Densities of the bands obtained for the proteins of interests were 
normalised based on GAPDH expression within the samples. 
 
2.18 Cell functional assays 
2.18.1 In vitro thiazolyl blue tetrazolium bromide (MTT) and 
crystal violet for cell proliferation assay 
MTT (3-(4,5-dimetheylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium 
was used for cell viability assays and response of cells to cytotoxic agents. Viable, 
metabolically active cells convert MTT into a purple coloured formazan product, 
which can subsequently be dissolved in DMSO and the resulting absorbance read on 
a plate spectrophotometer, corresponding to viable cell numbers (Riss et al., 2004).  
Sub confluent flasks were trypsinised and counted as described in section 2.5.2. 
Subsequently, 2,000 cells were seeded into replicate wells of a 96 well plate in 100µl. 
Appropriate concentrations of inhibitors or cytotoxic drugs were then added to obtain 
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a final volume and desired concentration in 200µl and incubated at 37.0°C, 5% CO2 
and 95% humidity for 48 hours.  Following incubation, 20µl of sterile MTT stock 
solution was added (providing working concentration of 0.5mg/m) and the plates 
incubated for a further 4 hours. Following this, the medium was gently aspirated to 
avoid disturbing crystals and 200µl of DMSO added and mixed resulting in a 
coloured solution. The absorbance of each well of the 96 well plate was then read on 
an ELx800 plate spectrophotometer at 540nm wavelength. Experiments were 
repeated a minimum of three times. Cell viability was determined based on the 
percentage difference between untreated control cells (chemotherapy and SphK1 
small inhibitor). 
Crystal violet based assays were undertaken by seeding 3,000 cells per well, in 
replicate wells and replicate plates (one plate per incubation point). At each 
incubation point, the medium was aspirated, cells fixed in 4% Formalin (Sigma-
Aldrich, Dorset, UK) for 10 minutes before aspiration of the Formalin and cell 
staining with 0.5% (v/v in distilled water) crystal violet (Sigma-Aldrich, Dorset, UK) 
for 5 minutes. Subsequently, crystal violet stain was dissolved in 10% acetic acid 
(Sigma-Aldrich, Dorset, UK) (v/v in distilled water) and read on ELx800 plate 
spectrophotometer at 540nm wavelength. 
 
2.18.2 In vitro Matrigel cell adhesion assay 
Matrigel cell adhesion assays were used to examine cell-matrix adhesion based on 
the cell’ capacity to attach to a Matrigel® Basement Membrane Matrix (Corning 
Incorporated, Flintshire, UK). 100µl of serum free medium (SFM) containing 5µg 
of matrigel was added to the wells of a 96 well plate and dehydrated at 55°C for 2 
hours in a Hybrdiser HB-1D drying oven. Subsequently, 100µl of SFM was used to 
rehydrate the matrigel for 30 minutes before gently removing the SFM and seeding 
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40,000 cells in 200µl of medium in replicate wells. The plate was then incubated for 
45 minutes before removing medium and washing thoroughly with PBS to remove 
non-adherent cells. Following washing, adherent cells were fixed in 4% formalin 
(Sigma-Aldrich, Dorset, UK) for 10 minutes before aspirating the formalin and 
staining with 0.5% (v/v) crystal violet (Sigma-Aldrich, Dorset, UK) for 5 minutes. 
Subsequently, stain was dissolved in 10% (v/v) acetic acid (Sigma-Aldrich, Dorset, 
UK) and read on an ELx800 plate spectrophotometer at 540nm wavelength. 
Experiments were repeated a minimum of three times. 
 
2.18.3 In vitro cell migration assay (wound healing assay) 
An Environmental Virtual Observatories (EVOS®) FL Auto Imaging System (Life 
technologies, CA, USA) equipped with EVOS® Onstage Incubator (Life 
technologies, CA, USA) was used to quantify the migration rate of control and 
SphK1 knockdown AGS and HGC27 cells in an in vitro scratch/wound healing 
migration assay. Cells were seeded in a 24 well (Greiner Bio-One Ltd., 
Gloucestershire, UK) plate and grown to confluence. The monolayer was then 
scraped using a sterile 200µl pipette tip to create a wound in each well before 
aspirating the medium, washing with PBS and replacing with fresh medium. The 
plate was then returned to the incubator and allowed to recover for 10 minutes before 
placing in the onstage incubator of the EVOS system, programmed to maintain an 
environment of 37°C, 5% CO2 and 80% humidity. The EVOS system was then 
programmed to capture multiple images of the wound at specific co-ordinates 
following 6, 12, 18 and 22 hours in each well.  
The distance between the two wound fronts was quantified using Image J at each 
time point, allowing cell migration to be monitored as the distance between the 
wound fronts reduced. Experiments were repeated a minimum of three times. 
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2.18.4 In vitro Matrigel invasion assay 
Impact of SphK1 knockdown on AGS and HGC27 cell invasion was quantified using 
a Matrigel cell invasion assay. Inserts with 8.0µm pores (Becton Dickinson, Oxford, 
UK), placed into wells of a 24 well plate, were coated with 100µl of  SFM containing 
50µg of Matrigel before dehydration at 55°C for 2 hours in a Hybrdiser HB-1D 
drying oven. Subsequently, 100µl of SFM was used to rehydrate the matrigel for 30 
minutes before gently removing the SFM and seeding 30,000 cells in 200µl of 
medium. 1ml of growth medium was added to the wells of the 24 well housing the 
inserts to sustain invasive cells and the plate was incubated for 3 days. Following 
incubation, cells / Matrigel remaining in the inside of the insert were removed with 
tissue paper and cells present on the underside of the insert were fixed in 4% formalin 
for 10 minutes, stained in 0.5% crystal violet for 5 minutes, washed, air dried and 
visualised under a Leica DMi1 microscope equipped with a MC120 HD camera. 
Images of several random fields were captured and quantified. The experiment was 
repeated a minimum of three times. 
 
2.19 Statistical analysis 
Statistical analysis was undertaken using the SPSS 24 and graphs prepared using 
Graph Pad Prism 8. Data was analysed using t-test or Mann Whitney test depending 
on data parameters. Clinical data was analysed using chi-squared tests, uni- and 
multi-variant analysis. Values of p < 0.05 were regarded as statistically significant.
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Chapter III 
 
Expression of sphingosine kinase 1 
(SphK1) in human gastric cancer 
tissues: potential clinical 
implications for SphK1 in gastric 
cancer
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3.1 Introduction 
The area of gastric cancer research has drawn much attention from many healthcare 
professionals due to the high cost of healthcare resources and high mortality/morbidity for 
patients seeking appropriate treatment based on the complexity of its underlying mechanisms. 
Despite advances in understanding of this disease research is still required to identify 
molecules that may be of therapeutic benefit, either as biomarkers of disease or to aid in the 
development of new therapeutic strategies.  
One such molecule is SphK1, a protein kinase involved in generation of S1P (Moruno 
Manchon et al., 2016). A pathway which, when subject to improper regulation has been linked 
to cancer development/progression (Nagahashi et al., 2018a). Similarly, SphK1 has been 
implicated to play a role in cancer, with an early key study, highlighting SphK1 as an oncogene,  
demonstrating enhanced in vitro and in vivo growth following SphK1 overexpression, which 
could be supressed following overexpression of a G82D dominant-negative kinase SphK1 
mutant or through treatment with an SphK1 inhibitor In keeping with this role of SphK1 
transcript and/or protein expression is frequently up-regulated in various types of cancer. 
Enhanced expression of SphK1 in cancerous, in comparison to normal adjacent tissues has 
been reported both in mRNA level and protein level, including gastric cancer (Li et al., 2009, 
Wang et al., 2018b), brain cancer (Li et al., 2008, Van Brocklyn et al., 2005), colon cancer 
(Kohno et al., 2006, Kawamori et al., 2009, Kawamori et al., 2006) and lung cancer (French 
et al., 2003, Johnson et al., 2005, Song et al., 2011, Yang et al., 2019), as well as in blood 
cancer (Bayerl et al., 2008, Le Scolan et al., 2005) and breast cancer (Ruckhaberle et al., 2008, 
Erez-Roman et al., 2010, Zhu et al., 2017). This research demonstrated that SphK1 played an 
important role in carcinogenesis. Furthermore, there are a growing number of studies that have 
associated that enhanced SphK1 expression with poorer patient outlooks, where it has been 
linked to enhanced tumour malignancy, disease progression, decreased patient survival rates 
and poor prognosis (Zhang et al., 2014b, Ruckhaberle et al., 2008, Van Brocklyn et al., 2005), 
Taken together, the above studies and wider literature strongly suggests an association 
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between SphK1 and cancer, with enhanced expression being linked to cancer development 
and/or disease progression (Zhang et al., 2014b). 
The aim of the current chapter was to explore the expression of SphK1 within a number of 
cohorts at both transcript and protein level and to further clarify its potential to act as a 
biomarker for progression and patient prognosis in gastric cancer. 
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3.2 Methods and materials 
3.2.1.1 Cohort 1 
This method is fully described in section 2.6 of the main methodology. Briefly, 322 fresh-
frozen tissues were used to undertake qPCR transcript analysis in which we got 183 paired 
normal tissue. Tissue was obtained from cT2-4N0M0 or cT1-4N1-3M0 gastric cancer patients 
treated between January 2006 and December 2007 in Peking University Cancer Hospital. All 
protocols were reviewed and approved by the local ethics committee and informed consent 
was obtained from the patients before therapy. 
 
3.2.1.2 Cohort 2 
263 paraffin-embedded tissues were used to undertake IHC protein analysis. Tissue was 
obtained from cT2-4N0M0 or cT1-4N1-3M0 gastric cancer patients treated between January 
2003 and December 2011 in Peking University Cancer Hospital. All protocols were reviewed 
and approved by the local ethics committee and informed consent was obtained from the 
patients before therapy. 
 
3.2.2 Immunohistochemisty 
This method is fully described in section 2.13 of the main methodology and as previously 
described (Gao et al., 2015). Staining score was independently assessed by two pathologists. 
Percentage of positive cells and intensity of cytoplasmic staining were analysed. 
 
3.2.3 Total RNA isolation and quantification 
This method is fully described in section 2.7 of the main methodology. In brief, total RNA 
isolation was performed with TRI Reagent kit (Sigma-Aldrich, Dorset, UK) as previously 
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described (Ye et al., 2014). RNA concentration and purity were measured on a 
Nanophotometer (IMPLEN; Geneflow ltd., Lichfield, UK) and samples standardised. 
 
3.2.4 Reverse Transcription (RT) 
This method is fully described in section 2.8 of the main methodology. Briefly a 20µl RT 
reaction was performed using 500ng total RNA template and the GoScriptTM Reverse 
Transcription System (Promega, Southampton, UK). The complementary DNA (cDNA) was 
then diluted with PCR water by a factor of 1:4 and stored at -20 °C. 
 
3.2.5 Quantitative real-time polymerase chain reaction (qPCR) 
The method is fully described in section 2.12 of the main methodology section. In brief, the 
current study quantified transcript copy number of interest using the AmplifluorTM Uniprimer 
system (Intergen company®, New York, USA). Primers sequences are shown in Table 3.1. 
3.2.6 Conventional polymerase chain (PCR) reaction and agarose gel electrophoresis 
This method is fully described in section 2.9 and 2.10 of the general methodology. In brief, 
PCR was performed with the Promega Green master mix (Promega, Southampton, UK) and 
1μl cDNA samples. SphK1 primer sequences used are indicated in table 3.2 
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Table 3.1. Primers used in qPCR analysis 
Primer Forward primer Reverse primer 
SphK1 5’- 
ACCATTATGCTGGCTATG
AG-3’ 
5’- 
ACTGAACCTGACCGTACAGAGACAGCAGGTT
CATGG-3’ 
CK19 5’-
CAGGTCCGAGGTTACTGA
C-3’ 
5’- 
ACTGAACCTGACCGTACACCGTTTCTGCCAG
T GTGTCTTC-3’ 
 ACTGAACCTGACCGTACA represents the Z sequence 
 
Table 3.2. Primers used in the PCR analysis. 
Primer Forward primer Reverse primer 
SphK1 5’- TGAACCATTATGCTGGCTA-3’ 5’- GTGCAGCAAACATCTCACT-3’ 
GAPDH 5’-GGGCAACGAACTCTTCTAC-3’ 5’-TCCAGGTGTCAAGAGTGAA-3’ 
  
108 
 
3.2.7 Protein extraction, quantification and western blotting 
This method is fully described in sections 2.14, 2.15 and 2.17 of the main methodology. In 
brief, following confluence, cells were extracted using a cell scraper, centrifuged to pellet and 
lysed in a lysis buffer for 1 hour on a rotating wheel. Subsequently, insolubles were removed 
through centrifugation, the samples quantified using a DC protein assay kit (Bio-Rad, Hemel 
Hempstead, UK), standardised, mixed 1:1 with 2X laemmli sample buffer (Sigma-Aldrich, 
Dorset, UK) and boiled for 5 minutes.  Sodium Dodecyl Sulphate Poly Acrylamide Gel 
Electrophoresis (SDS-PAGE) was used to separate protein samples before blotting onto PVDF 
membranes. Subsequently, the membranes were blocked in 10% skimmed milk for 60 min at 
room temperature before being probed with anti-SphK1 and anti-GAPDH antibodies (Santa-
Cruz Biotechnologies, CA, USA). Membranes were then incubated with a peroxidase-
conjugated secondary antibody (Sigma-Aldrich, Dorset, UK) and the protein bands visualised 
using the EZ-ECL Chemiluminescent Detection Kit (Geneflow ltd., Lichfield, UK). 
 
3.2.8 Statistical analysis 
Statistical analysis was performed using the SPSS statistical software package (SPSS Mac 
Standard version 24.0, SPSS Inc.). The relationship between SphK1 expression and tumour 
grade, TNM staging and nodal status was assessed using the Mann-Whitney U (mRNA), Chi-
square (protein) and Log-rank (protein) tests. Survival was analysed using Kaplan-Meier 
survival analysis (p-values by Cox Proportion Hazardous Analysis). p < 0.05 was considered 
statistically significant. 
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3.3 Results 
3.3.1 Gastric cancer patient cohort 
The gastric cancer clinical cohort (Cohort 1) (n = 322) was used to probe SphK1 
expression using quantitative PCR. The cohort consisted of 229 men (71.1%) and 93 
women (28.9%). All the patients underwent surgery without any prior treatment. The 
result was that 134 patients were alive, 185 patients died of gastric cancer, 15 patients 
had metastasis and 119 remained disease-free survival. 
Cardiff China Medical Research Collaborative (CCMRC) have a long-term 
relationship with PKUCH. Therefore, the team used GC patients tissue sample 
storing in PKUCH biobank. In 2013, RNA of GC samples were extracted and cDNA 
were reverse-transcribed and multiple genes were detected by qPCR. The above 
work is the basis on the previous work of whole team before I started to work in the 
laboratory. I used the qPCR data that had been generated and made statistical 
analysis. 
 
3.3.2 Gene expression of SphK1 in gastric cancer patients and 
association with clinicopathological parameters 
We evaluated the transcript copies of SphK1 in all patient tissues using real-time 
quantitative PCR is expressed as median SphK1 transcript copies/µl of cDNA from 
50ng total RNA and was standardised using CK19) and compared expression levels 
to patient clinicopathological data (Table 3.3). The results showed that SphK1 
expression was upregulated in tumour tissue compared to adjacent normal tissue (p 
< 0.001). Transcript levels of SphK1 were significantly upregulated in tumours at 
more advanced depth of invasion (T1+T2 versus T3+T4, p = 0.009), further lymph 
node metastasis (N0 versus N3, p = 0.0244) and more advanced grade of TNM stage 
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(TNM1 versus TNM4, TNM1+TNM2 versus TNM3 + TNM4, p = 0.0334, p = 
0.0225, respectively). Furthermore, statistical analysis revealed significant links 
between the different clinical outcomes and transcript levels (Alive versus Death, p 
= 0.0379). However, there was no significant correlation between the transcript level 
of SphK1 and distant metastasis, vascular invasion, tumour location or 
differentiation (all p > 0.05). 
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Table 3.3. The association of SphK1 transcript expression and clinical parameters. 
Category 
 
No. Median Q1 Q3 pa 
T/Nb 
     
<0.001  
Normal 183 0.10 0 21 
 
 
Tumour 322 2.50 0 56 
 
Gender      0.7876 
 Male 229 0.10 0 16  
 Female 93 0.10 0 29  
Location 
      
 
Cardia 66 0.30 0 53 
 
 
Fundus 21 2.90 0 52 0.3310  
Corpus 61 0.10 0 27 0.4796  
Pylorus 130 0.00 0 16 0.1696 
Differentiation 
     
 
Diff-H 1 0.00 N/A N/A 
 
 
Diff-HM   6 0.03 0 1.69 
 
 
Diff-M   62 0.03 0 6 0.3812  
Diff-ML   81 0.08 0 28 0.2121  
Diff-L   137 0.10 0 29 0.2510 
T stage 
     
 
T1 16 0.01 0 0.64 
 
 
T2 25 0.00 0 0 0.3706  
T3 31 6.20 0 83 0.0586  
T4 232 0.08 0 26 0.2526 
        
T1+T2 41 0.00 0 0 
 
 
T3+T4 273 0.10 0 28 0.009 
N stage 
  
0 
  
 
N0 71 0.00 0 5 
 
 
N1 48 0.00 0 8 0.8221  
N2 64 0.00 0 24 0.1375  
N3 133 0.00 0 45 0.0244 
   0.00     
N0 71 0.00 0 5 
 
 
N1+N2+N3 245 0.00 0 29 0.0519 
M stage 
  
0 
 
0.7139  
M0 280 0.10 0 13 
 
 
M1 41 0.00 0 93 
 
TNM stage 
  
0 
  
 
Ⅰ 25 0.00 0 0.60 
 
 
Ⅱ 59 0.02 0 10 0.5474 
 Ⅲ 220 0.20  30 0.0516  
Ⅳ 9 1.00 0 258 0.0334 
        
Ⅰ+Ⅱ 84 0.00 0 4 
 
 
Ⅲ+Ⅳ 229 0.00 0 32 0.0255 
Vascular invasion 
    
0.6462  
No invasion 152 0.00 0 23 
 
 
Invasion 155 0.10 0 19 
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Clinical outcome  
 
 
 
0 
 
0.0379  
Alive 134 0.00 0 4 
 
 
Death 185 0.40 0 45 
 
pa: Mann-Whitney U test 
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3.3.3 Association between SphK1 transcript expression and gastric 
cancer patient survival 
Using median value as the cut off to define high and low transcript level of SphK1, 
Kaplan-Meier survival curves revealed that patients with a low expression of SphK1 
generally had a better overall survival (OS) and disease-free survival (DFS) than 
those with SphK1 high expression in gastric cancer patients. However, this 
difference did not reach statistical significance (p = 0.196 and p = 0.570, respectively) 
(Figure 3.1. A). 
Although there was no statistical difference in the survival time in our own cohort, 
we examined the expression of SphK1 in GEO database to check whether the 
expression of SphK1 contributed to survival. In the GEO database (GSE26253) 
cohort, we found that the low expression of SphK1 had a better RFS compared to 
the high expression of SphK1 in GC patients (p = 0.034) (Lee et al., 2014) (Figure 
3.1. B).  
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Figure 3.1.A. Kaplan-Meier survival curves demonstrating the relationship between 
SphK1 mRNA expression and overall survival (Top panel) and disease-free survival 
(bottom panel) 
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Figure 3.1. B. Kaplan-Meier survival curves demonstrating the relationship between 
SphK1 mRNA expression and relapse free survival from GEO database (GSE26253). 
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3.3.4 Conventional PCR analysis of SphK1 expression in paired 
tissues in gastric cancer patients 
A subset of 10 gastric cancer samples and paired adjacent normal samples (5cm away 
from tumour margin), taken from the Biobank of Peking University Cancer Hospital, 
were used to explore the mRNA expression of SphK1 within gastric cancer and 
paired normal tissue samples (Figure 3.2). The results indicate that SphK1 is 
routinely higher in the tumour tissue in comparison to the paired normal equivalent, 
with the vast amounts of pairs demonstrating a substantially higher level in the 
tumour component that the normal paired equivalent. 
 
 
Figure 3.2. Representative images of SphK1 mRNA expression in gastric tissue of 10 
different patients showing tumour (T) and paired adjacent normal (N) tissues. 
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3.3.5 Protein expression levels of SphK1 in gastric cancer tissues 
Another gastric cancer clinical cohort (Cohort 2) (n = 263) was used to explore 
SphK1 protein expression using immunohistochemistry (IHC) analysis. Staining 
intensity was assigned as negative expression ‘-’ and ‘+’, ‘++’, ‘+++’ as positive 
expression. Immunostaining data were available for 100% (263/263) of cases, with 
6 cases lacking interpretable staining data. SphK1 expression was moderately 
positive (++) in 7.75% of cases (23/263), faintly positive (+) in 25.86% of cases 
(68/263) and the remaining 65.40% (172/263) of cases showed negative staining (-). 
In addition, SphK1 was found to be highly expressed in gastric cancer tissue in 
comparison to paired adjacent normal tissue (p < 0.001), and its distribution was 
mainly confined in the cytoplasm (Figure 3D). Representative staining patterns from 
3 patients are shown in Figure 3.3A.B.C.  
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Figure 3.3. A. Representative images of SphK1 immunohistochemical staining in gastric 
tissue of Patient 1(No. 62629) showing tumour (Top panel; Tumour), adjacent normal 
tissue (Middle panel; Normal) and H&E staining in the same patient tumour tissue (Bottom 
panel) (100x & 200x, respectively). 
 
 
119 
 
 
Figure 3.3. B. Representative images of SphK1 immunohistochemical staining in gastric 
tissue of Patient 2 (No. 62969) showing tumour (Top panel; Tumour), adjacent normal 
tissue (Middle panel; Normal) and H&E staining in the same patient tumour tissue (Bottom 
panel) (100x & 200x, respectively). 
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Figure 3.3. C. Representative images of SphK1 immunohistochemical staining in gastric 
tissue of Patient 3 (No. 65078) showing tumour (Top panel; Tumour), adjacent normal 
tissue (Middle panel; Normal) and H&E staining in the same patient tumour tissue (Bottom 
panel) (100x & 200x, respectively). 
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Figure 3.3. D. Representative images of SphK1 immunohistochemical staining in gastric 
tissue demonstrating higher SphK1 expression in higher TNM stage tissues and the 
cytoplasmic distribution of SphK1.  
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3.3.6 Expression of SphK1 in gastric cancer tissues and association 
with clinicopathological parameters 
The staining profile of SphK1 in gastric cancer tissues was further compared to 
patient clinical pathological information (Table 3.4; Figure 3.3D). Upon analysis it 
was seen that positive expression of SphK1 was positively associated with lymph 
node metastasis (N0 versus N1 versus N2 versus N3; p = 0.003, N0 versus N1 + N2 
+ N3; p = 0.003), distant metastasis (p = 0.004) and TNM stage (TNM1 versus 
TNM2 versus TNM3 versus TNM4; p < 0.004, TNM1 + TNM2 versus TNM3 + 
TNM4; p = 0.005). There was no significant correlation between SphK1 expression 
and gender, age, tumour location, tumour size, Lauren type, differentiation, histology, 
lymphovascular invasion and depth of invasion (all p > 0.05). However, an 
increasing trend in the expression of SphK1 was observed from T1+T2 to T3+T4, 
and from T1 to T2+T3+T4. Also, comparison between the absence and presence of 
lymphovascular invasion showed an increasing trend and near statistical significance 
(p = 0.084) (Table 3.4). 
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Table 3.4. Association of SphK1 expression with clinicopathological features in gastric 
cancer patients 
Clinicopathological 
Features  
SphK1 expression 
pb 
Negative (%) Positive (%) 
Gender   0.640 
Male 120 (64.5) 66 (35.5)  
 Female 52 (67.5) 25 (32.5)  
    
Age (year)   0.932 
 >60  86 (71.4) 46 (28.6)  
≤60 86 (74.1) 45 (25.9)  
    
Tumour location   0.950 
 Upper 1/3 36 (61.7) 17 (38.3)  
 Middle 1/3 40 (67.2) 20 (32.8)  
 Low 1/3 90 (78.3) 51(21.7)  
 Total 6 (100.0) 3 (0.0)  
    
Cardia & Non-
cardia 
  0.671 
 Cardia cancer 30 (68.2) 14 (31.8)  
 Non-cardia cancer 144 (64.8) 71 (35.2)  
    
Tumour size (cm)   0.512 
 >4.0 81 (67.5) 39 (32.5)  
 ≤4.0 91 (63.6) 52 (36.4)  
    
Lauren type   0.752 
 Intestinal type 32 (61.5) 20 (38.5)  
 Diffuse 95 (65.5) 50 (34.5)  
 Mixed type 45 (68.2) 21 (31.8)  
    
Differentiation   0.685 
 Well-Moderate 82 (69.2) 41 (30.8)  
 Poor 90 (75.8) 50 (24.2)  
   0.573 
 Well 6 (66.7) 3 (33.3)  
 Moderate 76 (66.7) 38 (33.3)  
 Poor 78 (62.4) 47 (37.6)  
 Singnet 12 (80.0) 3 (20.0)  
    
Histology   0.604 
 Adenocarcinoma 146 (66.1) 75 (33.9)  
 Other types* 26 (61.9) 16 (38.1)  
    
Lymphovascular 
invasion 
  0.084 
 Absent 93 (70.5) 39 (29.5)  
 Present 79 (60.3) 52 (39.7)  
    
Depth of invasion   0.286 
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 T1 13 (68.4) 6 (31.6)  
 T2 24 (72.7) 9 (27.3)  
 T3 1 (25.0) 3 (75.0)  
 T4 134 (64.7) 73 (35.3)  
   0.330 
 T1+T2 37 (71.2) 15 (28.8)  
 T3+T4 135 (64.0) 76 (36.0)  
   0.774 
 T1 13 (68.4) 6 (31.6)  
 T2+ T3+T4 159 (65.2) 85 (34.8)  
    
Lymph node 
metastasis 
  0.003 
  N0 49 (81.7) 11 (18.3)  
  N1 36 (73.5) 13 (26.5)  
  N2 26 (60.5) 17 (39.5)  
  N3 61 (55.0) 50 (45.0)  
   0.003 
  No 49 (81.7) 11 (18.3)  
  Yes 123 (60.6) 80 (39.4)  
    
Distant metastasis   0.004 
  No 160 (68.4) 74 (31.6)  
  Yes 12 (41.4) 17 (58.6)  
    
TNM stage   0.004 
  I 25 (75.8) 8 (24.2)  
  II 31 (81.6) 7 (18.4)  
  III 104 (63.8) 59 (36.2)  
  IV 12 (41.4) 17 (58.6)  
   0.181 
  I 25 (75.8) 8 (24.2)  
  II-IV 147 (63.9) 83 (36.1)  
   0.005 
  I+II 56 (78.9) 15 (21.1)  
  III+IV 116 (60.4) 76 (39.6)  
Other types*: Signet-ring cell carcinoma, mucinous adenocarcinoma and et al. 
pb: Chi-square test 
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3.3.7 Association of SphK1 staining in gastric cancer tissue with 
patient survival time 
Kaplan-Meier survival curves using data from all gastric cancer patients (n = 257) 
(Cohort 2) revealed that patients with positive SphK1 expression had worse overall 
survival (OS; p < 0.001) and disease-free survival (DFS; p < 0.001) than those that 
were negative for SphK1. Patients were divided into subgroups according to T stage, 
N stage, M stage and TNM stage. We found that positive SphK1 expression was 
associated with worse OS in patients with T2+T3+T4 (p < 0.001) (n = 85); and also 
in those patients in the TNM2+TNM3 (p = 0.002) (n = 66), N1+N2+N3 (p = 0.006) 
(n = 80), M0 (p = 0.003) (n = 74) and M1 (p = 0.028) (n = 17) subgroups. Although 
there was no statistical significance in N0 subgroup, SphK1 negative expression still 
showed a better OS and DFS in N0 subgroup (Figure 3.4). 
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Figure 3.4. Kaplan-Meier survival curves demonstrating the relationship between SphK1 
protein level and overall survival (Top panel) and disease-free survival (Bottom panel) 
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3.3.8 Univariate and multivariate analysis of SphK1 staining in 
gastric cancer tissues 
It was revealed using Univariate analysis (Table 3.5) that the protein expression of 
SphK1 correlated with tumour location (p = 0.021), tumour size (p = 0.002), 
lymphovascular invasion (p < 0.001), depth of invasion (T1+T2 versus T3+T4, p < 
0.001), lymph node metastasis (N0 versus N+, p < 0.001), distant metastasis (M0 
versus M1, p < 0.001) and SphK1 (Negative versus Positive, p < 0.001). However, 
there was no significant correlation between the expression level of SphK1 and 
gender, age, differentiation, Lauren type and histology (all p > 0.05). Multivariate 
analysis revealed that the expression of SphK1 was an independent prognostic factor 
in gastric cancer patients (p = 0.001). Analysis using all parameters as variants also 
showed that invading cardia (p < 0.001), differentiation (p = 0.011), lymphovascular 
invasion (p = 0.003), T status (p < 0.001), N status (p < 0.001) and M status (p < 
0.001) are independent factors for the overall survival (Table 3.5). 
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Table 3.5.Univariate and multivariate survival analysis of clinicopathological features of gastric 
carcinoma patients  
Clinicopathological Features Univariate analysis Multivariate analysis 
HR 95% CI pc HR 95% CI pd 
Gender       
Male vs. Female 1.12 0.790-1.579 0.53    
Age (year)       
  ≤60 vs. >60 0.830 0.610-1.132 0.240    
Cardia & Non-cardia       
  Cardia vs Non-cardia 1.69 1.160-2.476 0.006 2.396 1.607-3.573 <0.001 
Tumour location       
  Upper 1/3 0.424 0.204-0.878 0.021    
  Middle 1/3 0.237 0.112-0.499 <0.001    
  Low 1/3 0.259 0.130-0.520 <0.001    
  Total   <0.001    
Tumour size (cm)       
>4.0 vs. ≤4.0 0.620 0.455-0.845 0.002    
Lauren type       
Intestinal vs. 
Diffuse/Mixed 
0.975 0.668-1.424 0.898    
Differentiat on       
Well-Moderate vs. 
Poor 
1.30 0.954-1.776 0.096 1.503 1.098-2.057 0.011 
Hist logy       
Adenocarcinoma vs. Other 
types* 
1.350 0.907-2.007 0.138    
Lymphovascular invasion       
Absent vs. Present 2.056 1.502-2.815 <0.001 1.637 1.184-2.265 0.003 
Depth of invasion       
T1 0.000  0.937    
  T2 0.256 0.130-0.502 <0.001    
  T3 0.548 0.145-2.359 0.451    
  T4   0.001    
  T1+T2 vs. T3+T4 6.462 3.293-12.677 <0.001 3.611 1.787-7.295 <0.001 
Lymph node 
metastasis 
      
  N0 0.114 0.062-0.209 <0.001    
  N1 0.247 0.152-0.402 <0.001    
  N2 0.636 0.428-0.946 0.025    
  N3   <0.001    
  No vs. Yes 5.597 3.104-10.095 <0.001 3.370 1.797-6.319 <0.001 
Distant metastasis 
  No vs. Yes  
0.177 0.116-0.271 <0.001 0.277 0.179-0.428 <0.001 
SphK1       
 Negative vs. Positive 
 Positive 
1.895 1.385-2.594 <0.001 1.726 1.253-2.378 0.001 
Other types*: Signet-ring cell carcinoma, mucinous adenocarcinoma and et al; 
CI: Confidence Interval; HR, Hazard ratio. 
pc: Log-rank test; pd: Cox regression test 
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3.3.9 Protein expression of SphK1 in gastric cancer patients 
A subset of 12 gastric cancer samples and paired normal samples, taken from 
Biobank of Peking University Cancer Hospital, were used to explore the protein 
expression of SphK1 within gastric cancer samples using western blot (Figure 3.5). 
Similar to the earlier conventional PCR analysis, SphK1 protein levels were seen to 
be elevated in the majority of tumour tissues compared to their paired normal 
equivalents. 
 
 
 
Figure 3.5: Representative images of SphK1 protein expression in gastric tissue of 12 
different patients showing tumour (T) and paired adjacent normal (N) tissue
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3.4 Discussion 
GC represents the third greatest cause of cancer-related mortality and has the fifth 
highest incidence around the world (Torre et al., 2015). It is a key concern in China 
which almost half of GC patients worldwide (Ferlay et al., 2015). As early GC has 
no obvious symptoms, therefore, GC was mostly found in the advance and late stage. 
As a result, the 5-year survival rate in most countries is usually maintained at 20-40% 
(Allemani et al., 2018, Arnold et al., 2019). However, South Korea and Japan, with 
early gastroscopy screening, have a five-year survival rate of 60% . GC is a highly 
heterogeneous tumour, and there is an urgent need to understand the molecular 
mechanisms involved in the development and progression of gastric cancer in order 
to find better molecular markers and therapeutic targets. The identification of novel 
targets for use in the development of more effective anti-gastric cancer 
chemotherapy resistant strategies is urgent. Hence, developing new biomarkers for 
early detection of the tumour and more accurate prediction of disease outcomes as 
well as the patients’ response to chemotherapy regimens could significantly improve 
efficacy of the treatments and greatly decrease the mortality of gastric cancer. 
The current chapter explored the potential of SphK1, a molecule known to play a 
significant role in regulating oncogenesis, and which has been proposed to alter the 
balance between apoptotic (Guillermet-Guibert et al., 2009) and pro-survival 
signalling (Akao et al., 2006, Pchejetski et al., 2005). Previous studies have 
demonstrated that  the expression level of SphK1 is frequently up-regulated in 
various types of cancer, both at mRNA level and protein level, including gastric 
cancer (Li et al., 2009), brain cancer (Li et al., 2008, Van Brocklyn et al., 2005), 
colon cancer (Kohno et al., 2006, Kawamori et al., 2009, Kawamori et al., 2006) and 
lung cancer (French et al., 2003, Johnson et al., 2005, Song et al., 2011). Similar 
observations have also been identified in blood cancer (Bayerl et al., 2008, Le Scolan 
et al., 2005) and breast cancer (Ruckhaberle et al., 2008, Erez-Roman et al., 2010). 
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and enhanced SphK1 expression has also been linked with poorer patient outlooks, 
where it has been linked to enhanced tumour malignancy, disease progression, 
decreased patient survival rates and poor prognosis (Zhang et al., 2014b, 
Ruckhaberle et al., 2008, Van Brocklyn et al., 2005).  
In keeping with these observations in other cancers the data presented in the current 
chapter has shown that SphK1 expression is enhanced in tumour tissue compared to 
normal counterparts and is significantly correlated with depth of invasion, lymph 
node metastasis, distant metastasis, clinical stage and prognosis in gastric cancer 
patients, whether in the mRNA or protein level. This chapter has also demonstrated 
that the high expression of SphK1 is associated with poor prognosis of gastric cancer 
patients. Compared with previous work, the current study demonstrated poor 
prognosis in patients with high SphK1 expression at both mRNA and protein levels 
and is supported by the relatively large sample sizes to illustrate the relationship 
between SphK1 and prognosis. In addition, following multivariate analysis, SphK1 
was found to be an independent prognostic factor in patients with gastric cancer 
which also indicates that SphK1 may be a promising prognosis biomarker of gastric 
cancer patients. Protein level studies have found that OS of patients with high 
expression of SphK1 significantly better than patients with low SphK1 expression. 
However, in the study of mRNA levels, the survival curves of SphK1 high and low 
expression patients were not separated, which may be due to the large variability of 
real-time quantitative PCR and the expression of SphK1 at the gene level and protein 
level were not same.  
 Hence, the data presented in this chapter supports previous studies focused on GC 
(Li et al., 2009, Wang et al., 2018b).  Li et al., demonstrated enhanced SphK1 
expression at both mRNA and protein level in gastric cancer tissues and cell lines 
compared to the normal equivalents, with higher expression associated with clinical 
stage, T stage, M stage and survival rates, reporting it as an independent prognostic 
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factor (Li et al., 2009). More recently Wang et al., (Wang et al., 2018b) showed 
SphK1 was elevated in GC tumour tissue and also increased the S1P level. 
Knockdown SphK1 was related to tumour growth. In addition, the expression rate of 
SphK1 at the protein level was about 34%, and the expression rate of SphK1 in Li 
et.al., (Li et al., 2009) article is as high as 66%. The reason for this difference might 
be due to the antibody factor and the lower indoor temperature in the laboratory. 
 
In conclusion, the data presented in this chapter demonstrates and supports a link 
between SphK1 expression and gastric cancer prognosis and progression. 
Subsequent chapters will aim to explore the cellular significance and function of 
SphK1 in gastric cancer cells and its role in chemotherapeutic resistance.
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Chapter IV 
 
Establishment of SphK1 
knockdown models and its 
functional significance
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4.1 Introduction 
The expression of SphK1 is frequently dysregulated in a range of human cancers 
(Wang et al., 2019b). SphK1 has been established as playing a role in regulating 
oncogenesis and is able to alter the balance between apoptotic and survival signals 
(Limaye et al., 2005, Guillermet-Guibert et al., 2009, Akao et al., 2006, Pchejetski 
et al., 2005). The potential for shifting the balance away from S1P production and 
towards sphingosine and ceramide production has been investigated as a method to 
promote apoptosis and inhibit growth (Hannun and Obeid, 2008). Here, SphK1 plays 
an important role, acting as a kinase which can catalyse conversion of sphingosine 
into S1P and bring about biological function. 
Given its dysregulation in cancer and role in these important processes, the 
functional role of SphK1 has been investigated in a number of published studies 
exploring various type of cancer. Recently, a study by  Cao et al. has showed that 
miR-128 can directly target 3'-untranslated region (UTR) of SphK1 and plays a vital 
role in thyroid carcinoma progression (Cao et al., 2019). Another study also showed 
in vivo that SphK1 contributes to hepatocarcinogenesis, using SphK1 knockout 
(SphK1-/-) mouse models (Chen et al., 2018a). Shimizu’s study also demonstrates a 
link where ER- /PR- /HER2+ human breast cancer cells and mouse models display 
a reduced level of claudin-2 (CLDN2) expression in mice deficient in SphK1, 
highlighting a potential link between CLDN2 and SphK1. Hence, therapeutic 
targeting of SphK1 may present an interesting approach for HER2-positive breast 
cancer therapies (Shimizu et al., 2018). Furthermore, A recent study has 
demonstrated poorer prognosis of colorectal cancer patients with SphK1-positive 
expression compared with those displaying SphK1-negative expression and SphK1 
knockdown could inhibit EMT and cellular migratory capacity through focal 
adhesion kinase/protein kinase B / Matrix metalloproteinase (FAK /AKT / MMPs) 
axis (Liu et al., 2019).  
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Hence, SphK1 appears to be an interesting molecule that could influence the 
aggressive nature of cancer cells. The current chapter aims to assess the functional 
role of SphK1 in gastric cancer cells and its potential to regulate aggressive cellular 
characteristics. 
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4.2 Methods and materials 
4.2.1 Synthesis of SphK1 targeting ribozyme by touchdown PCR 
This method is described in section 2.11.1 of chapter II. In brief, touchdown PCR 
was carried out with specific sequences to synthesise different transgenes, labelled 
as ribozyme 1 and ribozyme 2, targeting different specific GTC or ATC sites with 
SphK1. Following this a portion of the products were run on a 2% agarose gel to 
confirm presence before undertaking cloning with the remaining product. 
 
4.2.2 TOPO TA cloning of SphK1 targeting ribozyme into the 
pEF6/V5-His-TOPO plasmid vector, incorporated transgene 
orientation check, plasmid amplification and extraction 
This methodology is described in section 2.11.2 of Chapter II. In brief, ribozyme 
transgenes were inserted into a pEF6 / V5-His-TOPO plasmid vector in accordance 
with the manufacturer’s instructions. Subsequently, insert orientation was confirmed 
using RbBMR and RbToPF (Table 4.1) primers and PCR, before amplifying 
colonies and harvesting plasmids using a Sigma GenElute plasmid kit in accordance 
with the manufacturer’s instructions (see section 2.11.3 of Chapter II).  
 
4.2.3 Transfection of gastric cancer cells using electroporation and 
generation of knockdown models 
This methodology is described in full in section 2.11.4 of Chapter II. In brief, HGC27 
and AGS cells were detached and seeded into electroporation curvettes together with 
either pEF control plasmid or plasmid containing SphK1 ribozyme transgene before 
being subjected to electroporation. Cells were subsequently transferred to fresh 
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flasks and underwent a selective period (5µg/ml blasticidin) before being transferred 
and routinely cultured in maintenance medium (0.5µg/ml blasticidin). 
 
4.2.4 Total RNA isolation and quantification 
This method is fully described in section 2.7 of Chapter II. In brief, total RNA 
isolation was performed with TRI Reagent kit (Sigma-Aldrich, Dorset, UK) as 
previously described (Ye et al., 2014). RNA concentration and purity were measured 
on a Nanophotometer (IMPLEN; Geneflow ltd., Lichfield, UK) and standardised. 
 
4.2.5 Reverse transcription (RT) 
This method is fully described in section 2.8 of Chapter II. Briefly a 20µl RT reaction 
was performed with 500ng total RNA and the GoScriptTM Reverse Transcription 
System (Promega, Southampton, UK). The complementary DNA (cDNA) was then 
diluted with PCR water by a factor of 1:4 and stored at -20 °C for further use. 
 
4.2.6 Polymerase Chain reaction (PCR) and agarose gel 
electrophoresis 
This method is fully described in section 2.9 and 2.10 of Chapter II. In brief, PCR 
was performed with the Promega Mix PCR Reaction mix (Promega, Southampton, 
 UK) and 1μl cDNA samples. SphK1 primer sequences used are indicated in Table 
4.1. 
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4.2.7 Quantitative real-time polymerase chain reaction (qPCR) 
The method is fully described in section 2.12 of Chapter II. In brief, the current study 
quantified transcript copy number of interest using the AmplifluorTM Uniprimer 
system (Intergen company®, New York, USA). Primers sequences are shown in 
Table 4.1. 
 
4.2.8 Protein extraction, quantification and western blotting 
This method is fully described in sections 2.14, 2.15 and 2.17 of Chapter II. In brief, 
following confluence, cells were extracted using a cell scraper, centrifuged to pellet 
and lysed in a lysis buffer for 1 hour on a rotating wheel. Subsequently, insolubles 
were removed through centrifugation, the samples quantified using a DC protein 
assay kit (Bio-Rad, Hemel Hempstead, UK), standardised, mixed 1:1 with 2X 
laemmli sample buffer (Sigma-Aldrich, Dorset, UK) and boiled for 5 minutes.  SDS-
PAGE was used to separate protein samples before blotting onto PVDF membranes. 
Subsequently, the membranes were blocked in 10% skimmed milk for 60 min at 
room temperature before being probed with anti-SphK1 (1:1000) and anti-GAPDH 
(1:4000) antibodies (Santa-Cruz Biotechnologies, CA, USA). Membranes were then 
incubated with a peroxidase-conjugated secondary antibody (1:10000) (Sigma-
Aldrich, Dorset, UK) and the protein bands visualised using EZ-ECL 
Chemiluminescent Detection Kit (Geneflow ltd., Lichfield, UK).  
 
4.2.9 Invasion assay 
This method is described in section 2.18 of Chapter II. In brief, cancer cells were 
seeded into inserts containing 8µm pores pre-coated with 50µg of Matrigel, 
suspended above a 24 well plate containing growth medium. Following 3 days 
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incubation, invaded cells, on the underside of the insert, were fixed in formalin, 
stained in crystal violet and visualised and counted under the microscope. 
 
4.2.10 Matrix-adhesion assay 
This method is described in section 2.18 of Chapter II. In brief, cancer cells were 
seeded into wells of a 96 well plate pre-coated with 5µg of Matrigel and incubated 
for 40 minutes. Following incubation, the plate was washed in PBS and adherent 
cells fixed in formalin and stained in crystal violet before extracting stain in acetic 
acid and measuring absorbance.  
 
4.2.11 Proliferation assay 
This method is described in section 2.18 of Chapter II. In brief, cancer cells were 
seeded into 96 well plates. Following 0, 1, 3 or 5 day incubation, media was removed 
from one plate and cells were formalin fixed and stained in crystal violet before 
extracting stain in acetic acid and measuring absorbance. Growth over the incubation 
periods was compared to original reference plates. 
 
4.2.12 Migration assay 
This method is described in full in section 2.18 of Chapter II. In brief, cancer cells 
were grown in a 24 well plate until confluent monolayers were formed. Cell 
monolayers were then scratched with a pipette tip to create a scratch or wound. 
Images of the wound were taken at several time points and the rate of migration as 
the wound closed calculated by determining the distance between the wound edges.  
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4.2.13 Statistical analysis 
Statistical analysis was undertaken using the SPSS 24 and Graphpad Prism 8 
statistical software packages. Data was found to be normalised and was therefore 
analysed using t-test. Values of p < 0.05 were regarded as statistically significant. 
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Table 4.1. Primers used in the study 
Name of Primer Sequence of Primer 
SphK1 F8  5’- TGAACCATTATGCTGGCTA-3’ 
SphK1 R8 5’- GTGCAGCAAACATCTCACT-3’ 
SphK1 F9 5’- TGAACCATTATGCTGGCTA-3’ 
SphK1 R9 5’- GTGCAGCAAACATCTCACT-3’ 
SphK1 F1 5’- ACCATTATGCTGGCTATGAG 
SphK1 Zr1 5’-ACTGAACCTGACCGTACA GAGACAGCAGGTTCATGG-
3’ 
GAPDH F8  5’-GGGCAACGAACTCTTCTAC-3’ 
GAPDH R8 5’-TCCAGGTGTCAAGAGTGAA-3’ 
GAPDH F1 5’- AAGGTCATCCATGACAACTT-3’ 
GAPDH Zr1 5’-ACTGAACCTGACCGTACA GCCATCCACAGTCTTCTG-3’ 
T7F  5’-TAATACGACTCACTATAGGG-3’ 
RbBMR 5’-TTCGTCCTCACGGACTCATCAG-3’ 
RbToPF 5’-CTGATGAGTCCGTGAGGACGAA-3’ 
BGHR 5’-TAGAAGGCACAGTCGAGG-3’ 
Z Sequence ‘ACTGAACCTGACCGTACA’  
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4.3 Results 
4.3.1 Expression profile of SphK1 in gastric cancer cell line 
candidates 
The expression levels of SphK1 were examined to determine the strategy for the 
establishment of in vitro models. RNA was isolated from 823, HGC27, 7901, AGS, 
NUGC3, MKN28 gastric cancer cells and GES1 normal epithelial cells followed by 
reverse transcription to cDNA and PCR. 
SphK1 was expressed in 823, HGC27, 7901, AGS, NUGC3, MKN28 and GES1 cell 
lines, furthermore, the gene expression levels of SphK1 exhibited moderate 
expression in most of cell lines. However, low expression of SphK1 was observed 
in 823 and NUGC3 cells (Figure 4.1). 
Following the gene expression profile of SphK1 in the clinical cohort in Chapter III 
and the expression levels of this molecule in gastric cancer cell lines, it was decided 
to establish knockdown cell lines for SphK1 to further explore the significance of 
SphK1in gastric cancer cell model systems. AGS and HGC27 lines were chosen for 
knockdown models. 
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Figure 4.1 Profiling of SphK1 in different gastric cancer cell line 
Different gastric cancer cell line cDNA samples were profiled for SphK1 and GAPDH. 
Representative RT-PCR demonstrating SphK1 expression in different gastric cancer cell 
lines. GAPDH is presented as a housekeeping control, negative control (NC) represents 
amplification of PCR water instead of cDNA. 
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4.3.2 Generation of SphK1 knockdown models using ribozyme 
transgene 
Touchdown PCR was carried out to synthesise transgenes. The products were 
visualised below 100bp which is in agreement with the size of the two transgenes 
(Figure 4.2 Top panel). The synthesised transgenes were cloned into a pEF6/V5-His-
TOPO plasmid vector, and the transgene orientation was checked using PCR and a 
combination of plasmid specific and ribozyme specific primers as previously 
described in the methodology sections. Examples of orientation checks are 
demonstrated in Figure 4.2 bottom panel. 
T7F vs BGHR gave an indication of the inserted product size, with T7F versus 
RbBMR indicating correct orientation and T7F versus RbToPF indicating incorrect 
orientation. Positive expression following amplification with the incorrect 
orientation (T7F versus RbToPF) primer pair rather than the correct orientation pair 
(T7F versus RbBMR), indicating that the transgene was mostly incorporated into 
those colonies in the incorrect orientation.  
Two randomly picked colonies with correctly orientation transgene inserts from each 
petri dish were chosen for further incubation. These colonies were inoculated and 
incubated in two universal tubes containing 5ml of selective LB broth (containing 
100µg/ml ampicillin) before plasmid extraction was undertaken.  
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Figure 4.2 Ribozyme transgene synthesis, incorporation and plasmid extraction 
Ribozyme transgenes, synthesised by touchdown PCR, were loaded on 2% agarose gel and 
separated by gel electrophoresis and two bands were visualised below 100bp marker. The 
predicted size of ribozyme 1 and ribozyme 2 transgene are 85bp and 81bp respectively (A 
top panel). Colonies had been transfected with ribozyme 1 and 2 incorporated plasmid were 
inoculated into PCR reaction mix for transgene orientation check (representative examples 
shown in B bottom panel).  
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4.3.3 Verification of SphK1 knockdown by ribozyme transgene in 
gastric cancer cell models 
SphK1 targeting ribozyme transgene incorporated plasmids (KD) and control 
plasmids (pEF) were transfected via electroporation into AGS and HGC27 gastric 
cancer cell lines. After the blasticidin selection period, RT-PCR, qPCR and western 
blot were used to verify knockdown of SphK1 in HGC27 and AGS.  
SphK1 knockdown was achieved using ribozyme transgene technology in both 
HGC27 and AGS cell models. Transcript expression levels of SphK1 in the 
transfected cells were examined using RT-PCR which demonstrated a reduction in 
SphK1 transcript in comparison to control (pEF) and wild type equivalent cells 
(Figure 4.3 A and B). The expression of SphK1 in two transfected cell lines (HGC27 
and AGS) was found to be significantly reduced, and by more than 50%, compared 
to the respective control cells (transfected with empty pEF6 plasmids alone) 
following band quantification (p < 0.01 in both cases). SphK1 knockdown in gastric 
cancer cell lines were further verified using qPCR (Figure 4.3 C) and western 
blotting, with subsequent band semi-quantification (Figure 4.3 D and E) to explore 
transcript and protein level respectively. Both qPCR and western blot analysis, 
similarly, suggested a significant and greater than 50% reduction in SphK1 levels in 
both knockdown cells compared to controls. Transfected HGC27 and AGS cells 
containing the ribozyme transgene plasmids were routinely tested to confirm 
continued knockdown of SphK1 expression in comparison to control cells. Cells 
transfected with control and transgene plasmid were designated as HGC27 pEF6, 
HGC27 SphK1-KD, AGS pEF6, AGS SphK1-KD. 
 
147 
 
Figure 4.3 Verification of SphK1 knockdown in HGC27 by RT-PCR 
A. The transcript level of SphK1 in wild type HGC27 cells transfected with control plasmid 
(pEF) and ribozyme sequence transgene incorporated plasmids (SphK1-KD) were detected 
by RT-PCR and normalised by the expression level of GAPDH, with band densitometry 
shown below blot. 
Experiments were repeated a minimum of three times. Data shown represents Mean ± 
SEM. * represents p<0.05, ** represents p<0.01. 
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Figure 4.3 Verification of SphK1 knockdown in AGS by RT-PCR 
B. The transcript level of SphK1 in AGS cells transfected with control plasmid (pEF) and 
ribozyme sequence transgene incorporated plasmids (SphK1-KD) were detected by RT-
PCR and normalised by the expression level of GAPDH. 
 Experiments were repeated a minimum of three times. Data shown represents Mean ± 
SEM. * represents p<0.05, ** represents p<0.01. 
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Figure 4.3 Verification of SphK1 knockdown in HGC27 and AGS by qPCR 
C. The transcript level of SphK1 in HGC27 and AGS cells transfected with control plasmid 
(pEF) and ribozyme sequence transgene incorporated plasmids (SphK1-KD) were detected 
by qPCR and normalised by the expression level of GAPDH. 
Experiments were repeated a minimum of three times. Data shown represents Mean ± 
SEM. * represents p<0.05, ** represents p<0.01. 
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Figure 4.3 Verification of SphK1 knockdown in HGC27 by western blotting 
D. The protein expression level of SphK1 and GAPDH in HGC27 cells transfected with 
control plasmid (pEF) and ribozyme sequence transgene incorporated plasmids (SphK1-
KD) were detected by western blotting, with band densitometry shown below blot. 
Experiments were repeated a minimum of three times. Data shown represents Mean ± 
SEM. * represents p<0.05, ** represents p<0.01. 
 
151 
 
Figure 4.3 Verification of SphK1 knockdown in AGS by RT-PCR, qPCR and western 
blotting 
E. The protein expression level of SphK1 and GAPDH in AGS cells transfected with 
control plasmid (pEF) and ribozyme sequence transgene incorporated plasmids (SphK1-
KD) were detected by western blotting, with band densitometry shown below blot, 
Experiments were repeated a minimum of three times. Data shown represents Mean ± 
SEM. * represents p<0.05, ** represents p<0.01. 
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4.3.4 In vitro cell invasion assay 
In order to examine the impact of SphK1 knockdown on the invasion ability of 
HGC27 and AGS cell lines, an in vitro cell invasion assay was conducted using both 
the HGC27 and AGS SphK1 knockdown cell models. 
In vitro invasion assay demonstrated that decreased expression of SphK1 did not 
lead to significant changes in the invasive capabilities of the HGC27 cell line (Figure 
4.4). Similarly, in vitro invasion assay demonstrated that decreased expression of 
SphK1 did not lead to significant changes in the invasive capabilities of the AGS 
cell line (Figure 4.5). 
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Figure 4.4 In vitro cell invasion assay on SphK1 knockdown HGC27 cell line 
A. Representative images of invaded cells. B. Graphical representation of quantified 
invaded cells on the underside of the insert. Experiments were repeated a minimum of three 
times. Data shown represents Mean ± SEM.  
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Figure 4.5 In vitro cell invasion assay on SphK1 knockdown AGS cell line 
A. Representative images of invaded cells. B. Graphical representation of quantified 
invaded cells on the underside of the insert. Experiments were repeated a minimum of three 
times. Data shown represents Mean ± SEM.  
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4.3.5 In vitro cell adhesion assay 
In vitro cell adhesion assays were performed to determine if SphK1 affects the 
adhesive ability of HGC27 and AGS on Matrigel matrix. Absorbance of cellular 
crystal violet stain dissolved in acetic acid was used to indicate levels of adherent 
cells.  
Enhanced levels of cell-matrix attachment were seen in both HGC27 (Figure 4.6A) 
and AGS (Figure 4.6B) SphK1 knockdown cells compared to the respective pEF 
control. In both HGC27 and AGS cells SphK1 knockdown significantly enhanced 
the quantity of attached cells when compared to the respective pEF control cell line 
(p < 0.01 and p < 0.001 respectively). 
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Figure 4.6 In vitro cell adhesion assay on SphK1 KD HGC27 cell lines 
A. The absorbance, representing adherent cell numbers was quantified in both HGC27 pEF 
control and HGC27 SphK1 knockdown cells.  
Experiments were repeated a minimum of three times. Data show represents Mean ± SEM. 
** represents p<0.01, *** represents p<0.001. 
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Figure 4.6 In vitro cell adhesion assay on SphK1 KD AGS cell lines 
B. The absorbance, representing adherent cell numbers was quantified in both AGS pEF 
and AGS SphK1 knockdown cells. Experiments were repeated a minimum of three times. 
Data show represents Mean ± SEM. ** represents p<0.01, *** represents p<0.001. 
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4.3.6 In vitro cell proliferation assay 
In order to examine the impact of SphK1 knockdown on the proliferative ability of 
HGC27 and AGS cells, an in vitro cell proliferation assay was conducted on the 
HGC27 and AGS SphK1 knockdown cell models. 
Proliferation assays demonstrated that both SphK1 knockdown HGC27 (Figure 4.7A) 
and AGS cell lines (Figure 4.7B) exhibited significantly reduced growth rates 
compared to the empty vector (pEF) controls on both day 3 (both p < 0.01 compared 
to respective pEF control) and day 5 incubations (both p < 0.001 compared to 
respective pEF control).  
 
159 
 
 
Figure 4.7In vitro cell proliferation assay on SphK1 knockdown HGC27 and AGS cell 
lines  
A. The proliferative rate of HGC27 cell line on day 1, 3, 5 was analysed as cell viability 
against the control group in each repeat; B. The proliferative rate of AGS cell line on day 1, 
3, 5 was analysed as cell viability against the control group in each repeat; Experiments 
were repeated a minimum of three times. Data shown represents Mean ± SEM. ** 
represents p<0.01, *** represents p<0.001. 
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4.3.7 In vitro cell migration assay 
An in vitro wound healing assay was conducted to investigate the effect of SphK1 
knockdown on HGC27 and AGS cell lines. The distance migrated between two 
wound edges of scratched HGC27 pEF and HGC27 SphK1-KD monolayers did not 
show any significant differences within the first six hours (p > 0.05). However, 
differences between the two groups were observed in the following time points, with 
significantly reduced rates of migration observed following SphK1-KD in 
comparison to the pEF control at 12, 18 and 22 hour time points (p < 0.05, p < 0.05 
and p < 0.01 respectively) (Figure 4.8). 
Similar trends were observed between AGS pEF6 and AGS SphK1-KD though 
significantly reduced rates of migration in the SphK1-KD, compared to the pEF 
control cells only appeared at 18 hours and 22 hours following wounding (p < 0.05 
and p < 0.01, respectively) (Figure 4.9). In summary, downregulation of SphK1 
decreased the migratory ability of HGC27 and AGS cell lines.  
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Figure 4.8In vitro cell migration assay on SphK1 knockdown HGC27 cell line 
A. Representative images of wounds at experimental start and end points are shown. B. 
Migration assays demonstrating the effect of SphK1 knockdown on the migratory ability of 
HGC27 cells. The distance migrated by wound edge at each time point are plotted on a line 
chart. Experiments were repeated a minimum of three times. Data shown represents Mean ± 
SEM. * represents p<0.05, ** represents p<0.01. 
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Figure 4.9 In vitro cell migration assay on SphK1 knockdown AGS cell line 
A. Representative images of wounds at experimental start and end points are shown. B. 
Migration assays demonstrating the effect of SphK1 knockdown on the migratory ability of 
AGS cells. The distance migrated by wound edge at each time point are plotted on a line 
chart. Experiments were repeated a minimum of three times. Data shown represents Mean ± 
SEM. * represents p<0.05, ** represents p<0.01. 
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4.4 Discussion  
Scientific study has demonstrated that SphK1 could regulate processes such as 
proliferation (Yuza et al., 2018), anti-apoptosis (Tsukamoto et al., 2015) cellular 
migration (Yuza et al., 2018) and invasion (Yuza et al., 2018) and angiogenesis (Dai 
et al., 2017).Therefore, it is of considerable importance to understand and establish 
the full significance of SphK1 and its expression status in human cancers. As SphK1 
was directly related to the survival time of gastric cancer patients and was associated 
with more aggressive subtypes in the previous chapter, we further investigated the 
function of SphK1 and its impact on gastric cancer cells using in vitro models. 
We firstly screened a number of gastric cancer cell lines before choosing AGS / 
HCG27 as they were readily available in our lab and are commonly used cell lines 
to represent GC, as well as easy to grow. However, I also would like to highlight the 
limitations, based on the initial screen only looked at transcript, not protein level and 
that the study could have been further enhanced by using cell lines with weak 
expression to conduct over expression model (e.g. 823 and NUGC3), which would 
be important future work for solidifying the trends observed here. 
The in vitro data showed that dysregulation of SphK1 contributed to cell migration, 
adhesion and growth which have shown similar trends to those present in the 
literature previously mentioned. Therefore, questions have been raised as to whether 
SphK1 may be useful as a therapeutic target to improve the clinical outcome of 
patients. 
Many studies have previously indicated that SphK1 may be a potential therapeutic 
target. For example, an early study by Xia et al. (Xia et al., 2012), in gastric cancer 
cells demonstrated that SphK1 can be downregulated by miR-124, which similarly 
inhibited in vivo and in vitro proliferation and tumorigenicity, potentially through 
an observed enhancement of FOXO1 transcriptional activity and suppression of 
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AKT activity. A SphK1 inhibitor, SKI-II, has been used to explore SphK1’s cellular 
role in gastric cancer cells and demonstrated the capacity to induce cell growth arrest 
and apoptosis via the upregulation of P27 and Bax and the downregulation of NF-
kB and Bcl-2 (Li et al., 2014a). A more recent study by Wang et al. (Wang et al., 
2018b), has similarly supported the importance of SphK1 in GC. In this study, they 
showed that SphK1 and S1PR1 appear to be a target of miR-330-3p. Overexpression 
of miR-330-3p caused downregulation of SphK1 and S1PR1 in a similar manner as 
their chemical inhibitors (FTY720 and VPC23019 respectively), having an in vitro 
and in vivo anti-tumour role. Furthermore, the study demonstrated that knocking 
down SphK1 expression in the gastric cancer cell lines MKN1 and KATO3 had a 
significant inhibitory effect on cellular proliferation, invasion and migration (Wang 
et al., 2018b). In addition, miRNA mediated downregulation of SphK1 has been 
reported to reduce migration of breast cancer cells, further highlighting SphK1 as a 
potential therapeutic target in other cancer types (Wang et al., 2019a, Cao et al., 2019, 
Doll et al., 2007, Sarkar et al., 2005). Overall, these findings are in keeping with the 
data presented in this chapter which demonstrate that targeting SphK1 reduces both 
gastric cancer cell proliferation and migration, though as highlighted above, we did 
not observe changes in invasive potential. Taken together this demonstrates and 
supports the potential of SphK1 as a therapeutic target. However, at the same time, 
another question has been raised as to which kind of target inhibitors are the most 
effective.  
Evidence supported that matrix metalloproteinases (MMPs), extracellular 
proteinases, promoted variety of physiology tumour progression. The MMP family 
was firstly reported in 1962 (Gross and Lapiere, 1962) and the function of MMP 
family were seen to be degradation the extracellular matrix (ECM) (Liotta et al., 
1980) and promoting epithelial-mesenchymal transition (EMT) (Xu et al., 2017b) 
leading to cell invasion and metastasis In the process of invasion, tumour cells pass 
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through the basement membrane, stroma and vascular basement membrane to enter 
into the blood vessels, and then transfer to distance sites. Many studies (Coussens et 
al., 2002, Winer et al., 2016) have indicated that the MMP degraded many important 
components in tissues. However, we did not observe any changes in invasion 
between control and SphK1 knockdown groups. One potential reason might be that 
different MMP members have different functions and/or are differently influenced 
by SphK1 expression. For example, MMP9 might play an important role in tumour 
invasion (Song et al., 2020) and in keeping with our results, our preliminary data 
suggested there was no changes in MMP9 in following SphK1 knockdown, though 
further investigation into such related mechanisms are needed. A previous report 
describing the crystal structure of SphK1 provided new direction and insight to 
design SphK1 inhibitors, which had aided in the development of more effective and 
specific inhibitors (Wang et al., 2013). Such inhibitors may be of great value as, in 
addition to a regulatory role of Sphk1 in basic cellular functions linked to cancer, it 
has also been linked to therapy resistance. For example, SphK1 has been implicated 
in the resistance of a number of cancers including prostate cancer (Alshaker et al., 
2016), CRC (Tan et al., 2014) and HNSCC (Hazar-Rethinam et al., 2015) 
Taken together, our current data and that present in the literature suggest that 
targeting SphK1 in gastric cancer could be an interesting therapeutic strategy. 
Evidence exists to suggest SphK1 may also contribute to chemo-resistance in these 
patients. This will be explored further in subsequent chapters. 
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Chapter V 
 
SphK1 and its Implication in 
Gastric Cancer Chemotherapy 
Resistance 
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5.1 Introduction 
Chemotherapy continues to be a key option of cancer treatment for patients and is 
designed to inhibit the proliferation and growth of cancer cells while limiting toxicity 
to host tissues (Moolgavkar et al., 2012). Frequently patients are diagnosed at a later 
or advanced stages of gastric cancer and will receive chemotherapy. Despite 
advances in chemotherapy regimens, response rates are limited by the development 
of resistance, resulting in poor patient prognosis. Hence, there is a strong clinical 
need to identify new markers or targets that could predict or combat resistance to 
chemotherapy. 
Chemotherapy agents induce cellular stress promoting cell death mechanisms and 
resulting in tumour suppression and this partially occurs through inducing the 
generation of S1P, whereas channelling ceramide for S1P generation can give rise to 
chemo-resistance (Ogretmen, 2018). SphK1 is an important endogenous resource of 
the generation of S1P. In keeping with this an increasing number of studies have 
demonstrated the importance of SphK1 and SphK1 pathway in the acquisition of a 
resistant phenotype in numerous cancers. For example, in prostate cancer, 
downregulation of SphK1 expression was able to sensitise LNCaP and PC-3 prostate 
cancer cell lines to the chemotherapeutic agents docexaxel and camptothecin 
(Pchejetski et al., 2008) and enhanced SphK1 expression has been noted to result in 
docetaxel resistance in prostate cancer cells (Alshaker et al, 2016). Similarly in 
pancreatic cancer, SphK1 activity and the subsequent ratio between ceramide and 
S1P have been shown to correlate with gemcitabine resistance (Guillermet-Guilbert 
et al 2009) and more recently it has been demonstrated that miR-506 could influence 
chemo sensitivity through a key mechanism involving downregulation of SphK1 (Li 
et al., 2016c). Hence, SphK1 appears to have potential as a therapeutic target to 
combat drug resistance and subsequently, detection of the sphingolipid products of 
SphK1 potentially also having roles as predictive biomarkers of therapy-resistance. 
168 
 
The current chapter focuses on exploring the relationship between SphK1 and the 
sensitivity of gastric cancer cell lines to common chemotherapeutic agents utilised 
in the treatment of gastric cancer and also aims to assess the potential of SphK1 
inhibitors to enhance the efficacy of chemotherapeutic agents on gastric cancer cells.  
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5.2 Methods and Materials 
5.2.1 Cell lines and reagents 
HGC27 and AGS cells, described in section 2.1 of chapter II, were used. Lines 
displaying SphK1 knockdown were created, using ribozyme transgenes, as described 
in section 2.11 of chapter II and shown in chapter IV. Culture conditions used are 
outlined in section 2.5.1 of chapter II. 
 
5.2.2 Patient derived cell lines 
Gastric cancer patients’ primary cells were obtained from PKUCH. 
 
Table 5-1 Gastric cancer primary cells used for drug test 
Cell line name Origin Tissue type Cell morphology 
SphK1-H 67 year-old male patient Adenocarcinoma Epithelial 
SphK1-L 45 year-old male Adenocarcinoma Epithelial 
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5.2.3 SphK1 inhibitor 
An SphK1 inhibitor named PF543 was purchased from TOCRIS, Inc. (UK) and 
aliquoted into 25ml aliquots. Aliquots were stored at -20°C until required for tissue 
culture. 
 
5.2.4 Cisplatin and 5-FU 
Cisplatin  and 5-FU were obtained from Peking University Cancer Hospital which was 
aliquoted into 5ml aliquots, stored at -20°C.  
 
5.2.5 MTT cytotoxicity assays 
This method is described in section 2.18.1 of the chapter II. In brief, cells were seeded 
and cultured in the presence or absence of cytotoxic agents or SphK1 inhibitors before 
the addition of MTT (final concentration 0.5mg/ml) and further culturing to allow 
formazan formation. Subsequently, medium was aspirated and DMSO added to 
solubilise crystals. Coloured solution was then read using a plate reader as an indication 
of cell viability.
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5.3 Results 
5.3.1 In vitro cisplatin cytotoxicity assay in AGS cell line 
The role of SphK1 in chemo agent cytotoxicity of the cisplatin chemotherapeutic agent 
was examined using an MTT cytotoxicity assay. In vitro cytotoxicity assays were carried 
out using control and SphK1 knockdown AGS gastric cancer cell lines in combination 
with a concentration gradient of Cisplatin. Percentage cell survival, in comparison to 
untreated cells, was quantified after 48 hours of treatment with cisplatin (Figure 5.1). 
The IC50 of the SphK1-KD group was found to be significantly lower than that of the 
control group with the IC50 of the SphK1-KD group identified as 8.277µM (95% CI 
7.808-8.775) and the IC50 of the control group as 13.25µM (95% CI 12.42-14.14), 
indicating that SphK1-KD could increase the sensitivity of the AGS cell line to cisplatin. 
Statistical analysis was also undertaken to compare control and SphK1-KD cell survival 
rates at the various cisplatin concentrations tested demonstrating significant reduction in 
SphK1-KD cell survival compared to control cell survival at cisplatin concentrations of 
31.25µM, 15.625µM, and 7.8125µM (p=0.03, p=0.0001 and p=0.001 respectively). 
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Figure 5.1 In vitro MTT cisplatin cytotoxicity assay in control and SphK1-KD AGS cell lines 
Graphical representation of cell survival rate at different concentrations of Cisplatin. Blue line 
represents SphK1-KD and black line represents Control. Experiments were repeated a minimum 
of three times. Data shown represents Mean ± SEM. * represents p < 0.05, ** represents p < 0.01, 
*** represents p < 0.001.  
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5.3.2 In vitro cisplatin cytotoxicity assay in HGC27 cell line 
In vitro cytotoxicity assay was carried out on control and SphK1 knockdown HGC27 
gastric cancer cells in combination with a concentration gradient of cisplatin. Percentage 
cell survival, in comparison to untreated cells, was quantified after 48 hours of treatment 
with cisplatin (Figure 5.2). The IC50 of the SphK1-KD group was found to be 
significantly lower than that of the control group, with the  IC50 of the SphK1-KD group 
identified as 8.748µM (95% CI 8.189-9.345) and the IC50 of control group as 14.44µM 
(95% CI 13.53-15.42), indicating SphK1 knockdown could influence the sensitivity of 
HGC27 cells to cisplatin. Statistical analysis were also undertaken to compare control 
and SphK1-KD cell survival at the various cisplatin concentrations tested, demonstrating 
significant reduction in SphK1-KD cell survival compared to control cell survival at 
cisplatin concentrations of 31.25µM, 15.625µM, 7.8125µM and 3.90625µM (p = 0.0009, 
p = 0.001, p = 0.001 and p = 0.04 respectively).  
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Figure 5.2 In vitro MTT cisplatin cytotoxicity assay in control and SphK1-KD HGC27 cell 
lines 
Graphical representation of cell survival rate at different concentrations of Cisplatin. Blue line 
represents SphK1-KD and Black line represents Control. Experiments were repeated a minimum 
of three times. Data shown represents Mean ± SEM. * represents p < 0.05, ** represents p < 0.01, 
*** represents p < 0.001.
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5.3.3 In vitro 5-FU cytotoxicity assay in AGS cell line 
In vitro cytotoxicity assay was carried out on control and SphK1 knockdown AGS 
gastric cancer cell lines over a concentration gradient of 5-FU.  Percentage cell survival, 
in comparison to untreated cells, was quantified after 48 hours of treatment with 5-FU 
(Figure 5.3). The IC50 of the SphK1-KD group was found to be significantly lower than 
that of the control group with the IC50 of the SphK1-KD group identified as 12.92µM 
(95% CI 11.92-14.01) and that of the control group as 35.45µM (95% CI 32.92-38.17). 
Statistical analysis was also undertaken to compare control and SphK1-KD cell survival 
rates at the various 5-FU concentrations tested, demonstrating significant reductions in 
SphK1-KD cell survival rates compared to control cells at 5-FU concentrations of 
312.5µM, 156.25µM, 78.125µM, 39.0625µM, 19.53125µM and 9.765625µM (p = 
0.004, p = 0.00005, p = 0.000003, p = 0.000004, p = 0.00002 and p = 0.0004 
respectively). 
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Figure 5.3 In vitro MTT 5-FU cytotoxicity assay in control and SphK1-KD AGS cell lines 
Graphical representation of cell survival rate at different concentration of 5-FU. Blue line 
represents SphK1-KD and black line represents Control. Experiments were repeated a minimum 
of three times. Data shown represents Mean ± SEM.  ** represents p < 0.01, *** represents p < 
0.001. 
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5.3.4 In vitro 5-FU cytotoxicity assay in HGC27 cell line 
In vitro cytotoxicity assay was carried out on control and SphK1 knockdown HGC27 
gastric cancer cell lines over a concentration gradient of 5-FU. Percentage cell survival, 
in comparison to untreated cells, was quantified after 48 hours of treatment with 5-FU 
(Figure 5.4). The IC50 of SphK1-KD group was found to be significantly lower than 
that of the control group, with the IC50 of the SphK1-KD group identified as 12.62µM 
(95% CI 11.63-13.69) and the IC50 of the control group identified as 28.97µM (95% CI 
27.27-30.77). Statistical analysis was also undertaken to compare control and SphK1-
KD cell survival rates at the various 5-FU concentrations tested demonstrating 
significant reductions in SphK1-KD cell survival compared to control cell survival at 5-
FU concentrations of 78.125µM, 39.0625µM, 19.53125µM and 9.765625µM (p = 0.002, 
p = 0.000007, p = 0.00002 and p = 0.00005 respectively).  
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Figure 5.4 In vitro MTT 5-FU cytotoxicity assay in control and SphK1-KD HGC27 cell lines 
Graphical representation of cell survival rate at different concentrations of 5-FU. Blue line 
represents SphK1-KD and Black line represents Control. Experiments were repeated a minimum 
of three times. Data shown represents Mean ± SEM. ** represents p < 0.01, *** represents p < 
0.001. 
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5.3.5 Impact of PF543 on in vitro cisplatin AGS cytotoxicity  
As shown in the results above, we hypothesized that SphK1 played an important role in 
chemotherapy resistance and was of interest as a potential therapeutic target. Therefore, 
we searched for small molecule inhibitors targeting SphK1, identifying and selecting a 
specific small molecule inhibitor named PF543, for use in further cytotoxicity assays. 
In vitro MTT cytotoxicity assays were carried out on AGS gastric cancer cell lines, over 
a concentration gradient of cisplatin, in the presence or absence of PF543 (12.5nM). 
Percentage cell survival, in comparison to untreated cells, was quantified after 48 hours 
of treatment with cisplatin with or without PF543 (Figure 5.5). The IC50 of the 
cisplatin+PF543 group was found to be significantly lower than that of the cisplatin 
alone group, with the IC50 of the cisplatin+PF543 group being 7.637µM (95% CI 7.230-
8.143) and the IC50 of cisplatin alone group being 14.40µM (95% CI 13.67-15.18). 
Statistical analysis was also undertaken to compare the survival rates of AGS cells 
treated alone or with a combination of cisplatin+PF543, at the various cisplatin 
concentrations tested, identifying significantly lower survival rates in cisplatin+PF543 
compared to cisplatin alone groups at cisplatin concentrations of 31.25µM, 15.625µM, 
and 7.8125µM and 3.90625µM (p = 0.01 p = 0.0001, p = 0.000009 and p = 0.0006 
respectively). 
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Figure 5.5 In vitro MTT cytotoxicity assay demonstrating the impact of PF543 on cisplatin 
toxicity in the AGS cell line 
Graphical representation of cell survival rate at different concentrations of cisplatin alone and in 
combination with PF543. Blue line represents cisplatin+PF543 and black line represents cisplatin 
alone. Experiments were repeated a minimum of three times. Data shown represents Mean ± SEM. 
* represents p < 0.01, *** represents p < 0.001. 
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5.3.6 Impact of PF543 on in vitro cisplatin HGC27 cytotoxicity  
In vitro cytotoxicity assays were carried out on HGC27 gastric cancer cells, over a 
concentration gradient of cisplatin, in the presence or absence of PF543 (12.5nM). 
Percentage cell survival, in comparison to untreated cells, was quantified after 48 hours 
of treatment with cisplatin with or without PF543 (figure 5.6). The IC50 of the 
cisplatin+PF543 group was found to be significantly lower than that of the cisplatin 
alone group, with the IC50 of the cisplatin+PF543 group being 9.195µM (95% CI 8.677-
9.744) and the IC50 of cisplatin alone group being 20.43µM (95% CI 19.40-21.52). 
Statistical analysis was also undertaken to compare the survival rates of HGC27 cells 
treated with cisplatin alone or a combination of cisplatin+PF543, at the various cisplatin 
concentrations tested, identifying significantly lower survival rates in cisplatin+PF543 
compared to cisplatin alone groups at cisplatin concentrations of 62.5µM, 31.25µM, 
15.625µM, 7.8125µM and 3.90625µM (p = 0.000001, p = 0.0001, p = 0.000005, p = 
0.00001 and p = 0.005 respectively).
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Figure 5.6 In vitro MTT cytotoxicity assay demonstrating the impact of PF543 on cisplatin 
toxicity in the HGC27 cell line 
Graphical representation of cell survival rate at different concentration of cisplatin alone and 
cisplatin+PF543. Blue line represents cisplatin+PF543and black line represents cisplatin alone. 
Experiments were repeated a minimum of three times. Data shown represents Mean ± SEM. ** 
represents p < 0.01, *** represents p < 0.001. 
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5.3.7 Impact of PF543 on in vitro 5-FU AGS cytotoxicity 
In vitro MTT cytotoxicity assays were carried out on AGS gastric cancer cells, over a 
concentration gradient of 5-FU, in the presence or absence of PF543 (12.5nM). 
Percentage cell survival, in comparison to untreated cells, was quantified after 48 hours 
of treatment with 5-FU with or without PF543 (Figure 5.7).The IC50 of the 5-FU+PF543 
group was found to be significantly lower than that of the 5-FU alone group with the 
IC50 of 5-FU+PF543 group identified as 18.31µM (95% CI 16.92-19.81) and the IC50 
of 5-FU alone group identified as 35.65µM (95% CI 33.20-38.28). Statistical analysis 
was also undertaken to compare the survival of AGS cells treated with 5-FU alone or a 
combination of 5-FU+PF543 at the various 5-FU concentrations tested, identifying 
significantly lower survival rates in 5-FU+PF543 group compared to the 5-FU alone 
group at 5-FU concentrations of 156.25µM, 78.125µM, 39.0625µM and 19.53125µM 
(p = 0.0001, p = 0.000003, p = 0.0003 and p = 0.00003 respectively).  
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Figure 5.7 In vitro MTT cytotoxicity assay demonstrating the impact of PF543 on 5-FU 
toxicity in the AGS cell line 
Graphical representation of cell survival rate at different concentrations of 5-FU alone and in 
combination with PF543. Blue line represents 5-FU+PF543 and Black line represents 5-FU alone. 
Experiments were repeated a minimum of three times. Data shown represents Mean ± SEM. *** 
represents p < 0.001. 
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5.3.8 Impact of PF543 on in vitro 5-FU HGC27 cytotoxicity 
In vitro MTT cytotoxicity assays were carried out on HGC27 gastric cancer cells, over 
a concentration gradient of 5-FU, in the presence or absence of PF543 (12.5nM). 
Percentage cell survival, in comparison to untreated cells, was quantified after 48 hours 
of treatment with 5-FU with or without PF543 (Figure 5.8). The IC50 of the 5-
FU+PF543 group was found to be significantly lower than that of the 5-FU alone group 
with the IC50 of the 5-FU+PF543 group identified as 12.83µM (95% CI 11.75-14.00) 
and the IC50 of the 5-FU alone group identified as 31.12µM (95% CI 29.12-33.26). 
Statistical analysis was also undertaken to compare the survival rates of HGC27 cells 
treated with 5-FU alone or a combination of the 5-FU+PF543 at the various 5-FU 
concentrations tested, identifying significantly lower survival rates in the 5-FU+PF543 
group compared to 5-FU alone groups at 156.25µM, 78.125µM, 39.0625µM, 
19.53125µM and 9.765625µM (p = 0.04, p = 0.00001, p = 0.000009, p = 0.000003 and 
p = 0.00008 respectively). 
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Figure 5.8 In vitro MTT cytotoxicity assay demonstrating the impact of PF543 on 5-FU 
toxicity in the HGC27 cell line 
Graphical representation of cell survival rate at different concentrations of 5-FU alone and in 
combination with PF543. Blue line represents 5-FU+PF543 and black line represents 5-FU alone. 
Experiments were repeated a minimum of three times. Data shown represents Mean ± SEM. * 
represents p < 0.05, *** represents p < 0.001. 
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5.3.9 Impact of PF543 on in vitro cisplatin cytotoxicity in primary 
gastric cancer patient cell lines expressing high levels of SphK1 
Previous results in human gastric cell lines have implicated a role for SphK1 in the 
responsiveness of these cells to chemotherapeutic agents and that targeting SphK1 can 
increase the sensitivity to these drugs. Following on from these results we obtained a 
number of primary gastric cancer lines generated in Peking University Cancer Hospital 
and conducted the cytotoxicity assay again. 
In vitro MTT cytotoxicity assays were carried out on patient primary gastric cancer cell 
lines expressing high levels of SphK1 (SphK1-H) over a concentration gradient of 
cisplatin, in the presence or absence of PF543 (12.5nM). Percentage cell survival, in 
comparison to untreated cells, was quantified after 48 hours (Figure 5.9). The IC50 of 
the cisplatin+PF543 group was found to be significantly lower than that of the cisplatin 
alone group with the IC50 of the cisplatin+PF543 group identified as 14.45µM (95% CI 
13.81-15.12) and the IC50 of the cisplatin alone group as 27.17µM (95% CI 25.53-
28.92). Statistical analysis was also undertaken to compare the survival rates of SphK1-
H primary cell lines treated with cisplatin alone or a combination of cisplatin+PF543 at 
the various cisplatin concentrations tested, identifying significantly lower survival rates 
in the cisplatin+PF543 compared to cisplatin alone groups at cisplatin concentrations at 
31.25µM, 15.625µM and 7.8125µM (p = 0.03, p = 0.000006 and p = 0.0000004 
respectively).
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Figure 5.9 In vitro MTT cytotoxicity assay demonstrating the impact of PF543 on cisplatin 
toxicity in primary gastric cancer cell lines expressing high levels of SphK1 (SphK1-H)  
Graphical representation of cell survival rate at different concentrations of cisplatin alone and in 
combination with PF543. Blue line represents cisplatin+PF543 and black line represents cisplatin 
alone. Experiments were repeated a minimum of three times. Data shown represents Mean ± SEM. 
* represents p < 0.05, *** represents p < 0.001. 
 
189 
 
5.3.10 Impact of PF543 on in vitro cisplatin cytotoxicity in primary 
gastric cancer patient cell lines expressing low levels of SphK1 
In vitro MTT cytotoxicity assays were carried out on patient primary gastric cancer cell 
lines expressing low levels of SphK1 (SphK1-L), over a concentration gradient of 
cisplatin, in the presence or absence of PF543 (12.5nM). Percentage cell survival, in 
comparison to untreated cells, was quantified after 48 hours (Figure 5.10). The IC50 of 
the cisplatin+PF543 group was found to be similar to the cisplatin alone group, with the 
IC50 of the cisplatin+PF543 group identified as 33.87µM (95% CI 31.06-36.94) and the 
IC50 of the cisplatin alone group as 35.53µM (95% CI 32.97-38.28).  
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Figure 5.10 In vitro MTT cytotoxicity assay demonstrating the impact of PF543 on cisplatin 
toxicity in primary gastric cancer cell lines expressing low levels of SphK1 (SphK1-L) 
Graphical representation of cell survival rate at different concentrations of cisplatin alone and in 
combination with PF543. Blue line represents cisplatin+PF543 and black line represents cisplatin 
alone. Experiments were repeated a minimum of three times. Data shown represents Mean ± SEM 
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5.3.11 Impact of PF543 on in vitro 5-FU cytotoxicity in primary gastric 
cancer patient cell lines expressing high levels of SphK1 
In vitro MTT cytotoxicity assay were carried out on patient primary gastric cancer cell 
lines expressing high levels of SphK1 (SphK1-H) over a concentration gradient of 5-FU, 
in the presence and absence of PF543 (12.5nM). Percentage cell survival, in comparison 
to untreated cells, was quantified after 48 hours (Figure 5.11). The IC50 of the 5-
FU+PF543 group was found to be significantly lower than that of the 5-FU alone group, 
with the IC50 of the 5-FU+PF543 group identified as 23.30µM (95% CI 21.56-25.18) 
and  the IC50 of the 5-FU alone group as 53.94µM (95% CI 48.86-59.54). Statistical 
analysis was also undertaken to compare the survival rates of the SphK1-H primary cells 
treated with 5-FU alone or a combination of 5-FU+PF543, at the various concentrations 
tested, identifying significantly lower survival rates in the 5-FU+PF543 compared to the 
5-FU alone group at 5-FU concentrations of 156.25µM, 78.125µM, 39.0625µM and 
19.53125µM (p = 0.000001, p = 0.00002, p = 0.00004 and p = 0.0005 respectively). 
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Figure 5.11 In vitro MTT cytotoxicity assay demonstrating the impact of PF543 on 5-FU 
cytotoxicity in primary gastric cancer cell lines expressing high levels of SphK1 (SphK1-H) 
Graphical representation of cell survival rate at different concentrations of 5-FU alone and in 
combination with PF543. Blue line represents 5-FU+PF543 and black line represents 5-FU alone. 
Experiments were repeated a minimum of three times. Data shown represents Mean ± SEM. *** 
represents p < 0.001. 
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5.3.12 Impact of PF543 on in vitro 5-FU cytotoxicity in primary gastric 
cancer patient cell lines expressing low levels of SphK1 
In vitro MTT cytotoxicity assay was carried on patient primary gastric cancer cell lines 
expressing low levels of SphK1 (SphK1-L), over a concentration gradient of 5-FU, in 
the presence and absence of PF543 (12.5nM). Percentage cell survival, in comparison to 
untreated cells, was quantified after 48 hours (Figure 5.12). The IC50 of the 5-
FU+PF543 group was found to be similar to the 5-FU alone group, with the IC50 of 
the5-FU+PF543 group identified as  40.11µM (95% CI 36.16-44.50) and the IC50 of the 
5-FU alone group as 40.83µM (95% CI 36.41-45.78).
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Figure 5.12 In vitro MTT cytotoxicity assay demonstrating the impact of PF543 on 5-
FU toxicity in primary gastric cancer cell lines expressing low levels of SphK1 (SphK1-
L) 
Graphical representation of cell survival rate at different concentrations of 5-FU alone and in 
combination with PF543. Blue line represents 5-FU+PF543 and black line represents 5-FU 
alone. Experiments were repeated a minimum of three times. Data shown represents Mean ± 
SEM.  
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5.4 Discussion 
Resistance to chemotherapeutic agents is a major issue and significant challenge in 
numerous human cancers and new therapy opinions combating such resistance are 
key interest to researchers. In recent years, new strategies, based on sensitising 
tumour cells to chemotherapeutic agents through the addition of relatively low 
toxicity small inhibitors have gained scientific interest. In such approaches, 
application of decreased doses of toxic agents given in combination with non-toxic 
or low toxicity small inhibitors with the aim of complementing treatment efficacy 
and sensitising cells to the toxic agent. SphK1, categorised as a bioactive lipid 
enzyme, is a central element in the sphingolipid rheostat (Pulkoski-Gross et al., 2015, 
Maceyka et al., 2012, Pyne and Pyne, 2013, Pitson, 2011, Cuvillier et al., 1996) 
which has been recognised as a promising therapeutic target for many types of cancer 
where it is frequently found to be dysregulated, contributes to progression (Wang et 
al., 2018b, Li et al., 2018a) and links to chemotherapeutic resistance (Li et al., 2016c, 
Alshaker et al., 2016). Additionally, numerous small inhibitors targeting SphK1 have 
been developed, raising the potential of targeting SphK1 and such processes in a 
clinical setting (Lima et al., 2018, Kreitzburg et al., 2018). 
In our study, firstly, we performed an initial preclinical evaluation of the role of 
SphK1 in chemo-resistance of gastric cancer. In both AGS and HGC27 gastric 
cancer cell lines, displaying positive expression of SphK1, the IC50 value for both 
cisplatin and 5-FU was significantly decreased following SphK1 knockdown. 
Interestingly, cell viability and chemotherapeutic drugs are dose-dependent. At 
relatively high concentrations and relatively low concentrations, SphK1 appears to 
have a limited role in the responsiveness of the cell lines tested to these 
chemotherapeutic agents. However, within the appropriate drug concentration range, 
downregulating the expression of SphK1 expression enhanced the responsiveness of 
cells to the chemotherapeutic drugs. Whilst preliminary, this data suggests that 
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SphK1 may play a role in the chemotherapy resistance of gastric cancer. A study 
from Hazar-Rethinam et al., (Hazar-Rethinam et al., 2015) also indicated that knock 
down SphK1 could lead to the chemosensitivity of SCC cells to doxorubicin in vitro 
and in vivo. Similarly, SK1-I had the same function which could combat 
chemoresistance in SCC cells. Similarly, SphK1 has been identified as contributing 
to chemotherapy resistance in a number of cancers. For example in head and neck 
squamous cell carcinoma (HNSCC) E2F7 has been demonstrated to enhance 
resistance to doxorubicin through SphK1 induction and activation of AKT and 
subsequently that targeting or inhibition of SphK1 can enhance doxorubicin 
sensitivity in in vitro and in vivo models (Hazar-Rethinam et al., 2015). Similarly in 
pancreatic cancer, the ratio between ceramide and S1P has been suggested to predict 
gemcitabine resistance in pancreatic cancer cells and such resistance appeared to 
correlate with SphK1 activity, where targeting or inhibition of SphK1 enhanced 
sensitivity whereas transfection with SphK1 cDNA, and enhanced SphK1 activity, 
reduced sensitivity to gemcitabine (Guillermet-Guibert et al., 2009). This is further 
supported by a study by Li et al, which identified SphK1 as a target of miR-506, a 
miR whose reduced expression is associated with poorer prognosis in pancreatic 
cancer, and similarly demonstrated that targeting of SphK1 in pancreatic cancer cell 
lines could enhance gemcitabine sensitivity (Li et al., 2016c). 
In addition to knockdown models, we also focused on identifying whether inhibition 
of SphK1 using small inhibitors could also alter the resistance of gastric cancer cell 
lines to chemotherapy drugs. We conducted a preclinical evaluation of SphK1 
inhibitor, PF543, as a sensitiser for a conventional chemotherapeutic drug currently 
being using in clinical practice. Importantly, compared with the chemotherapy drug 
alone group, the IC50 of the gastric cancer cell lines with high expression of SphK1 
was significantly reduced after treatment with PF543 in combination with the 
chemotherapy drug. Similar implications have been reported in relation to an S1P 
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pathway inhibitor, FTY720, which has been demonstrated to enhance the efficacy of 
gemcitabine when added in combination, resulting in smaller tumours compared to 
controls or individual therapies alone, in a clear cell renal carcinoma (CCRC) in vivo 
model (Gstalder et al., 2016).Taken together, these data indicate that SphK1 
expression levels can be used as the criteria for evaluation of the resistance of gastric 
cancer cells and PF543 can be used as a sensitizer of chemoresistance. Subsequently, 
given the importance of the observed capacity of SphK1 knockdown or targeting of 
SphK1 with PF543 in commercial cell line models of gastric cancer we aimed to 
explore such relationships in a more clinically relevant model. Therefore, we used 
the primary cell line of gastric cancer patients in Peking University Cancer Hospital. 
The results showed that PF543 can effectively reduce the sensitivity to chemotherapy 
drugs in patients whose tumour cells displayed high expression of SphK1, but this 
effect was not observed in patients with low SphK1 expression. Such data is in 
keeping with the literature and further validates the significance of SphK1 as a 
potential biomarker for chemo-resistance or as a target for enhancing gastric tumour 
cell sensitivity to chemotherapeutics.  
However, some reports have also indicated little or no impact on cellular 
proliferation, despite altering S1P levels, following application with some SphK1 
inhibitors, including PF543 (Kharel et al., 2011, Schnute et al., 2012) and additional 
study is required to fully clarify their role. 
In conclusion, our current data suggests that the level of SphK1 may indicate 
responsiveness of gastric cancer cells to chemotherapy and furthermore targeting or 
inhibiting SphK1 in patients with high SphK1 may be of benefit to enhance 
sensitivity to chemotherapy or prevent resistance. SphK1 inhibitors may therefore 
be of benefit to such patients but further work is required to fully establish their 
clinical benefit. 
 
198 
 
 
 
 
 
 
 
 
 
 
Chapter VI 
 
Potential downstream mechanisms 
of SphK1 in gastric cancer
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6.1 Introduction 
SphK1 expression is dysregulated in many cancers and is associated with cancer 
progression and resistance to therapy (Hazar-Rethinam et al., 2015, Li et al., 2016c, 
Wang et al., 2018b, Li et al., 2018a, Yang et al., 2019). In keeping with this data 
results outlined in previous chapters have indicated that enhanced expression of 
SphK1 correlates with poorer survival rates of gastric cancer patients, impacts on 
cellular function of gastric cancer cells and also influences the ability of gastric 
cancer cell lines and primary cell lines derived from gastric cancer patients to 
respond to 5-FU and cisplatin. Taken together, this suggests a role for SphK1 in 
gastric cancer biology and that its expression may be useful as a potential target for 
reversing chemoresistance.  
Mechanisms acting upstream and downstream of SphK1 are beginning to be 
identified. The oncogenic potential of SphK1 has previously been attributed to both 
gain of function, relating to enhanced S1P mediated signalling, or non-oncogenic 
addiction, relating to cancer cell dependence on SphK1, or this signalling system for 
sustained survival (Li et al., 2019a) , with little evidence suggesting SphK1 gene 
mutations are related to cancer (Pyne et al., 2012a). SphK1 location has been linked 
with its role in cancer progression with SphK1 phosphorylation state and cellular 
localisation being suggested to be important in cancer transformation. More recent 
studies have aided in establishing the mechanisms through which SphK1 acts and 
can be regulated. For example SphK1 has been shown to influence the process of 
EMT and impacts on the expression of EMT markers E-cadherin and vimentin 
through FAK / AKT / MMP2/9 signalling pathway (Liu et al., 2019). Other studies 
have also identified SphK1 as a target of a number of miRNA’s, proposing regulation 
of SphK1 by these miRNAs contributes to their cancer related effects (Cao et al., 
2019, Wang et al., 2019a).In order to further clarify the impact of SphK1 in gastric 
cancer biology and potential mechanisms through which SphK1 may contribute to 
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chemoresistance we next aimed to identify key pathways which are altered in 
response to enhanced levels of S1P, a product of SphK1, and may hence be 
mechanisms through which SphK1 exerts its role. The current chapter aims to 
identify potential mechanistic pathways downstream of SphK1/S1P using a protein 
microarray analysis. 
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6.2 Methods and materials 
6.2.1 Cell lines and reagents 
HGC27 and AGS cells, described in section 2.1 of chapter II, were used. Lines 
displaying SphK1 knockdown were created, using ribozyme transgenes, as described 
in section 2.11 of chapter II and shown in chapter IV. Culture conditions used are 
outlined in section 2.5.1 of chapter II. 
 
6.2.2 Kinexus protein array and data analysis 
Control AGS or AGS cells treated with S1P were cultured as outlined and described 
in sections 2.1 and 2.5.1 of chapter II. Protein samples from control and treated AGS 
cells were extracted and sent to Kinexus Bioinformatics (Canada) for microarray 
analysis as outlined in section 2.16 of chapter II. Results were returned following 
analysis and samples compared based on the percentage change from control (%CFC) 
or Z-ratios between control and treated AGS cells. 
 
6.2.3 Protein extraction, quantification, SDS-PAGE and Western 
blot analysis 
Extraction, quantification and analysis of protein expression in AGS and HGC27 
SphK1 knockdown samples was undertaken as outlined in section 2.14, 2.15 and 
2.17 of chapter II. 
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6.3 Results 
6.3.1 Potential downstream signalling investigation 
To explore global signalling events in AGS cells following treatment with S1P, a 
protein array was undertaken using the Kinexus 880 platform. The array probes with 
more than 850 antibodies returning information on a combination of total and  
phosphorylated protein expression. Figure 6.1 shows representative images from the 
array. Following analysis, the samples were scaled based on their percentage change 
from control and the top 50 upregulated total proteins shown in Table 6.1, the top 50 
downregulated total proteins shown in Table 6.2, the top 50 upregulated 
phosphoproteins shown in Table 6.3 and the top 50 downregulated phosphoproteins 
shown in Table 6.4. The Kinexus array returned a vast amount of data, including the 
interesting observation that S1P treatment enhanced phosphorylation at Ser 473 of 
AKT, a key signalling molecule linked to cancer progression and therapy resistance. 
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Figure 6.1 Kinexus images of array outlining comparison between AGS control (bottom, 
ID21) and AGS+S1P (top, ID23) protein samples. 
Protein expression correlates with the signal intensity. Decreasing signal intensity 
corresponds with a red to orange to yellow to green to blue transition. 
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Table 6.1 Top 50 upregulated total proteins following S1P treatment 
Data summarised from Kinexus report and is based on scaling according to percentage 
change from control (%CFC) 
Target 
Protein 
Name 
Phospho 
Site 
(Human)/P
an specific 
Full Target 
Protein Name 
Globally 
Normaliz
ed - 
AGS 
Control  
Globally 
Normaliz
ed - 
S1P 
Treated 
AGS 
%CFC 
(Treate
d from 
Contro
l) 
ROKa Pan-specific Rho-associated protein kinase 2 292 1177 308 
PP2A/Ca Pan-specific 
Protein-serine 
phosphatase 2A - 
catalytic subunit - 
alpha isoform 110 310 186 
RONa Pan-specific 
Macrophage-
stimulating 
protein receptor 
alpha chain 193 513 170 
Synapsin 1 Pan-specific Synapsin 1 isoform Ia 197 515 165 
Catenin b Pan-specific 
Catenin (cadherin-
associated protein) 
beta 1 2445 5759 138 
Smad2/3 Pan-specific 
SMA- and 
mothers against 
decapentaplegic 
homolog 2/3 125 298 142 
SOD (Cu/Zn) Pan-specific Superoxide dismutase 1 85 197 135 
Smac/DIAB
LO Pan-specific 
Second 
mitochondria-
derived activator 
of caspase 74 153 110 
DUSP11 Pan-specific 
Phosphatidylinosit
ol-3,4,5-
trisphosphate 5-
phosphatase 2 4682 8592 86 
Rac1 Pan-specific 
Ras-related C3 
botulinum toxin 
substrate 1 151 291 95 
Caspase 7 Pan-specific 
Caspase 7 (ICE-
like apoptotic 
protease 3 (ICE-
LAP3), Mch3) 217 399 86 
IKKg/NEMO Pan-specific 
I-kappa-B kinase 
gamma/NF-kappa-
B essential 
modulator 146 267 85 
PKG1 Pan-specific 
cGMP-dependent 
protein kinase 1, 
alpha isozyme 193 323 69 
PARP1 Pan-specific 
Poly [ADP-ribose] 
polymerase 1 
(ADPRT) 7603 11788 57 
BCL Pan-specific B-cell lymphoma protein 2 alpha 66 108 66 
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PTP-PEST Pan-specific 
Protein tyrosine 
phosphatase, non-
receptor type 12 42 67 64 
ZAP70 Pan-specific 
Zeta-chain (TCR) 
associated protein-
tyrosine kinase, 70 
kDa 197 304 56 
A-Raf Pan-specific 
A-Raf proto-
oncogene 
serine/threonine-
protein kinase 4252 6219 48 
Jun Pan-specific 
Jun proto-
oncogene-encoded 
AP1 transcription 
factor 176 267 54 
CDK1 Pan-specific 
Cyclin-dependent 
protein-serine 
kinase 1 407 611 52 
STAT5A Pan-specific 
Signal transducer 
and activator of 
transcription 5A 3848 5549 46 
PKC h Pan-specific Protein kinase C eta type 35 54 57 
CDK1 Pan-specific 
Cyclin-dependent 
protein-serine 
kinase 1 10352 14610 43 
Cdc25B Pan-specific Cell division cycle 25B phosphatase 1974 2851 46 
MEK5 Pan-specific 
MAPK/ERK 
protein-serine 
kinase 5 (MKK5) 4413 6028 38 
p38b MAPK Pan-specific 
Mitogen-activated 
protein-serine 
kinase p38 beta 5678 7722 38 
HspBP1 Pan-specific Hsp70 binding protein 1 169 242 45 
VHR Pan-specific 
Dual specificity 
protein 
phosphatase 3 615 858 41 
KDEL 
Receptor, 
KR10 
Pan-specific 
ER lumen protein 
retaining receptor 
1 1278 1759 39 
eIF2a Pan-specific 
Eukaryotic 
translation 
initiation factor 2 
alpha 146 205 42 
Striatin Pan-specific Striatin 18283 23580 31 
Cdc25C Pan-specific Cell division cycle 25C phosphatase 4105 5414 34 
MKP2 Pan-specific 
MAP kinase 
phosphatase  2 
(VH2) 237 327 39 
STAT3 Pan-specific 
Signal transducer 
and activator of 
transcription 3 
(acute phase 
response factor) 1160 1555 36 
ZIPK Pan-specific ZIP kinase (death associated protein- 3954 5194 33 
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serine kinase 3 
(DAPK3)) 
Flt3 Pan-specific 
Receptor-type 
tyrosine-protein 
kinase FLT3 6237 8103 32 
Cdc25A Pan-specific Cell division cycle 25A phosphatase 4944 6430 32 
DUSP1 
(MKP1) Pan-specific 
MAP kinase 
phosphatase  1 
(CL100, VH1) 9676 12425 30 
ALK Pan-specific Anaplastic lymphoma kinase 16709 21155 28 
SMG1 Pan-specific 
Lambda/iota 
protein kinase C-
interacting protein 43 60 41 
ZIPK Pan-specific 
ZIP kinase (death 
associated protein-
serine kinase 3 
(DAPK3)) 4355 5608 30 
MKK7 Pan-specific 
MAPK/ERK 
protein-serine 
kinase 7 (MKK7) 56 78 40 
PP2A/Aa/b Pan-specific 
Protein-serine 
phosphatase 2A - 
A  regulatory 
subunit - alpha 
and beta isoforms 7429 9469 29 
PDK2 Pan-specific 
Pyruvate 
dehydrogenase 
kinase isoform 2 10974 13879 28 
LAR Pan-specific 
LCA antigen-
related (LAR) 
receptor tyrosine 
phosphatase 142 192 37 
Hsp47 Pan-specific 
Heat shock 47 
kDa protein 
(collagen-binding 
protein 1, colligin 
1) 265 355 36 
PP2A/Bb Pan-specific 
Protein-serine 
phosphatase 2A - 
B regulatory 
subunit - beta 
isoform 9563 12040 27 
PP2Cd Pan-specific 
Protein-serine 
phosphatase 2C - 
catalytic subunit - 
delta isoform 187 251 36 
Elk 1 Pan-specific 
ETS domain-
containing protein 
Elk-1 91 124 37 
Cyclin D1 Pan-specific Cyclin D1 (PRAD1) 18055 22432 26 
  
207 
 
Table 6.2 Top 50 downregulated total proteins following S1P treatment 
Data summarised from Kinexus report and is based on scaling according to percentage 
change from control (%CFC) 
Target 
Protein 
Name 
Phospho 
Site 
(Human)/P
an specific 
Full Target 
Protein Name 
Globally 
Normalized 
- 
AGS 
Control  
Globally 
Normalized 
- 
S1P 
Treated 
AGS 
%CFC 
(Treated 
from 
Control) 
PKCl Pan-specific 
Protein-serine 
kinase C 
lambda/iota 930 30 -97 
Nek2 Pan-specific 
NIMA (never-in-
mitosis)-related 
protein-serine 
kinase 2 291 93 -68 
p70 S6K Pan-specific 
Ribosomal 
protein S6 kinase 
beta-1 133 46 -65 
MEKK1 Pan-specific MAPK/ERK kinase kinase 1 95 36 -61 
p107 Pan-specific 
Retinoblastoma 
(Rb) protein-
related p107 
(PRB1) 4957 2119 -57 
VGFR3 Pan-specific 
Vascular 
endothelial 
growth factor 
receptor-protein-
tyrosine kinase 3 
(VEGFR3) 12503 5557 -55 
Akt2 
(PkBb) Pan-specific 
RAC-beta 
serine/threonine-
protein kinase 60 27 -54 
Yes Pan-specific 
Yamaguchi 
sarcoma proto-
oncogene-
encoded tyrosine 
kinase 62 28 -54 
Wee1 Pan-specific Wee1 protein-tyrosine kinase 9047 4870 -45 
SMG1 Pan-specific 
Lambda/iota 
protein kinase C-
interacting 
protein 76 41 -45 
p35 Pan-specific 
CDK5 regulatory 
subunit p25 and 
p35 7045 3866 -44 
Raf1 Pan-specific 
Raf1 proto-
oncogene-
encoded protein-
serine kinase 3184 1761 -44 
TYK2 Pan-specific 
Protein-tyrosine 
kinase 2 (Jak-
related) 11456 6566 -42 
MKK6 Pan-specific 
MAPK/ERK 
protein-serine 
kinase 6 (MKK6) 18788 11100 -40 
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TBK1 Pan-specific 
Serine/threonine-
protein kinase 
TBK1 6040 3584 -40 
4E-BP1 Pan-specific 
Eukaryotic 
translation 
initiation factor 
4E binding 
protein 1 
(PHAS1) 237 142 -39 
PKG1b-
NT Pan-specific 
cGMP-dependent 
protein kinase 1, 
beta isozyme 4487 2758 -38 
STAT6 Pan-specific 
Signal transducer 
and activator of 
transcription 6 4719 2930 -37 
MEK3 Pan-specific 
MAPK/ERK 
protein-serine 
kinase 3 beta 
isoform (MKK3 
beta) 2029 1292 -36 
NFkappa
B p65 Pan-specific 
NF-kappa-B p65 
nuclear 
transcription 
factor 4102 2614 -35 
Bak Pan-specific 
Bcl2 homologous 
antagonist/killer 
(BCK2L7) 2839 1856 -34 
PAK3 Pan-specific 
p21-activated 
kinase 3 (beta) 
(serine/threonine-
protein kinase 
PAK 3) 3567 2333 -34 
PP4C 
(X/C) Pan-specific 
Protein-serine 
phosphatase X - 
catalytic subunit 
(PPX/C) 86 57 -33 
MSH2 Pan-specific 
DNA mismatch 
repair protein 
mutS homolog2, 
colon cancer, 
nonpolyposis type 
1 455 302 -33 
Hsc70 Pan-specific Heat shock 70 kDa protein 8 2545 1713 -32 
MEK5 Pan-specific 
MAPK/ERK 
protein-serine 
kinase 5 (MKK5) 1943 1313 -32 
JNK2 Pan-specific 
Jun N-terminus 
protein-serine 
kinase (stress-
activated protein 
kinase (SAPK)) 2 67 46 -31 
FasL Pan-specific 
Tumor necrosis 
factor ligand, 
member 6 321 223 -30 
SNF1lK Pan-specific 
Serine/threonine-
protein kinase 
SIK1 130 91 -29 
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Caveolin 
1 Pan-specific Caveolin 1 67 47 -29 
Cdc2 p34 Pan-specific 
Cyclin-dependent 
protein-serine 
kinase 1 4204 2974 -28 
PAK a Pan-specific 
p21-activated 
kinase 1 (alpha) 
(serine/threonine-
protein kinase 
PAK 1) 3965 2812 -28 
Lck Pan-specific 
Lymphocyte-
specific protein-
tyrosine kinase 2435 1738 -28 
Src Pan-specific 
Src proto-
oncogene-
encoded protein-
tyrosine kinase 1347 964 -28 
Cdc25C Pan-specific 
Cell division 
cycle 25C 
phosphatase 4263 3094 -27 
IRAK1 Pan-specific 
Interleukin 1 
receptor-
associated kinase 
1 (Pelle-like 
protein kinase) 41 30 -26 
PKCz Pan-specific Protein-serine kinase C zeta 2564 1889 -25 
SG2NA Pan-specific Striatin-3 9530 7030 -25 
MELK Pan-specific 
Maternal 
embryonic 
leucine zipper 
kinase 6425 4755 -25 
FAS Pan-specific 
Tumor necrosis 
factor 
superfamily 
member 6 (Apo1, 
CD95) 4279 3171 -25 
CDK9 Pan-specific 
Cyclin-dependent 
protein-serine 
kinase 9 3153 2349 -25 
Wip1 Pan-specific Protein phosphatase 1D 3144 2373 -24 
CDK6 Pan-specific 
Cyclin-dependent 
protein-serine 
kinase 6 4196 3178 -23 
Hsp90 Pan-specific 
Heat shock 90 
kDa protein 
alpha/beta 2917 2209 -23 
PDK3 Pan-specific 
Pyruvate 
dehydrogenase 
kinase isoform 3 485 367 -23 
Bcl2 Pan-specific B-cell lymphoma protein 2 alpha 182 139 -23 
PKD 
(PKCm) Pan-specific 
Protein-serine 
kinase C mu 
(Protein kinase 
D) 2506 1920 -22 
PSD-95 Pan-specific Disks large homolog 4 455 349 -22 
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MEK3b Pan-specific 
MAPK/ERK 
protein-serine 
kinase 3 beta 
isoform (MKK3 
beta) 217 169 -21 
IAP1 Pan-specific 
Cellular inhibitor 
of apoptosis 
protein 1 
(baculoviral IAP 
repeat-containing 
protein 3, 
apoptosis 
inhibitor 2 
(API2)) 34 27 -20 
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Table 6.3 Top 50 upregulated phospho- proteins following S1P treatment 
Data summarised from Kinexus report and is based on scaling according to percentage 
change from control (%CFC) 
Target 
Protein 
Name 
Phospho Site 
(Human) 
Full Target 
Protein Name 
Globally 
Normaliz
ed - 
AGS 
Control  
Globally 
Normaliz
ed - 
S1P 
Treated 
AGS 
%CF
C 
(Treat
ed 
from 
Contr
ol) 
STAT1 Y701 
Signal transducer 
and activator of 
transcription 1 
alpha 283 976 249 
Tau S199/202 
Microtubule-
associated protein 
tau 317 903 189 
RSK1/2 S221/S227 
Ribosomal S6 
protein-serine 
kinase 1 771 2046 169 
Mnk1 T197+T202 
MAP kinase-
interacting protein-
serine kinase 1 
(calmodulin-
activated) 54 148 179 
STAT5A S780 
Signal transducer 
and activator of 
transcription 5A 168 417 151 
Raf1 S259 
Raf1 proto-
oncogene-encoded 
protein-serine 
kinase 33 81 147 
Vimentin S33 Vimentin 134 309 134 
Rb T821 
Retinoblastoma-
associated protein 
1 328 712 120 
Tau S422 
Microtubule-
associated protein 
tau 331 699 114 
S6 S235 40S ribosomal protein S6 264 555 112 
4E-BP1 T45 
Eukaryotic 
translation 
initiation factor 4E 
binding protein 1 
(PHAS1) 133 281 114 
PTEN S380/S382/S385 
Phosphatidylinosit
ol-3,4,5-
trisphosphate 3-
phosphatase and 
protein 
phosphatase and 
tensin homolog 
deleted on 
chromosome 10 579 1191 108 
Rad17 S645 Rad17 homolog 92 176 93 
JAK2 Y1007+Y1008 Janus protein-tyrosine kinase 2 34 63 89 
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APP T743 Amyloid beta A4 protein 1006 1732 74 
Rac1/cdc4
2 S71 
Ras-related C3 
botulinum toxin 
substrate 1 164 290 79 
Rb S795 
Retinoblastoma-
associated protein 
1 60 102 72 
Met Y1230/Y1234/Y1235 
Hepatocyte growth 
factor (HGF) 
receptor-tyrosine 
kinase 223 366 66 
BMX 
(Etk) Y40 
Bone marrow X 
protein-tyrosine 
kinase 46 76 69 
IR/IGF1R Y1162/Y1163 
Insulin receptor / 
Insulin-like growth 
factor 1 receptor 175 284 64 
Kit Y721 
Mast/stem cell 
growth factor 
receptor Kit 204 327 62 
Akt1 
(PKBa) S473 
RAC-alpha 
serine/threonine-
protein kinase 1756 2717 57 
SHP2 S576 
Protein-
tyrosine phosphatas
e 1D (SHP2, 
SHPTP2, Syp, 
PTP2C) 204 326 62 
p53 S392 
Tumor suppressor 
protein p53 
(antigenNY-CO-
13) 510 802 59 
PTEN S380/T382/T383 
Phosphatidylinosit
ol-3,4,5-
trisphosphate 3-
phosphatase and 
protein 
phosphatase and 
tensin homolog 
deleted on 
chromosome 10 154 243 60 
FRS2 Y349 
Fibroblast growth 
factor receptor 
substrate 2 1785 2704 53 
Cyclin E T395 Cyclin E1 927 1417 55 
Huntingtin S421 Huntington's disease protein 47 76 62 
Chk1 S280 
Checkpoint 
protein-serine 
kinase 1 275 424 56 
p70 S6K S424 Ribosomal protein S6 kinase beta-1 106 165 58 
Estrongen 
Receptor S104 
Estrogen receptor 
alpha 334 507 54 
PKA Cb S338 
cAMP-dependent 
protein-serine 
kinase catalytic 
subunit beta 1107 1648 51 
213 
 
VEGFR2 Y1214 
Vascular 
endothelial growth 
factor receptor-
tyrosine kinase 2 
(Flk1) 86 134 57 
eIF4G S1232 
Eukaryotic 
translation 
initiation factor 4 
gamma 1 568 851 52 
PYK2 Y579 Protein-tyrosine kinase 2 112 171 54 
Tau S404 
Microtubule-
associated protein 
tau 349 522 51 
IkBa Y42 
Inhibitor of NF-
kappa-B alpha 
(MAD3) 158 239 53 
B23 
(NPM) T199 
B23 
(nucleophosmin, 
numatrin, nucleolar 
protein NO38) 216 324 51 
IRS1 Y1179 Insulin receptor substrate 1 4316 6144 44 
Rb S612 
Retinoblastoma-
associated protein 
1 6413 8997 42 
IRS1 S639 Insulin receptor substrate 1 109 163 51 
MST3 T184 
Mammalian 
STE20-like 
protein-serine 
kinase 3 2332 3314 44 
Tau S199 
Microtubule-
associated protein 
tau 533 772 47 
CDK1/CD
C2 T161 
Cyclin-dependent 
protein-serine 
kinase 1/2 157 231 49 
Tau T231 
Microtubule-
associated protein 
tau 212 306 46 
JNK 1/2/3 T183/Y185 
Jun N-terminus 
protein-serine 
kinase (stress-
activated protein 
kinase (SAPK)) 
1/2/3 362 519 45 
FKHR S319 Forkhead box protein O1 154 223 47 
FAK S722 
Focal adhesion 
protein-tyrosine 
kinase 425 603 44 
Jun T91 
Jun proto-
oncogene-encoded 
AP1 transcription 
factor 796 1112 41 
IkBe S22 NF-kappa-B inhibitor epsilon 137 197 45 
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Table 6.4: Top 50 downregulated phospho-proteins following S1P treatment 
Data summarised from Kinexus report and is based on scaling according to percentage 
change from control (%CFC) 
Target 
Protein 
Name 
Phospho 
Site 
(Human) 
Full Target 
Protein Name 
Globally 
Normalize
d - 
AGS 
Control  
Globally 
Normalize
d - 
S1P 
Treated 
AGS 
%CFC 
(Treate
d from 
Control
) 
p38a 
MAPK T180/Y182 
Mitogen-
activated 
protein-serine 
kinase p38 alpha 1447 29 -98 
PKCe S729 Protein-serine kinase C epsilon 2125 446 -79 
RSK1/2/3 T573 
Ribosomal S6 
protein-serine 
kinase 1 123 51 -58 
Rb S608 
Retinoblastoma-
associated 
protein 1 50 23 -54 
MEK1 S298 
MAPK/ERK 
protein-serine 
kinase 1 
(MKK1) 61 29 -52 
Msk1 S376 
Mitogen & 
stress-activated 
protein-serine 
kinase 1 88 42 -51 
Myc S373 
Myc proto-
oncogene 
protein 630 305 -51 
PKCt S695 Protein-serine kinase C theta 307 184 -39 
Ron Y1238 
Macrophage-
stimulating 
protein receptor 
alpha chain 48 29 -39 
RelB S552 Transcription factor RelB 820 516 -36 
Tyrosine 
Hydroxylas
e 
S40 
Tyrosine 
hydroxylase 
isoform a 72 47 -34 
Src Y418 
Src proto-
oncogene-
encoded protein-
tyrosine kinase 487 331 -31 
FAK Y576+Y577 
Focal adhesion 
protein-tyrosine 
kinase 744 512 -30 
Ezrin T567 Cytovillin 2 87 60 -30 
IRAK4 T345+S346 
Interleukin 1 
receptor-
associated 
kinase 4 57 39 -30 
TBK1 S172 
Serine/threonine
-protein kinase 
TBK1 30149 20945 -30 
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PPP1R11 Y64 
Protein 
phosphatase 1 
regulatory 
subunit 11 4351 3031 -29 
p70 S6K T421/S424 
Ribosomal 
protein S6 
kinase beta-1 31 22 -28 
Tau T205 
Microtubule-
associated 
protein tau 474 337 -28 
MEK1 T386 
MAPK/ERK 
protein-serine 
kinase 1 
(MKK1) 75 55 -26 
eIF2a S52 
Eukaryotic 
translation 
initiation factor 
2 alpha 947 693 -26 
EGFR Y1197 
Epidermal 
growth factor 
receptor-
tyrosine kinase 168 124 -25 
Ephrin-B2 Y316 
EPH-related 
receptor tyrosine 
kinase ligand 5 241 179 -25 
p38d 
MAPK Y182 
Mitogen-
activated 
protein-serine 
kinase p38 delta 
(MAPK13) 5911 4408 -24 
CDK6 Y13 
Cyclin-
dependent 
protein-serine 
kinase 6 272 208 -23 
Bcr Y177 
Breakpoint 
cluster region 
protein 4658 3583 -22 
PKCm 
(PKD) S916 
Protein-serine 
kinase C mu 
(Protein kinase 
D) 1501 1157 -22 
EGFR Y998 
Epidermal 
growth factor 
receptor-
tyrosine kinase 4428 3425 -22 
SMC1 S957 
Structural 
maintenance of 
chromosomes 
protein 1A 3751 2934 -21 
MEK2 
mouse T394 
MAPK/ERK 
protein-serine 
kinase 2 
(MKK2) 
(mouse) 6514 5101 -21 
PKCd Y311 Protein-serine kinase C delta 9051 7144 -20 
c-Cbl Y700 
Signal 
transduction 
protein CBL 241 191 -20 
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PDGFRa S847+pY849 
Platelet-derived 
growth factor 
receptor kinase 
alpha 4655 3794 -17 
Rb T356 
Retinoblastoma-
associated 
protein 1 62 50 -17 
MST3 T190 
Mammalian 
STE20-like 
protein-serine 
kinase 3 7021 5725 -17 
eIF4B S422 
Eukaryotic 
translation 
initiation factor 
4B 325 268 -17 
Lck Y394 
Lymphocyte-
specific protein-
tyrosine kinase 1706 1410 -16 
Kit Y703 
Mast/stem cell 
growth factor 
receptor Kit 6356 5263 -16 
MKK3 S218 
MAPK/ERK 
protein-serine 
kinase 3 beta 
isoform (MKK3 
beta) 5446 4512 -16 
4E-BP1 S65 
Eukaryotic 
translation 
initiation factor 
4E binding 
protein 1 
(PHAS1) 129 108 -16 
PKCg T514 Protein-serine kinase C gamma 7394 6191 -15 
ERK1 Y204 
Extracellular 
regulated 
protein-serine 
kinase 1 (p44 
MAP kinase) 2180 1827 -15 
AurKB S227 
Aurora Kinase B 
(serine/threonine 
protein kinase 
12) 6818 5751 -15 
A-Raf Y302 
A-Raf proto-
oncogene 
serine/threonine-
protein kinase 10667 9010 -14 
GSK3a T19+pS21 
Glycogen 
synthase-serine 
kinase 3 alpha 45 38 -14 
PKCt S676 Protein-serine kinase C theta 340 290 -14 
Jun S73 
Jun proto-
oncogene-
encoded AP1 
transcription 
factor 2205 1911 -12 
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TrkB Y705 
BNDF/NT3/4/5 
receptor- 
tyrosine kinase 194 170 -11 
ASK1 S966 
Apoptosis signal 
regulating 
protein-serine 
kinase 1 146 130 -10 
Gab1 Y627 
GRB2-
associated 
binder 1 134 121 -8 
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6.3.2 Potential downstream signalling investigation 
Following on from the initial summary of the most up and down-regulated proteins, 
the results of the Kinexus micro array were further analysed by a bioinformatician, 
Dr You Zhou, Systems Immunity Research Institute, Division of Infection and 
Immunity, Cardiff University. At the same time, we gave Dr. You the following 
inclusion and exclusion criteria  
• Related to tumour progression in human.  
• Related to chemotherapy resistance 
• Related to clinical significance 
The data indicated that there were a number of protein candidates demonstrating  
significantly changed levels of phosphorylation after the addition of S1P in AGS 
cells. One of the most significant changes was seen in Protein Kinase B (Akt/PKB). 
 
 
 
Figure 6.2 Bioinformatics analysis of the KinexusTM protein-array data.  
Red represents upregulated and Green represents downregulated.
219 
 
6.3.3 Potential downstream signalling investigation 
Previous analysis highlighted AKT as a potential pathway downstream of 
SphK1/S1P. Given the significance of AKT/mammalian target of rapamycin (mTOR) 
in cell signalling and cancer cell survival, we further aimed to verify the protein 
expression level of total AKT and its phosphorylation at Ser473 between 
HGC27/AGS pEF and HGC27/AGS-SphK1-KD cell lines as this may be a key 
molecule governing the effects brought about by SphK1 suppression. It was found 
that downregulation of SphK1 correlated with the decrease of AKT Ser473, but 
appeared to have no influence on total AKT protein levels. Furthermore, we explored 
the downstream protein mTOR which is often activated by AKT. Interestingly, a 
decrease in p-mTOR (Ser2448), and potentially total m-TOR expression was 
discovered following SphK1 knockdown (Figure 6.3). 
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Figure 6.3 Western blotting verification of potential mechanistic actions, examining the 
relationship between SphK1 and AKT/m-TOR 
Western blot verification on the protein expression level of AKT, AKT ser473, mTOR and 
mTOR Ser2448 in protein extracts from AGS/HGC27 SphK1-KD and AGS/HGC27 pEF. 
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6.4 Discussion 
Both the literature and data presented throughout this thesis have demonstrated a role 
for SphK1 in promoting cancer progression and enhancing resistance to 
chemotherapy. Whilst the mechanisms downstream of SphK1 are beginning to be 
elucidated. 
Currently, a number of pathways have been identified as acting downstream of 
SphK1 to regulate its pro-cancerous effects. For example, in CRC cell lines the 
inhibition of SphK1 resulted in a decreased migratory capacity and also reduced 
expression of FAK / pFAK as well as the EMT markers Slug, vimentin and N-
cadherin, whilst enhancing E-cadherin levels. Consistent with this, chemical 
inhibition of FAK has similar effects to SphK1 inhibition on migration and EMT 
marker expression suggesting a link between SphK1, FAK and EMT in CRC (Xu et 
al., 2017a). Additional work subsequently explored this relationship in clinical 
samples and its impact on metastasis, demonstrating an up regulation of SphK1, 
vimentin, FAK and pFAK, and downregulation of E-cadherin, in metastatic 
compared to non-metastatic tumour and also, using knockdown and over-expression 
models, demonstrated SphK1 was involved in migration, EMT traits and regulated 
the expression of pFAK, MMP2/9 and AKT, which could subsequently be removed 
through FAK inhibition (Liu et al., 2019). Further studies focusing on lung cancer 
have similarly suggested links with the AKT pathway. Overexpression or 
knockdown A549 models have demonstrated SphK1 to be linked with invasion and 
migration, EMT marker (E-cadherin and Snail) expression and activation of AKT, 
where enhanced SphK1 brought about activation of AKT and subsequently traits 
associated with SphK1 overexpression could be negated through AKT inhibition 
(Zhu et al., 2015). This observation is similarly supported in an additional study 
exploring the impact of the long non coding (Lnc)RNA HULC in non-small cell lung 
cancer (NSCLC) (Liu et al., 2018). In this study the authors demonstrate HULC can 
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enhance SphK1 expression and levels of phospho-AKT, but not total levels of AKT 
and that inhibition of SphK1 or AKT is able to reduce the cellular effects of HULC, 
whilst SphK1 inhibition can also reduce AKT phosphorylation but was not itself 
inhibited by AKT inhibition (Liu et al., 2018). 
In our study, we aimed to identify potential signalling pathways in which SphK1 
could be linked and which may account for its observed role in cancer progression 
and chemoresistance. We conducted a Kinexus protein microarray following 
treatment with S1P in AGS cells to screen a large number of protein and 
phosphoproteins which highlighted AKT as a potential partner. This observation was 
interesting given the potential links observed in other cancers between SphK1 and 
AKT (Liu et al., 2018, Zhu et al., 2015, Liu et al., 2019). This was further validated 
using conventional western blot techniques in both AGS and HGC27 gastric cell 
models, where ribozyme transgene suppression of SphK1 reduced phosphorylation 
of AKT, but not total protein levels, and mTOR and appeared to further confirm the 
relationship. In addition to the AKT link, bioinformatics analysis also suggested a 
potential relationship with vimentin and a number of FAK phospho-residues were 
also seen to be altered following S1P treatment.  
Similarly, potential links between FAK and vimentin were also observed following 
S1P treatment and scaling of phosphoproteins, though in our study S1P treatment 
brought about a decrease in the phosphorylation in the catalytic loop Y576/Y577 
residues and an increase in S722 phosphorylation, which may potentially contrast 
with proposed SphK1 FAK links (Liu et al., 2019, Xu et al., 2017a). However, this 
may be due to the use of S1P treatment for the Kinexus microarray work, which in 
itself presents some limitations. For example, whilst SphK1 is a key kinase involved 
in the generation of S1P, the levels of S1P receptors within the cell line were not 
characterised/quantified making it difficult to understand the full significance and 
similarly it may not highlight any non-S1P related impacts of SphK1 within the cell 
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line. Hence direct observations following SphK1 manipulation should be clarified in 
the future. The reason why we used AGS for the Kinexus microarray is that AGS 
was readily available in our lab and was purchased from a commercial company with 
stable characters. Due to the cost of sending sample and the time limitation, we 
utilised AGS due to its readiness at the time of the Kinexus study and as it was a 
representative line used in our earlier work. of cell line at the time of study. This 
model provides preliminary insight, additional work characterizing effects of S1P 
treatment or SphK1 manipulation on a range of gastric cell lines are key in 
establishing downstream effectors. Netherthless, due to the indication that SphK1 or 
S1P signalling can influence phosphorylation and activation of AKT is of relevance 
and suggests that this relationship is common across many cancer types. AKT is a 
key pathway (Porta et al., 2014) across cancer types and is involved in the regulation 
of numerous cellular traits involved in cancer progression, including survival, 
proliferation and migration and represents a pathway of interest for therapeutic 
intervention. Enhanced activation of AKT is observed in many malignancies 
including gastric cancer where some reports have indicated links with poorer 
outlooks and resistance to chemotherapy (Oki et al., 2005, Almhanna et al., 2011, 
Cinti et al., 2008, Nam et al., 2003).  
Taken together with the data from previous chapters the relationship between SphK1 
and AKT in gastric cancer represents an interesting avenue to explore. 
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Chapter VII 
 
General Discussion 
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7.1 Introduction  
In the past decades, gastric cancer has become the fifth largest malignant tumour in 
the world (Bray et al., 2018), which seriously threatens the survival and health of the 
population. In China, gastric cancer is also an important fatal factor threatening the 
population. Although the incidence of gastric cancer has decreased in recent years, 
our 5-year survival rate still has a significant difference with our neighbours Japan 
and South Korea (Chen et al., 2018b), and also, the poor response to chemotherapy 
drugs for patients in advanced stages is one of the important reasons for poor survival. 
Therefore, the discovery of new molecular targets for treatment of gastric cancer has 
been the focus and direction of doctors and scientists working on gastric cancer 
research. 
SphKs is a sphingosine metabolizing enzyme found in different organisms. SphKs 
have been identified in mammals. SphK1 is an oncogenic enzyme and the activity of 
SphK1 is closely associated to cell transformation, proliferation and tumour cell 
survival (Li et al., 2009). Our research hopes to define the function of SphK1 in 
gastric cancer and discover whether SphK1 serves as a new molecular markers for 
predicting the development and progression of gastric cancer. 
 
7.2 Biological characteristics of SphK1 
In 1998, Olivera et al. (Olivera et al., 1998) for the first time extracted SphK1 from 
rat kidney cells with a relative molecular mass of 49kDa. Subsequently, Kohham et 
al., (Kohama et al., 1998) successfully purified two SphK1 variants rats, named 
SphK1 a and SphK1b, respectively, and found that the amino acid sequences of the 
two differ only in the 382-388 polypeptides. In 2006, Venkataraman (Venkataraman 
et al., 2006) found that there are three SphK1 subtypes in the human body, named 
SphK1a, SphK1b, SphK1c. SphKs are members of the evolutionarily conserved 
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lipidase family, and the putative amino acid sequences of SphKs provided by NCBI 
are derived from thirty species spanning 4 epigenetic phyla. 
 
7.3 SphK1 biological function 
7.3.1 SphK1 and sphingosine 1 phosphate 
S1P, Sphingosine (SP) and Ceramide (Cer) are key molecules involved in the process 
of sphingolipid metabolism. The effects of signalling molecules are manifested in 
important cellular processes including cancer progression. S1P is widely present in 
cells of various tissue systems in eukaryotes such as sputum (eg gastrointestinal tract, 
endocrine, reproductive), respiratory system and blood, lymphoid tissue, etc.) 
(Limaye, 2008). As a special ligand for the GPCR, the biological effects of S1P are 
mainly mediated by the GPCR family, including five specific subtypes, also known 
as S1PRs(1-5) (Zhang et al., 2007). S1P regulates different pathologies and 
physiological processes, including tumour formation, lymphocyte response, immune 
and allergic reactions, and angiogenesis and maturation. S1P not only act as a second 
messenger in the cell, but also act as an intercellular signalling molecule to interact 
with the S1P receptor on the cell surface to produce a wide range of biological effects, 
such as inhibition of apoptosis, stimulation of cell proliferation and regulation of 
adhesion molecule expression (Kim et al., 2009). 
It has been reported that S1P plays an important role in regulating the survival and 
development of tumours. The rate-limiting enzyme that catalyses the production of 
S1P is SphK1. Hormones play a very important role in the development of tumours. 
SphK1 affects cell proliferation by regulating S1P production. It has multiple 
functions in areas such as death, migration and adhesion molecule expression 
(Hannun and Obeid, 2008). In addition to many bioactive agents that activate SphK1, 
receptor-type tyrosine kinases and intracellular proto-oncoproteins also activate 
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SphK1. The expression of SphK1 not only stimulates cell growth, but also leads to 
malignant transformation of cells. Therefore, the SphK1 / S1P pathway has been 
investigated as a signalling pathway for apoptosis and proliferation in recent years. 
 
7.4 The role of SphK1 in tumorigenesis  
7.4.1 SphK1 and tumour cell proliferation, apoptosis 
SphK1 can be activated by many growth factors, cytokines and mitogens, and PDGF, 
PMA, TNF-a, FCS can activate SphK1. Although the molecular mechanisms by 
which these growth factors activate SphK1 are not fully understood, they 
demonstrate the importance of SphK1 in the development of tumorigenesis. At the 
same time, since its activation involves translocation to the cell membrane, it is 
speculated that its location is also important for its signalling function. Pitson et al., 
(Pitson et al., 2005) suggested that phosphorylation of SphK1 and its translocation 
from cytoplasm to membrane may be the key to the malignant phenotype of cells, 
which not only promotes the proliferation of malignant cells, but also protects the 
apoptotic pathway. Chamberlain et al., (Safadi-Chamberlain et al., 2005) used Myr-
SphK1 to inhibit SphK1 activity; they hypothesized that the inhibition mechanism 
of SphK1 after anti-tumour therapy depends on p53, however, studies have found 
that in the p53 (-) human promyelocytic leukemia cell line HL-60, SphK1 was also 
down-regulated after addition of doxorubicin and etoposide, suggesting that SphK1 
inhibition in these cells does not depend on the expression of p53. The experimental 
data on human pro-adenocarcinoma cell lines PC-3 and LNCaP showed that SphK1 
was down-regulated after anti-tumour treatment regardless of the status of p53 in 
these cell lines, suggesting that multiple pathways may be involved (Neubauer et al., 
2016). In terms of the significance of SphK1 inhibition in tumour apoptosis, it is 
speculated that by inhibiting SphK1, Cer produced by stimulating factors will not be 
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converted into S1P, and S1P is responsible for shifting tumour cells away form an 
apoptotic stat to a proflierative growth state. Contrary to the function of SphK1, 
SphK2 functions to induce apoptosis, but it has not yet been studied in detail in the 
pathogenesis or treatment of tumours. 
The strong evidence that SphK1 initially became a potential target for cancer 
research comes from data from Vada et al. which found that SphK1 may be a product 
of an oncogene, in nude mice by using a classical cell transformation model. 
Fibroblasts overexpressing SphK1 phenotypes in tissue culture acquire the ability to 
form tumours. In many tumour tissues (such as stomach, rectum, small intestine, 
brain, breast, colon, lung, ovary, uterus, kidney), the expression of SphK1 mRNA is 
significantly higher than that of healthy controls (Summary in Table 1.3).  Wang et 
al. (Wang et al., 2018b) reported SphK1 was expressed level in GC tissues and 
peripheral blood. The expression of SphK1 in tumour tissue was higher than that in 
normal tissue. In addition, S1P produced by SphK1 was more expressed in tumour 
patients’ serum than in normal patients’ serum in another dataset (Wang et al., 
2018b).Similarly, downregulation of SphK1 expression will result in slower tumour 
cell growth, promote apoptosis and enhance chemotherapy sensitivity. Malavaud et 
al. (Malavaud et al., 2010) used the different effects of the topoisomerase inhibitor 
camptothecin and the anti-microtubule drug paclitaxel on human prostate cancer cell 
lines PC-3 and LNCaP to study their association with SphK1 and subsequent 
Cer/S1P. The relationship between the results showed that only in the cell lines 
sensitive to these chemotherapeutic drugs, SphK1 was significantly inhibited and the 
Cer/S1P ratio was increased, and tumour cells showed significant apoptosis, 
confirming that SphK1 is an important factor in tumour cell sensitivity. Visentin et 
al., (Visentin et al., 2006) found that neutralization of S1P with a specific monoclonal 
antibody significantly slowed the growth of multidrug-resistant tumours in murine 
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xenografts and allogeneic models, such as lung cancer, colon cancer, breast cancer, 
and melanin tumour and ovarian cancer.  
 
7.4.2 S1P, SphK1 and tumour angiogenesis 
Angiogenesis is a key link in tumour growth and metabolism. The method of anti-
tumour angiogenesis has developed rapidly. Nowadays, bevacizumab (Avastin; 
Genentech CA), an anti-vascular endothelial growth factor (VEGF) antibody 
combined with traditional chemotherapy drugs for the treatment of colorectal cancer 
has been widely used. Recently, more and more evidence has shown that S1P is one 
of the most effective angiogenic factors. S1P is more effective than VEGF or 
hepatocyte growth factor (HGF) in promoting endothelial cell migration, thus 
promoting angiogenesis (Milstien and Spiegel, 2006). OH-Lee et al (Lee et al., 1999) 
showed that S1P combined with EDG-1 can stimulate DNA synthesis and induce 
vascular endothelial cell migration in vascular endothelial cells and is stronger than 
basic fibroblast growth factor (bFGF) and VEGF. S1P induces endothelial cell 
migration and adhesion and promotes the formation of tubular structures in 
endothelial cells. S1P stimulates umbilical vein endothelial cells to form a tubular 
structure in the extracellular matrix. The most direct evidence for S1P-promoting 
tumour angiogenesis comes from the use of anti-S1P murine monoclonal antibody 
(mAb) as a molecular sponge to selectively absorb and neutralize S1P, ie, human 
malignant tumours treated with mAbs in mice, this treatment blocks endothelial cell 
migration and capillary formation, inhibits angiogenesis induced by VEGF and 
bFGF, and prevents tumour-associated angiogenesis, while also preventing the 
release of pro-angiogenic cytokines from tumours ( VEGF, IL-2 and IL-6). 
SphK1 mainly affects tumour angiogenesis by generating S1P. Many tumour-
associated growth factors and angiogenic factors can be phosphorylated by SphK1 
promoting their downstream signal transduction. At the same time, there is some 
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evidence that SphK1 is involved in angiogenesis. Endothelial cells removed from 
serum and extracellular media display improved survival rates following 
overexpression of SphK1, suggesting that SphK1 plays an important role in 
angiogenesis under stress conditions (Whetton et al., 2003). After knocking out the 
SphK1 gene, mice died of haemorrhage due to dysplasia of the endothelial cells in 
the embryonic stage, so SphK1 may play a decisive role in the formation and 
maturation of new blood vessels. 
 
7.5 Relationship between SphK1 and gastric cancer 
7.5.1 Expression of SphK1 in gastric cancer tissues 
In the early stage, we conducted a large-scale tissue microarray screening of freshly 
matched gastric cancer tissue samples from gastric cancer patients admitted to our 
hospital (PKUCH) from 2006 to 2007. We aimed to get identify differences at the 
transcription level and lay the foundation for further research. In 322 freshly matched 
gastric cancer tissues, we found that the expression of SphK1 in tumour tissues was 
significantly upregulated by tissue microarray screening, which was statistically 
significant. After further refinement analysis, we found that SphK1 was positively 
correlated with the advanced TNM stage of the patient's tumour and the degree of 
lymph node metastasis, which is consistent with the experimental results in other 
tumours (Wang et al., 2018b). 
Comparing to Li et al. (Li et al., 2009) who detected SphK1 in normal gastric mucosa 
epithelium, gastric cancer cell line, gastric cancer tissues and matched normal tissues 
by RT-PCR, western blot and immunohistochemistry in 10 normal human gastric 
mucosa tissues and 175 gastric cancer tissues. The expression of SphK1 in gastric 
cancer at mRNA and protein levels was significantly higher than that in normal 
gastric tissues. 115 of the 175 gastric cancer tissues expressed SphK1 protein 
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(65.7%). The expression of SphK1 protein in gastric cancer was associated with 
multiple clinical and pathological factors such as clinical stage, T stage and M stage 
and vascular invasion in gastric cancer patients, which was consistent with the results 
of our study (Table 3.5). Patients with expression of SphK1 protein had shorter 
survival time, and the survival rate of patients was negatively correlated with the 
expression level of SphK1 protein which we clarify in Figure 3.4.Next, in order to 
test the expression of SphK1 at the protein level, we collected paraffin-embedded 
sections of gastric cancer patients in our hospital for immunohistochemistry. We 
found that the expression of SphK1 in gastric cancer patients was significantly higher 
than that in normal tissues adjacent to the cancer, and it was statistically significant. 
This is consistent with our findings on the level of transcription on tissue microarrays. 
Our study found that patients with positive SphK1 expression had significantly 
shorter survival than patients with negative SphK1 expression, both in terms of 
overall survival and disease-free survival, and we concluded that this might be 
related to intracellular function of SphK1. In the Cox regression model, we found 
that SphK1 can be used as an independent prognostic factor for patients with gastric 
cancer. Based on the above studies, we can speculate that SphK1 can be used as a 
good molecular target for predicting the prognosis of patients with gastric cancer. 
At the same time, we did have limitations in our study. Firstly, we used fresh frozen 
samples from 2006 to 2007, and we extracted RNA in 2014. Therefore, it is possible 
that such long storage may have resulted in increased RNA degradation and thus 
affected the results of our study. However, it is suggested from the literature that 
Kelly et al. (Kelly et al., 2019) reported that 11 years storage didn’t affect the 
integrity and histomorphology of tissues preserved under qualified preservation 
conditions. The biobank of PKUCH is a qualified one with worldwide standards. In 
addition, the expression rate of SphK1 at the protein level was about 34% in our 
study and the expression rate of SphK1 in Li et.al., (Li et al., 2009) article is as high 
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as 66%. The reason for this difference might be due to the antibody factor and the 
lower indoor temperature in the laboratory 
Our research not only draws conclusions at the RNA level, but also from protein 
level which make our results reliable. And also, our results indicate SphK1 might be 
a promising targeting in gastric cancer treatment (Chapter III). 
 
7.5.2 SphK1 and proliferation of gastric cancer cells 
Yin et al. (Yin et al., 2019) reported that GC cells promoting autophagy in HPMCs, 
was inhibited by blocking TGF-β1 secreted by GC cells, while inhibiting expression 
of SphK1 in HPMC can inhibit TGF-β1-induced autophagy. SphK1 regulates HPMC 
autophagy and promotes the growth of GC cells in vitro and in vivo. Overexpression 
of SphK1 can induce fibrosis in HPMCs. Mechanically, elevated SphK1 levels 
promoted tumour bioactive sphingolipid dysregulation, of which ceramide decreased 
and S1P increased (Yin et al., 2019).  
 
Similarly, we established an SphK1 knockdown cell line and carried out cell function 
studies to observe the impact of knockdown of SphK1 on cancer cell function. My 
in vitro data showed that dysregulation of SphK1 contributed to the cell migration, 
adhesion and growth which are similar trends to those present in the literature 
previously mentioned. Therefore, questions have been arisen as to whether SphK1 
may be useful as a therapeutic target to improve the clinical outcome of patients 
(Chapter IV). 
Here, I also want to clarify the limitations of our research. In functional assays, due 
to time and budget issues, we only knocked down gastric cancer cell lines with high 
SphK1 expression, rather than overexpressed SphK1 in gastric cancer cell lines with 
low SphK1 expression. Therefore, our evidence was not sufficiently strong. At the 
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same time, the establishment of knock down gene expression cell lines has off-target 
effects. Therefore, it is more convincing to establish overexpression cell lines and 
compare them with existing research. 
At the same time, we should have more experiments such as cell cycle and apoptosis 
to observe whether SphK1 affects tumour biological behaviour through these 
processes. In confirming the effect of SphK1 on tumour cells, limited conclusions 
can be drawn with only one experiment method, such as migration. It should be 
verified at the level of molecular markers, such as whether migration affects EMT 
and detect molecular markers such as E-cadherin, N-cadherin, Snail, Slug and 
Vimentin. 
. 
7.5.3 SphK1 and chemoresistance of gastric cancer cells 
A major challenge in developing effective cancer therapies involves implementation 
of effective treatment regimen, using biomarkers to identify patients who might 
benefit from the treatment and making the conventional chemotherapeutic 
approaches more effective and resilient to resistance mechanisms in the patients by 
using molecule antagonist and agonist.  
Research has indicated that chemotherapy resistance occurs when inhibited the 
expression of SphK1 (Li et al., 2016c). For example, inhibited expression of SphK1 
enhances docetaxel and camptothecin sensitivity in LNCaP and PC-3 cells (prostate 
cancer cells), respectively (Pchejetski et al., 2008). Similar result suggests that 
elevated SphK1 promoted daunorubicin resistance in leukaemia cells (Sobue et al., 
2008), cisplatin resistance in lung cancer cells (Min et al., 2005) docetaxel resistance 
in prostate cancer cell (Alshaker et al., 2016) and oxaliplatin resistance in colon 
cancer cells (Nemoto et al., 2009). Furthermore, an additional study has 
demonstrated the ability of SphK1 to bring about the overexpression of transcript 
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levels of the downstream transcription factor, E2F7, mediating the chemoresistance 
of anthracycline in HNSCC (Hazar-Rethinam et al., 2015). Another study has 
demonstrated the capacity of a SphK inhibitor to repair the resistance to etoposide 
and doxorubicin through inducing apoptosis, a finding that is  identical to the 
observation that reduced ceramide accumulation and sustained SphK1 activity may 
result in chemotherapeutic resistance (Heffernan-Stroud and Obeid, 2013). 
In our study, we performed an initial preclinical evaluation of the role of SphK1 in 
chemoresistance of gastric cancer. In all two SphK1 high expression gastric cancer 
cell lines (AGS and HGC27), the IC50 was significantly decreased in SphK1-KD 
group comparing with SphK1 control group both following treatment with cisplatin 
or 5-FU according to different drug concentrations. Interestingly, cell viability and 
chemotherapeutic drugs are dose dependent. At relatively high concentrations and 
relatively low concentrations, SphK1 has a limited role in chemotherapy resistance, 
but within the appropriate drug concentration range, downregulating the expression 
of SphK1 expression was significantly decreasing the IC50 concentration of 
chemotherapeutic drugs. Furthermore, we also studied the small molecule inhibitor 
of SphK1, named PF543. After using PF543 to inhibit SphK1, we found that 
compared with no small molecule inhibitors group, the small molecule inhibitor 
group could significantly reduce the IC50 of chemotherapy drugs in both the AGS 
or HGC27 cell line and in the cisplatin or fluorouracil chemotherapy group. Wang 
et al. (Wang et al., 2018a) reported that the use of PF543 in TNBC cells increased 
the sensitivity of the cells to chemotherapy drugs which showed similar findings to 
ours. At the same time, we used the patient derived primary cell lines established in 
PKUCH and selected one which showed high expression of SphK1 and one with low 
expression of SphK1 for subsequent research. The experimental group treated with 
PF543 showed that PF543 in the SphK1 high expression group significantly 
increased the sensitivity of chemotherapy, but not in the low expression group. This 
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preliminarily indicated that SphK1 play a role in the chemotherapy resistance of 
gastric cancer (Chapter V). 
In my future research, I would like to build up a mouse model to further verify that 
knockdown of SphK1 can contribute to chemosensitivity in gastric cancer cell. This 
would further investigate whether SphK1 can be a potential target to covert 
chemoresistance of gastric cancer patients. 
Our research has well demonstrated at the cellular level that reducing SphK1 
expression enhanced the chemosensitivity of fluorouracil and cisplatin. At the same 
time, in the primary cells derived from patients and gastric cancer cell lines, it has 
also been proved that the use of small molecule inhibitors PF543 in high expression 
of SphK1 cell lines lead to increase in the sensitivity of cells to chemotherapy. On 
the other hand, there is no such effect in a patient derived primary cell line with low 
expression of SphK1. However, these studies are all at the 2-Dimensional level, and 
they couldn’t simulate the real environment in the human body. With the continuous 
advancement of research technology, emerging Patient Derived Organoids (PDO) 
(Vlachogiannis et al., 2018) and Patient Derived Tumour Xenograft (PDTX) (Ben-
David et al., 2017) have further simulated the microenvironment in human tumour. 
Therefore, our research should further validate our hypotheses on these models. 
 
7.6 The mechanisms of SphK1 in gastric cancer cells 
Previous research has focused on the study of the function and the effect on 
chemoresistance of SphK1 in cells. SphK1 localized to the endoplasmic reticulum 
within the cytoplasm, and many molecules activate SphK1 and promoted its 
expression. These factors include seven transmembrane receptor activators, tyrosine 
kinase receptors, pro-inflammatory factors, immunoglobulins, calcium ions and 
protein kinase receptors. Activation of SphK1 is achieved by translocation to the 
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vicinity of the cell membrane, and this translocation requires phosphorylation of 
ERK at the Ser225 site, which also increases the expression of SphK1. Other 
experiments have demonstrated this from another perspective. SphK1 cannot be 
translocated near the cell membrane in cells with SphK1 Ser225 mutations, and thus 
does not promote cell proliferation and survival (Ren et al., 2002).  
Another study demonstrated that the deletion of SphK1 inhibited the growth of 
thymic lymphomas in p53 null mice and extended the survival time. SphK1 enhances 
the expression of sphingosine and ceramide, in order to mediate P53 tumour 
suppressive role in cancer, and also influences the cell cycle process and 
chemosensitivity (Heffernan-Stroud et al., 2012). The study of Liu et al. (Liu et al., 
2019) indicated that SphK1 was overexpressed in colon cancer, which affected the 
prognosis, metastasis and survival of patients. SphK1 affected the metastasis through 
affecting cancer cell EMT. At the same time, elevated expression of SphK1 
promoted the expression of p-FAK, AKT and MMP2/9. FAK small inhibitors 
inhibited the expression of the above proteins and the inactivation of FAK signalling 
pathways (Liu et al., 2019). 
In recent years, research discovered that SphK1 is a target of micro RNA (miRNA), 
and that this will subsequently impact many downstream signalling pathways. Wang 
et al. study (Wang et al., 2019a) demonstrated that miR-506-3p directly targeted and 
inhibited SphK1 expression on osteosarcoma. In this study, transfection with miR-
506-3p mimics reduced the ability of invasion of osteosarcoma cell lines, which 
could be subsequently reversed through SphK1 overexpression. Furthermore, miR-
506-3p played an important role in MET and autophagy. Similarly, a study by Cao 
et al. (Cao et al., 2019), also highlighted a link between SphK1 and miR-128 in PTC 
and FTC. In this study SphK1 was identified as a target of miR-128 and the 
expression of SphK1 was reduced in PTC and FTC tissues where it notably showed 
a negative correlation with miR-128 expression. Additionally, the inhibitory effect 
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of miR-128 on growth rate and tumour weight identified using in vivo models also 
appeared to suppress SphK1 expression. SphK1 plays an important role in the 
occurrence and development of cancer and affects different signalling pathways. 
NF-κB is well established as a key signalling pathway in apoptosis and as being 
involved in cancer development and progression (Zhang et al., 2017). In keeping 
with SphK1’s role, links between SphK1 and NF-κB have been previously observed. 
One such study by Alvarez et al. (Alvarez et al., 2010) have demonstrated a role for 
SphK1/S1P in  apoptosis through regulation of NF-κB signalling by ubiquitination 
of TRAF2, RIP1, IκB kinase, IκBa and the degradation of IκBa (Alvarez et al., 2010). 
Further links have also been demonstrated in a subsequent study by Liang et al. 
(Liang et al., 2013) indicating that overexpression of SphK1 and subsequent 
upregulation of S1P drives a persistent amplification loop from SphK1/S1P/S1PR1 
to NF-kB/IL-6/STAT3 (Liang et al., 2013). 
In our study, we aimed to identify potential signalling pathways in which SphK1 
could be linked and which may account for its observed role in cancer progression 
and chemoresistance. Our observation was interesting given the potential links 
observed in other cancers between SphK1 and AKT (Liu et al., 2018, Zhu et al., 
2015, Liu et al., 2019). This was further validated using conventional western blot 
techniques in both AGS and HGC27 gastric cell models, where ribozyme transgene 
suppression of SphK1 reduced phosphorylation of AKT, but not total protein levels, 
and mTOR and appeared to further confirm the relationship. In addition to the AKT 
link, bioinformatics analysis also suggested a potential relationship with vimentin 
and a number of FAK phospho-residues were also seen to be altered following S1P 
treatment (Chapter VI). Furthermore, Peng et al. (Peng et al., 2010) reported that in 
cisplatin-resistant cell lines, there was a higher phosphorylation of Akt. At the same 
time, inhibition of Akt phosphorylation made drug-resistant cells sensitive to 
cisplatin. In addition, if the phosphorylation of Akt / mTOR was inhibited in 
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common ovarian cell lines, cancer cells could be made more sensitive to cisplatin. 
This study also strongly confirmed that resistance to cisplatin works through the Akt 
/ mTOR pathway which explained the high expression SphK1 activation Akt / 
mTOR signalling pathway which affects drug gastric cancer patient chemoresistance. 
In our research, due to the fact that the knock down cell line was not yet established 
and commercial SphK1 inhibitors were not available at that time, we chose to use 
exogenous S1P instead. This is another limitation in our research. Therefore, we will 
use the established knockdown cell line and SphK1 inhibitor to explore the 
downstream signalling pathway in the future. Furthermore, in establishing an over-
expression cell line, we can compare the same change of signalling pathway in the 
knockdown and over-expression cell lines. 
 
7.7 Conclusion 
In summary, SphK1 is overexpressed in many types of tumours and plays a role in 
promoting growth, cell apoptosis, and angiogenesis. SphK1expression is closely 
related to cell biological behaviour such as proliferation, migration and apoptosis of 
human gastric cancer cells and the occurrence and metastasis of GC. However, the 
up-regulated expression of SphK1 in tumour cells and its role in tumorigenesis and 
development and chemoresistance and related molecular mechanisms are still 
unclear, and further in-depth studies are needed. However, based on my current 
research, I believe that SphK1 is expected to become a potential new target for 
gastric cancer therapy and play a significant role in GC chemoresistance. 
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